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ABSTRACT OF THESIS  
 
Method Development and Validation of the Quantitation of 19 Antipsychotics using 
Deuterated Internal Standards 
 
Antipsychotic drugs or neuroleptics are used primarily for psychiatric disorders such as 
schizophrenia, psychosis, and bipolar disorder. In forensic science antipsychotics are 
drugs of considerable interest because of their potential abuse, involvement in suicides, 
and they are frequently associated with sudden death investigations. Well-characterized 
and fully validated analytical data is necessary to generate reproducible and reliable 
results. As a result, data can be correctly interpreted and objectively demonstrate in its 
applicability for the intended use. This research has developed and validated a method 
that is selective, sensitive and accurate using liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) for the simultaneous determination of approximately 19 
antipsychotics with deuterated internal standard in postmortem human blood. Compound 
optimization parameters for detecting a specific compound as well as a quantitative assay 
of the antipsychotic compounds were accomplished. Validation parameters such as 
determination of linearity, within and between day accuracy and precision, carryover 
evaluation, matrix effect and recovery, and peak purity and selectivity study were 
performed. These parameters yielded results for all of the compounds with only two 
(mesoridazine and thiothixene) requiring further study to improve their performance. The 
validated method has been successfully used to analyze postmortem human blood for 
application in forensic toxicology. 
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CHAPTER ONE:  Introduction 
1.1 Antipsychotic 
 
Antipsychotic drugs or neuroleptics are used primarily for psychiatric disorders 
such as schizophrenia, psychosis, and bipolar disorder. They have also been used for non-
psychotic disorders such as depression, behavioral disorders, mood stabilizers, hypnotic 
(sleep) medications and many other off-label uses [1]. Toxicity varies considerably with 
each drug however the general effects are similar including sedation, hypotension, 
tachycardia, dysrhythmias and seizures. Most antipsychotics are divided into two groups; 
the typical or first-generation antipsychotics, and the atypical or second-generation 
antipsychotics.  
 
A first generation of antipsychotics are known as typical antipsychotics, and were 
discovered in the 1950s when chlorpromazine, which was developed as a surgical 
anesthetic, was used on psychiatric patients because of its sedative and powerful calming 
effect. Because of this tranquilizing effect, typical antipsychotics have also been referred 
to as the major tranquilizers [2]. Regular and high levels of sedation are common among 
this group of antipsychotics and when used heavily they can be incapacitating. It is 
believed that by blocking dopamine receptors from excess dopamine released in the 
brain, psychotic experiences can be controlled. Typical antipsychotics block the 
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dopamine D2 receptor, but are very unselective blocking "D2-like family" receptors in the 
mesocortical pathway, tuberoinfundibular pathway and the nigrostriatal pathway. This 
lack of selectivity is believed to be responsible for many of the side-effects caused by 
these drugs. These unwanted side effects such as extrapyramidal motor control 
disabilities, include problems like acute dystonias, akathisia, parkinsonism, tardive 
dyskinesia, tachycardia, hypotension, seizures, hyperprolactinaemia, and many others 
that can become permanent [3] [4]. Typical antipsychotics are classified based on their 
potency which is a measure of the relative effectiveness of antipsychotics compared to 
chlorpromazine [5]. High-potency antipsychotics have a high affinity for the D2 receptors 
and are more likely to cause adverse effects (extrapyramidal effects) associated with 
these receptors. However, there are fewer adverse effects (sedation) caused by other 
receptors due to the increased selectivity for the D2 receptors. Low-potency 
antipsychotics have low selectivity of the D2 receptors lowering symptoms such as 
extrapyramidal effects but increasing those such as sedation [6]. Potency, however, does 
not equate to efficacy because despite differences in structure and D2 receptor affinity, all 
typical antipsychotics have clinically similar efficacy at their standard dose. Because of 
the chronic nature of the treated disorders, antipsychotic medications are rarely 
discontinued once started, potentially causing permanent chemical dependence leading to 
a much worse psychosis [7]. They are usually only stopped if the side-effects become too 
severe or a patient has been symptom free for a long period of time. Discontinuation of 
typical antipsychotics requires critical managing, consistent treatment and a good 
understanding of the withdrawal symptoms (nausea, emesis, anorexia, diarrhea, 
3 
 
rhinorrhea, diaphoresis, myalgia, paresthesia, anxiety, agitation, restlessness, and 
insomnia), some of which may be permanent, such as Tardive dyskinesia. 
 
 
 Figure 1: Clinically effective antipsychotic dose 
affinity to cloned human DA D
atypical antipsychotic medications
 
 
vs. binding 
2 receptor for (a) typical and (b) 
 (NM Richtand et al). 
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The first atypical antipsychotic, clozapine, was discovered in the 1950s and 
introduced clinically in the 1970s but many others have been developed more recently. 
Second generation (atypical) antipsychotics are potent serotonin antagonists, readily bind 
with D3 and D4 dopamine receptors (restricted to the neurons of the limbic system and 
cerebral cortex) and act considerably less on D2 receptors reducing the adverse effects. 
Unlike typical antipsychotics, the affinity for D2 receptors does not correlate with their 
clinically effective dose and important differences between typical and atypical 
antipsychotics are the side effects (Figure 1). Atypical antipsychotics have a greater 
efficacy than that of typical antipsychotics for the treatment of psychosis and are easier to 
discontinue being less likely to cause physical dependency and withdrawal symptoms. 
However, atypical antipsychotics are excreted faster than the typical antipsychotics so 
relapses into psychosis are greater. There are still a number of harmful and adverse 
effects that vary among these different antipsychotics such as lowered life expectancy, 
weight gain, decrease in brain volume, agranulocytosis, diabetes, sexual dysfunction, 
tardive psychosis, and tardive dysphrenia [8] [9].  
 
In 2008, antipsychotics were among the leading class of prescribed drugs in the 
US and had a global value of about $22 billion [8]. Increasing off-label (non-FDA 
approved)  uses for atypical antipsychotics are targeting an increasing array of psychiatric 
indications such as dementia in older people, attention-deficit/hyperactivity disorder, 
conduct disorder, and affective disorders in children and adolescents [11] and for the 
treatment of irritability in children and adolescents with autism [12]. Unfortunately, the 
side effects of using antipsychotics for off-label usages are unknown leading to the deaths 
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of patients taking the drugs. Use of these drugs continues to increase despite studies 
indicating that adverse side-effects are more severe in children than adults [13] [14] [15]. 
These drugs can increase the risk of sudden cardiac death, with mortality rates increasing 
with age and dosage [16] [17]. Although atypical antipsychotic drugs have a favorable 
adverse effect profile relative to traditional antipsychotics, there is still much needed 
study into the severity of their side-effects. Many of these drugs carry warnings stating 
elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an 
increased risk of death. The risk of death is increased when these drugs are combined 
with alcohol, certain food items or other medications. Toxicity among antipsychotic 
drugs is extremely variable with patients surviving massive overdoses and others dying as 
a result of taking therapeutic doses. This variability may result from the fact that the 
metabolic pathways and multiple drug interactions of antipsychotics are not completely 
understood [18].  
 
In forensic science, the antipsychotics are drugs of considerable interest because 
of their potential abuse and their involvement in suicides and intoxication. Many deaths 
caused by atypical antipsychotic toxicity are often related to cardiovascular 
complications, but pulmonary, neurological, endocrine and gastrointestinal complications 
have also caused fatalities. This can result in misdiagnosing the actual cause of death 
unless antipsychotic drugs are tested for and the role they play in certain deaths is 
understood. This requires that an assay to identify and quantitate these drugs from sub to 
supratherapeutic doses be developed and validated. 
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1.2 Antipsychotics in this Study 
 
In an effort to validate a method to identify and quantitate antipsychotics in 
postmortem human blood, 19 antipsychotics were chosen. The choice of which drugs to 
use was based on prescribed antipsychotics in case files found at the scene in the last two 
years. Also considered were drugs commonly used in Western New York and already 
screened for by the Erie County Toxicology Lab. Table 1 contains these drugs and the 
various structures, categories and classes they belong to and Table 2 contains drug forms, 
dosage, therapeutic blood levels and other drug information.  Lastly Table 3 contains the 
TIAFT reference blood level list of these drugs with their therapeutic and toxic amounts. 
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Table 1: Antipsychotics in this study, grouped by chemical 
class, type, potency for typical, and structure. 
 
 
 
Chlorpromazine Low Potency Typical
Promethazine Low Potency Typical
Trifluoperazine Medium Potency Typical
Fluphenazine High Potency Typical
Perphenazine Medium Potency Typical
Mesoridazine Low Potency Typical
Thioridazine Low Potency Typical
Piperazine Phenothiazines
Aliphatic Phenothiazines
Piperidine Phenothiazines
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Haloperidol High Potency Typical
Pipamperone Low Potency Typical
Ziprasidone
Thiothixene Medium Potency Typical
Butyrophenone
Thioxanthines
Indoles
Atypical
10 
 
 
 
 
 
Clozapine
Loxapine Medium Potency Typical
Olanzapine
Quetiapine
Risperidone
Paliperidone          
(9-Hydroxyrisperidone)
Aripiprazole
Buspirone
Atypical
Other
Benzodiazepines
Atypical
Generalized 
Anxiety 
Disorder
Atypical
Atypical
Atypical
Atypical
11 
 
1.2.1 9-hydroxyrisperidone 
 
Paliperidone (Brand names: INVEGA and INVEGA Sustenna), also known as 9-
hydroxyrisperidone, is an atypical antipsychotic developed by Janssen Pharmaceutica. 
Racemic 9-hydroxyrisperidone is itself licensed for the management of schizophrenia 
(Paliperidone®). It was approved by the US Food and Drug Administration (FDA) for 
schizophrenia in 2006 (Invega), 2009 (Invega Sustenna). Invega is an extended release 
formulation for once-daily dosing and Invega Sustenna (paliperidone palmitate) is a long-
acting injectable formulation for once-monthly dosing. 9-hydroxyrisperidone is an active 
metabolite of the atypical antipsychotic risperidone by hydroxylation and N-
demethylation. There are only a few reported cases of paliperidone overdose, with the 
highest amount ingested being 405 mg (Invega package insert). Observed signs and 
symptoms included extrapyramidal symptoms and gait unsteadiness. Since 9-
hydroxyrisperidone is an active metabolite, overdoses reported with risperidone will be 
similar.  
 
1.2.2 Aripiprazole 
 
Aripiprazole (Brand names: Abilify, Abitat, Aripiprex) is an atypical 
antipsychotic antidepressant used in the treatment of schizophrenia, bipolar disorder, and 
clinical depression. Aripiprazole is a dopamine D2-receptor antagonist that has been used 
since 1999. It was approved by the US Food and Drug Administration (FDA) for 
schizophrenia (2002), bipolar disorder (2004), depressive disorder (2007), and irritability 
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in children with autism (2009). Off-label uses consist of the treatment of behavioral 
problems in elderly people with dementia and the treatment of other behavior problems. 
Overdose symptoms may result in drowsiness, vomiting, confusion, seizure, or coma 
however no fatalities have been reported. 
 
1.2.3 Buspirone 
 
Buspirone (Brand name: Buspar) is a psychoactive drug and pharmaceutical 
medication used primarily as an anxiolytic, specifically for generalized anxiety disorder. 
It is the first drug of this type in a chemical group known as the azaspirodecanediones, 
which are chemically unrelated to other existing anxiolytic or antipsychotic agents. 
Buspirone was approved by the US Food and Drug Administration (FDA) for generalized 
anxiety disorder (1986). Buspirone is sometimes used off-label for augmentation of 
selective serotonin reuptake inhibitor (SSRI) therapy for depression. An overdose with 
Buspirone can cause an increase in symptoms such nausea, vomiting, drowsiness, and 
stomach pain however no fatal cases have been reported [17].  
 
1.2.4 Chlorpromazine 
 
Chlorpromazine (Thorazine, Largactil) is a typical antipsychotic synthesized in 
1952, and the first drug developed with specific antipsychotic action. Chlorpromazine is 
the first and most useful of the phenothiazine derivatives due to its ability to dramatically 
improve the prognosis of patients in psychiatric hospitals. Off-label uses for 
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chlorpromazine have been in the treatment of severe migraines, and in cancer patients to 
improve nausea and intensify and prolong the analgesic action of opioids given. 
Therapeutic doses of chlorpromazine are capable of causing severe adverse effects that 
can be potentially fatal. Sudden death ("phenothiazine sudden death") has also occurred 
with many psychiatric patients receiving large daily doses of chlorpromazine or other 
phenothiazines [17]. 
 
1.2.5 Clozapine 
 
Clozapine (Brand name: Clozaril, Azaleptin, Leponex, Fazaclo, Froidir; 
Denzapine, Zaponex, Klozapol, Clopine). This was the first of the atypical antipsychotics 
to be developed, and it was first introduced in Europe in 1971, however it was voluntarily 
withdrawn by the manufacturer in 1975 after it was shown to cause agranulocytosis 
(dangerous decrease of white blood cells) that led to fatalities. Since Clozapine is more 
effective than any other antipsychotic for treating schizophrenia, it is usually used as a 
last resort in patients that have not responded to other anti-psychotic treatments. In 1989, 
the U.S. Food and Drug Administration (FDA) approved clozapine's use for treatment-
resistant schizophrenia with required blood testing and in 2002 for reducing the risk of 
suicidal behavior for patients with schizophrenia. Clozapine has a black box warning for 
agranulocytosis, seizures, myocarditis, and adverse cardiovascular and respiratory effects. 
Off-label uses have included treatment of intractable chronic insomnia, schizoid 
personality disorder, resistant bipolar disorder, resistant paranoid personality disorder, 
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and resistant delusional disorder. In addition to the therapeutic hazards acute overdose 
can cause hypotension, cardiac arrhythmias, respiratory depression, coma and death [17].   
 
1.2.6 Fluphenazine 
 
Fluphenazine (Brand name: Permitil, Prolixin) belongs to the piperazine class of 
phenothiazines and is a typical antipsychotic drug. It was approved by the U.S. Food and 
Drug Administration (FDA) in 1968 for the treatment of psychoses such as schizophrenia 
and acute manic phases of bipolar disorder. Fluphenazine can cause irreversible side 
effects such as tardive dyskinesia and potentially fatal neuroleptic malignant syndrome. 
Some patients have been placed on very high doses of fluphenazine without any adverse 
effects (300-1200 mg per day [20]) however other have died at lower doses. 
 
1.2.7 Haloperidol 
 
Haloperidol (Brand names: Haldol, Serenace) a butyrophenone derivative is a 
typical antipsychotic used in the treatment of schizophrenia. It has pharmacological 
effects similar to the phenothiazines. Haloperidol was discovered by Paul Janssen and 
was developed in 1958 by Janssen Pharmaceutica. It was approved by the U.S. Food and 
Drug Administration (FDA) in 1967. Off-label uses for haloperidol have mainly been for 
its sedating effects. High-doses of haloperidol have resulted in bradycardia, hypothermia, 
sinus arrhythmia, neuromuscular rigidity, tremors, coma, and death [17]. 
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1.2.8 Loxapine 
 
Loxapine (Brand names: Daxoline, Loxapac, Loxitane) is a typical antipsychotic 
medication, approved by the U.S. Food and Drug Administration (FDA) in 1976 for the 
treatment of schizophrenia. Loxapine is a dibenzazepine derivative that is structurally 
similar to clozapine and behaves as an atypical antipsychotic [21]. High-doses of 
loxapine have caused dizziness, confusion, weakness, extrapy-ramidal effects, stupor, 
tachycardia, profound hypotension, respiratory depression, seizures, coma, and death 
[17]. 
 
1.2.9 Mesoridazine 
 
Mesoridazine (Brand name: Serentil) is a side-chain sulfoxide of thioridazine 
belonging to the class of drugs called phenothiazines, used in the treatment of 
schizophrenia. It is a metabolite of thioridazine and was first synthesized in 1963 and has 
been in clinical use since 1965. Although it’s pharmacological activity is similar to 
thioridazine, its effects have shown it to be more potent. Mesoridazine was withdrawn 
from the United States market in 2004 because it may cause life-threatening irregular 
heartbeats [20]. Blood concentrations of mesoridazine are similar in high-dose chronic 
therapy to those of fatal cases and deaths have been reported with ingestion of 2.5 to 10 g 
of the drug [17]. 
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Table 2: Medical and chemical information about 
antipsychotics in this study ( [17] and other sources) 
 
 
  
 
 
 
 
 
Drug Form Dose Daily Dose Range 
Plasma 
Concentration 
Oral Tablets 3 - 12 mg
Intramuscular Injection 39 - 234 mg
Free Base Tablets 2 - 30 mg 120-452 µg/L
Syrup 1 mg/mL
Intramuscular Injection 7.5 mg/mL
Buspirone Hydrochloride Salt Oral Tablets 5 - 10 mg 15 - 60 mg 0.21-3.07 µg/L
Oral Tablets
Rectal Suppositories
Syrup 10 mg/5 mL
Concentrate 30-100 mg/mL
Intramuscular Injection 25 mg/mL
Clozapine Free Base Oral Tablets 25 and 100 mg 12.5-400 mg 0.06-0.65 mg/L
Tablets 1-10 mg 
Syrup 2.5 mg/5 mL 
Intramuscular Injection 2.5 mg/mL 
Decano/Enanthate Esters Intramuscular Injection
Tablets 0.5-20 mg
Concentrate 2 mg/mL 
Parenteral Injection 5 mg/mL 
Intramuscular Injection 50 - 100 mg/mL
Decanoate ester Intramuscular Injection
Succinate Salt Capsules 5-50 mg
Concentrate 25 mg/mL
Intramuscular Injection 50 mg/mL
Intramuscular Injection
Oral Tablets
Olanzapine Free Base Oral Tablets 2.5-10 mg 10-20 mg 9.3 - 26 µg/L
Intramuscular Injection 5-10 mg
Oral Tablets 12-64 mg
Enanthate Ester Intramuscular Injection
Tablets 12.5-50 mg
Syrup 6.25 mg/5 mL
Parenteral Injection 25 and 50 mg/mL 
Rectal Suppositories 12.5-50 mg 
Quetiapine Fumarate Salt Oral Tablets 25 - 200 mg 150-750 mg 0.14 - 0.402 mg/L
Risperidone Free Base Oral Tablets 1-4 mg 2-6 mg 4-27 µg/L
Tablets
Concentrate
Thiothixene Hydrochloride Salt Intramuscular Injection 20-60 mg 0.002 - 0.1 mg/L
Tablets 1-10 mg 2-40 mg 0.5-28 µg/L
Concentrate 10 mg/mL
Intramuscular Injection 2 mg/mL 6 mg
Tablets
Capsules
Parenteral Injection 10 mg/mL 
Ziprasidone
100-800 mg
Hydrochloride Salt
Hydrochloride Salt
Hydrochloride SaltTrifluoperazine
Thioridazine Hydrochloride Salt Oral
Loxapine
Hydrochloride Salt
Hydrochloride Salt
10-300 mg
Chlorpromazine
Fluphenazine
Oral
Oral
Oral
Promethazine
Oral
Oral
Oral
Perphenazine
Mesoridazine Besylate Salt
Haloperidol Lactate Salt
Free Base
Hydrochloride Salt
45-139 µg/L10-120 mg
0.05 - 3.9 mg/L
0.002 - 0.030 mg/L
50-400 mg 0.10 - 1.05 mg/L
Oral 5 - 20 mg
100 mg every 14 days
2 - 30 mg 
0.0003 - 0.03 mg/L
25-150 mg 3-99 µg/L
0.5-245 µg/L
0.26-22.6µg/L 
25 - 2400 mg 0.010-0.3 mg/L 
2.5-20 mg
12.5-100 mg every 1-3 weeks.
50-450 mg once monthly
20-250 mg
0.5 - 100 mg
Type
9-Hyroxyrisperidone
Aripiprazole Oral
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1.2.10 Olanzapine 
 
Olanzapine (Brand names: Zyprexa, Zalasta, Zolafren, Olzapin, Oferta, 
Zypadhera) is an atypical antipsychotic that is a serotonin and dopamine-receptor 
antagonist with anticholinergic properties. Olanzapine was approved by the U.S. Food 
and Drug Administration (FDA) in 1996 for the treatment of schizophrenia and bipolar 
disorder. Olanzapine is structurally similar to clozapine, and is classified as a 
benzodiazepine. Off-label uses of olanzapine have included generalized anxiety disorder, 
[23] panic disorder, [24] delusional parasitosis, [25] post-traumatic stress disorder, [26] 
anorexia nervosa, [27] Tourette syndrome [28] and stuttering [29]. Overdoses with 300 
mg of olanzapine in an adult caused only drowsiness and slurred speech however death 
has been reported after an acute overdose of 600 mg, but others have survived after acute 
overdoses of 1000 mg or more [17].  
 
1.2.11 Perphenazine 
 
Perphenazine (Brand name: Trilafon) is a typical antipsychotic drug and a 
chlorpromazine analogue, classified as a piperazinyl phenothiazine. It was first 
synthesized in 1956 and approved by the U.S. Food and Drug Administration (FDA) that 
same year. High-dose therapy and overdoses of perphenazine can have numerous adverse 
reactions such as extrapyramidal effects, tardive dyskinesia, anticholinergic effects, 
drowsiness, postural hypotension, blood dyscrasias, obstructive jaundice and sudden 
death [17].  
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1.2.12 Pipamperone 
 
Pipamperone (Brand name: Dipiperon) is an antipsychotic drug (a butyrophenone 
derivative) used in the treatment of schizophrenia [30]. Pipamperone is used for its 
sedative effects in chronic psychotic patients [31]. Pipamperone in supratherapeutic doses 
may lead to torsade de pointes, a life-threatening ventricular tachyarrhythmia [32]. 
 
1.2.13 Promethazine 
 
Promethazine (Brand names: Phenergan, Remsed. Zipan, Promethegan, 
Romergan, Fargan, Farganesse, Prothiazine, Avomine, Atosil, Receptozine, Lergigan, 
and Sominex) is a typical antipsychotic. Promethazine is a phenothiazine derivative and a 
H1 receptor antagonist that since 1950 has been used as an antihistamine (allergic 
reactions & common cold), sedative and occasionally for insomnia. Promethazine is also 
used to prevent and treat motion sickness, nausea and vomiting or pain after surgery.  It is 
available over the counter in many other countries and is not used as an antipsychotic 
having only a tenth of the antipsychotic strength of chlorpromazine. Adverse reactions to 
promethazine are similar to related antipsychotics however an overdose of promethazine 
can cause coma, convulsions, circulatory failure and respiratory depression which has 
caused death in a child younger than 2 (Promethazine package insert). 
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1.2.14 Quetiapine 
 
Quetiapine (Brand names: Seroquel, Ketipinor), is an atypical antipsychotic and a 
dibenzothiazepine derivative developed in 1993 and FDA approved in 1997 for the 
treatment of schizophrenia, and mania-associated bipolar disorder. Quetiapine is 
structurally similar to clozapine, and is classified as a benzodiazepine but unlike 
clozapine it exhibits lesser affinity for dopaminergic, adrenergic and histamine receptors. 
Quetiapine has been used off-label to treat obsessive-compulsive disorder, post-traumatic 
stress disorder, autism, alcoholism [33], Borderline Personality Disorder [34], Tourette 
syndrome, [35] and for sleep disorders or anxiety disorders [36] [37]. Acute overdoses 
have resulted in sedation, hypotension and tachycardia (Seroquel package insert, 1997), 
but coma and death have occurred in adults [17]. 
 
1.2.15 Risperidone 
 
Risperidone (Brand names: Risperdal) is an atypical antipsychotic approved by 
the United States Food and Drug Administration (FDA) in 1993 for the treatment of 
schizophrenia, schizoaffective disorder, the mixed/manic states associated with bipolar 
disorder (2003), and irritability in children and adolescents with autism (2006). In 2007, 
risperidone was approved for treatment of schizophrenia in youths ages 13–17 and for 
treatment of bipolar disorder in youths and children ages 10–17.  Risperidone has many 
off-label uses such as for the treatment of various anxiety disorders, treatment-resistant 
depression, Tourette syndrome, disruptive behavior disorders in children, and eating 
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disorders [38]. Acute overdose may cause tachycardia, hypotension, akathisia, dystonia 
seizures and death.  
 
1.2.16 Thioridazine 
 
Thioridazine (Melleril, Mellaril, Novoridazine, Thioril) is a typical antipsychotic 
belonging to the phenothiazine drug group, synthesized in 1958 and made clinically 
available in 1959 for the treatment of schizophrenia, schizoaffective disorder, and short-
term treatment of severe behavioral problems in children. Off-label thioridazine may be 
prescribed to treat acute mania, psychotic depression, and severe psychotic depression. 
Thioridazine, has been associated with Torsades de pointes type arrhythmias and sudden 
death, as a result it is reserved for use in patients who failed to respond to, or have 
intolerable adverse effects for more widely used antipsychotics. Patients receiving 
therapeutic doses have died from adverse effects (neuroleptic malignant, ventricular 
arrhythmias, agranulocytosis) and overdoses are common, with many of these episodes 
being fatal. 
 
1.2.17 Thiothixene 
 
Thiothixene (Navane) is a typical antipsychotic drug of the thioxanthene class that 
was synthesized in 1964 and made available the treatment of psychoses like 
schizophrenia in 1965. Thiothixene is not for use in psychotic conditions related to 
dementia because it may cause heart failure, sudden death, or pneumonia in older adults 
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with dementia-related conditions however off-label uses have included psychotic 
depression, agitation, and dementia. Overdose symptoms may include drowsiness, 
dizziness, extrapyramidal symptoms, tachycardia, hypotension, tardive dyskinesia, blood 
dyscrasias, and death [17]. 
 
1.2.18 Trifluoperazine 
 
Trifluoperazine (Eskazinyl, Eskazine, Jatroneural, Modalina, Stelazine, 
Terfluzine, Trifluoperaz, Triftazin) is an atypical antipsychotic of the phenothiazine 
chemical class. Trifluoperazine was approved by the U.S. Food and Drug Administration 
for treatment of psychotic disorders, including schizophrenia, schizoaffective disorder, 
and drug-induced psychosis. It may also be used for short-term treatment of severe 
anxiety, agitation, violent or dangerous behavioral problems, and to treat severe nausea 
and vomiting. Off-label trifluoperazine may be prescribed with a mood stabilizer to treat 
acute mania, since the mood stabilizer has a slower onset of action. It has declined in use 
because of the high frequency of severe tardive dyskinesia. Overdoses with 
trifluoperazine can cause sedation, agitation, convulsions, fever, coma, hypotension 
cardiac arrest, and death. 
 
1.2.19 Ziprasidone 
 
Ziprasidone (marketed as Geodon, Zeldox by Pfizer) is an atypical antipsychotic that is a 
dopamine antagonist, chemically related to risperidone. It gained FDA approval in 2001 
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for the treatment of schizophrenia, mania and mixed states associated with bipolar 
disorder, and the intramuscular injection form was approved for acute agitation in 
schizophrenic patients. In 2009, the pharmaceutical company Pfizer pled guilty to 
illegally marketing ziprasidone (Geodon) as an effective treatment of conditions such as 
depression, bipolar maintenance, mood disorder, anxiety, dementia, and obsessive 
compulsive disorder. Pfizer sales representatives sent out unsolicited details to doctors 
explaining off-label uses and dosages not approved by the FDA because they were 
considered unsafe. (Pfizer paid $2.3 billion in the settlement) [37]. Adverse reactions to 
ziprasidone have included headache, sedation and postural hypotension; however, in 
older adults with dementia-related conditions, it may cause heart failure, sudden death, or 
pneumonia. 
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Table 3: TIAFT reference blood level list of therapeutic 
and toxic substances. 
 
 
 
 
 
"TIAFT reference blood level list of therapeutic and toxic substances” September 2004 
Therapeutic levels are the steady state concentrations that need to be reached for the drug to exert a 
significant clinical benefit without causing unacceptable side effects. 
Toxic levels are serum concentrations above which unacceptable, concentration dependent, side- or 
toxic effects might appear. 
Substance (Mol. weight) - Matrix - [Ref. Concentration Therapeutic mg/L (T=trough; P=peak)] - [Ref. 
Concentration Toxic mg/L (T=trough; L=lethal)]; 
[(10)20-40(50)]: means: normally between 20-40 mg/L, but some authors or clinicians are using ranges 
between 10 and 50 mg/L. * case report Bold = changed after April 2005 
• Buspirone (385.5) - Serum - [0.0009-0.005(0.01)] - [-] 
• Chlorpromazine (318.9) - Serum - [0.03-0.5; child 0.04-0.1] - [0.5-2; L2] 
• Clozapine (326.8) - Serum - [0.1-0.6(0.8)] - [( seizures >0.5); 0.8-1.3; L 3] 
• Fluphenazine (437.5) - Serum - [(0.0002-)0.001-0.017] - [0.05-0.1] 
• Haloperidol (375.9) - Serum - [0.005- 0.015 (0.04)] - [(side effect 0.01);0.05-0.1; L 0.5] 
• Loxapine (327.8) - Serum - [0.01-0.03(-0.1)] - [1; L7.7] 
• Olanzapine (312.4) - Serum - [0.01-0.05(0.1)] - [0.2; L 1*] 
• Perphenazine (404.0) - Serum - [0.0004-0.03] - [0.05-0.1] 
• Pipamperone (375.5) - Serum - [0.1-0.4] - [0.5-0.6] 
• Promethazine (284.4) - Serum - [(0.05)0.1-0.4] - [1; L 2.4*] 
• Quetiapine (383.5) - Serum - [T (0.025)0.075-0.17; P 0.14-0.365] - [1.8*; L 7-] 
• Risperidon (410.5) - Serum - [(0.004)0.01-0.03 (0.09)] - [L 1.8*] 
• 9-hydroxyrisperidon (426.5) - Serum - [sum 0.015-0.06] - [0.08] 
• Thioridazine (370.6) - Serum - [0.2-1] - [2(5); L 3-10] 
• mesoridazine (386.6) - Serum - [0.3(0.2-1.6)] - [-] 
• Trifluoperazine (407.5) - Serum - [(0.001-)0.005-0.05] - [0.1-0.2] 
• Ziprasidone (412.9) - Plasma - [0.02-0.06] - [-] 
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1.3 Solid Phase Extraction (SPE) 
 
When analyzing compounds in blood, urine or other mediums, it is important to 
recognize the effects of the matrix of that medium. These are called matrix effects and are 
the combined effects of all components in the sample other than the analyte which causes 
interference in the measurement of the quantity. When analyzing compounds with 
methods such as LC-MS(MS), especially employing electrospray ionization, ion 
enhancement or suppression can cause variability in results [40] [41] [42] [43]. 
Removing the various constituents of the matrix would reduce matrix effects, thus 
diminishing its impact on the measurements of the analysis and improving the results 
[44] [45]. This can be achieved by sample preparation with liquid–liquid extraction 
(LLE) or solid-phase extraction (SPE) both of which can help isolate specific 
compounds, remove interfering matrix components, and produce a sample that is 
concentrated enough for detection. When considering the analytes of this study LLE and 
SPE have shown similar results but SPE (Figure 6) has produced slightly better 
recoveries and was selected for use [46] [41] [47] [48]. SPE also offers the benefit of 
complete phase separations translating to cleaner extracts, a reduction in the use of 
organic solvents, less time and labor intensive, and easier to automate. Three basic types 
of SPE are normal phase, reversed phase, and ion exchange. 
 
Normal phase uses a nonpolar liquid phase (mobile phase) and a polar modified 
solid phase (stationary phase) and relies on hydrophilic interactions (hydrogen bonding, 
polar-polar, pi-pi, dipole-dipole, and dipole-induced dipole interactions). This method 
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involves a polar analyte of interest and a mid- to nonpolar sample matrix. The analytes of 
interest are eluted by employing a polar solvent to disrupt the binding forces between the 
compound and the sorbent (stationary phase) [12].  
 
Reversed phase uses a polar liquid phase (mobile phase) and a nonpolar modified 
solid phase (stationary phase) and relies on hydrophobic interactions (nonpolar-nonpolar 
and van der Waals forces). This method involves a mid- to nonpolar analyte of interest 
and a polar or slightly polar sample matrix. The analytes of interest are eluted by 
employing a nonpolar solvent to disrupt the binding forces between the compound and 
the sorbent [13].  
 
Ion Exchange uses a charged group on the stationary phase’s surface and relies on 
electrostatic attraction to retain compounds that are charged when in a solution. The 
choice of bonded silica cartridges is dependent on the charge of the compounds (anionic 
or cationic). Ion exchange SPE procedures depend heavily on the pH of the sample and 
conditioning solutions, so for retention of the analyte, the pH of the sample must be one 
at which the analyte and the functional groups on the silica surface (sorbent) are charged 
oppositely. The analytes of interest can be eluted by disrupting the electrostatic bond with 
a solution having a pH that neutralizes either the compound or sorbent’s functional group. 
This can also be done with a solution containing an ionic species that displaces the 
analyte.  
 
 
 Figure 2: 
 
 
 
The antipsychotics
would be the preferred method of SPE and more specifically cation e
anion exchange) which 
recovery of weak cations is
aliphatic sulfonic acid groups (pKa <1) are used. These groups are bonded to the surface 
and are charged over the whole pH range, isolating strong or weak cationic compounds 
Components of Solid Phase Extraction (SPE) 
 used in the study are basic compounds, therefore Ion exchange 
xchange
retain positively charged cations, such as bases. When 
 required, cation exchange sorbents containing silica with 
26 
 
 (oppose to 
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charged in solution of the correct pH range (matrix must be 2 pH units below its pKa). 
Weak cations can be isolated and eluted with a solution at 2 pH units above the cation’s 
pKa (neutralizing the analyte), or by adding a different cation that displaces the analyte. 
Recoveries of strongly cationic species require cation exchange sorbents containing silica 
with aliphatic carboxylic acids (pKa 4.8). These groups are bonded to the surface and are 
charged in solutions of at least 2 pH units above the pKa and will isolate charged cations. 
Analytes can be recovered for both strong and weak cations by neutralizing carboxylic 
acid functional groups (2 pH units below its pKa) or employing different cations that 
displaces the analyte [14]. 
 
Once the appropriate column, pretreatments, solvents, and pH are determined the 
solid phase extraction can be performed. Ion exchange SPE procedures may require that 
pretreatment of the sample is done to ensure proper pH and increase SPE recoveries. The 
SPE tube packing may require conditioning to charge the functional groups of the 
stationary phase. The sample is then transferred to the SPE tubes where the solution 
passes through the packing while the analyte, of interest is retained on the packing. Then 
the solution that was used in the sample or one that will not remove the retained analytes 
is added to the SPE tube to wash off unwanted and unretained materials. To elute the 
analyte the sorbent bed is rinsed with a solution that will remove the analytes of interest 
leaving any additional impurities behind. 
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1.4 Liquid Chromatography Tandem Mass Spectrometry 
 
Liquid Chromatography Tandem Mass Spectrometry has a wide range of 
functions and uses; however this discussion will be primarily limited to their capabilities, 
uses and applications as performed in this study. High performance liquid 
chromatography coupled with tandem mass spectrometry is being more commonly used 
for the detection of antipsychotic drugs in many biological mediums [46] [50] [53] [54] 
[55] [56] [57] [58] [59]. In forensic toxicology, there is a need for the detection of low-
dose antipsychotic drugs in postmortem blood which requires a high degree of sensitivity 
and selectivity. Other methods such as GC-MS and gas chromatography coupled with 
nitrogen phosphorous detection (GC-NPD), require thermal stability of the drugs and 
demonstrate inferior sensitivity and selectivity [60]. Liquid chromatography systems 
coupled with other detection methods such as UV detection (HPLC-UV) have also 
yielded inferior sensitivity and selectivity [61] [60]. LC–MS(MS) provides the superior 
sensitivity and selectivity required for the detection of low-dose antipsychotics in 
postmortem blood and is the best choice for this type of analysis [50] [62] [63] [55].  
 
1.4.1 High Performance/Pressure Liquid Chromatography (HPLC) 
 
In the early 1900s, Russian botanist, Mikhail S. Tswett separated compounds (leaf 
pigments), extracted from plants using a solvent, and a column packed with particles. He 
filled an open glass column with specific types of particles and poured his solvent extract 
of plant leaves into the column followed by pure solvent. As the sample passed down 
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through the column by gravity, different colored bands could be seen separating because 
some components were moving faster than others. The compounds that were more 
strongly attracted to the particles slowed down, while other compounds more strongly 
attracted to the solvent moved faster. To describe his colorful experiment Tswett coined 
the name chromatography or liquid/column chromatography. The acronym HPLC was 
coined by a chemical engineer and physical chemist named Csaba Horváth in 1970, for 
his work in liquid chromatography where a pump (rather than gravity) provides the 
higher pressure required to move the mobile phase and analyte through the densely 
packed column. With the advances in performance such as smaller particles and higher 
pressures, the acronym was changed to high performance liquid chromatography.  
 
Liquid chromatography separation occurs based on the interactions of the sample 
with the mobile and stationary phases and many stationary/mobile phase combinations 
can be used to separating a mixture. There are four basic types of chromatography in 
which the mobile phase is a liquid: adsorption chromatography (liquid-solid); ion-
exchange chromatography, size exclusion chromatography (gel), and partition 
chromatography. 
 
Adsorption, or liquid-solid, chromatography was discussed at the beginning of 
this section because it was what Tswett discovered. It utilizes a mobile liquid or gaseous 
phase that is adsorbed onto the surface of a stationary solid phase of silica or alumina. 
Their adsorption characteristics are similar, however, alumina offers the advantages of 
higher sample capacity and its wider range of useful forms [27]. The choice of the mobile 
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phase composition is very important since it is the only variable able to be optimized and 
the equilibration between the mobile and stationary phase will determine the separation 
characteristics of different analytes. Absorption would not be useful when considering the 
number of analytes, the small amount, and possible pH restrictions. However, the sample 
collection and analysis alone make this method a nonviable option. 
 
Ion-exchange chromatography (IC), separates analytes based on their respective 
charges by employing a charged stationary phase to separate charged compounds. In 
conventional methods, HPLC columns packed with anion-exchange or cation-exchange 
resins carry charged functional groups which interact with oppositely charged groups of 
the compound to be retained. This method would not be useful in this study because the 
analytes are not ionic species. 
 
Size-exclusion chromatography SEC (gel permeation - organic solvent used, gel 
filtration - aqueous solution used) is primarily used with high-molecular-weight species, 
separating molecules according to their size (hydrodynamic volume). Packings for size-
exclusion chromatography consist of silica or polymer particles containing uniform pores 
into which solute and solvent molecules can diffuse. Molecules that are larger than the 
average pore size of the packing are not retained (excluded) and elute first. Molecules 
with diameters smaller than the pores can enter the pores and depending on how small 
they are, can spend more time navigating through the maze of pores and are last to be 
eluted. This method is not appropriate for this study due to it requirement of a least a 10% 
difference in molecular weight for reasonable resolution in addition to the restriction on 
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the number of analytes because of the short time scale [27].  
 
Partition chromatography is the most widely used of all of the four types of liquid 
chromatographic procedures and is the type used in this study. Within partition 
chromatography, there is liquid-liquid and bonded-phase chromatography where 
molecules equilibrate (partition) between a liquid stationary phase and the mobile phase. 
In liquid-liquid, the stationary phase is held on the surface of the packing by physical 
adsorption. However, this suffers from disadvantages such as loss of stationary phase by 
dissolution in the mobile phases, which further prohibits the use of liquid-phase packings 
for gradient elution due to solubility issues. Bonded-phase is primarily used where the 
stationary phase is chemically bonded to the support surfaces. There are two types of 
partition chromatography distinguished based upon the relative polarities of the mobile 
and stationary phases which are normal-phase and reversed-phase chromatography.  
 
The term “normal” in Normal-phase HPLC came from the fact that in the 1970s 
most liquid chromatography was done in this way with non-bonded silica or alumina with 
its stronger affinity for polar compounds was useful in separating species based on 
polarity. Normal-phase HPLC (NP-HPLC), or adsorption chromatography uses a polar 
stationary phase and a non-polar, non-aqueous mobile phase to separate analytes that are 
soluble in non-polar solvents retaining more polar analytes by the polar stationary phase. 
The strength with which analytes are retained depends on their polarity, steric effects, the 
polar stationary phase, and the degree of polar solvents in the mobile phase. Therefore, in 
non-polar solvents, the least polar analytes are more soluble so they have a lower 
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retention time and are eluted first. By increasing the polarity of the mobile phase, the 
least polar analytes are less soluble and polar solvents tend to deactivate the polar 
stationary phase so they have a higher retention times, decreasing the elution time. The 
problems with normal-phase chromatography are retention times may be variable and 
gradient elution can be difficult because of water adsorption by the commonly used silica 
columns. The problems with alumina are it has a low theoretical plate number (N), 
variable retention times, and low sample recovery [27] [63].   
 
Most high performance liquid chromatography is currently performed on columns 
with reversed-phase packings. Reversed phase HPLC (RP-HPLC or RPC) has a bonded 
non-polar stationary phase and an aqueous, relatively polar mobile phase. Alkyl chains 
are bonded covalently to the support surface to reverse the elution order so polar 
compounds are eluted first hence the term ‘reverse”. Mobile phases usually consist of a 
mixture of water or aqueous buffers and various concentrations of organic solvents 
miscible in water such as methanol, acetonitrile or tetrahydrofuran (THF). The addition 
of organic solvents to water or aqueous buffers can change retention times by making the 
mobile phase more hydrophobic, decreasing the affinity of the hydrophobic analytes to 
the hydrophobic stationary phase (de-sorption). Reversed-phase chromatography works 
primarily by hydrophobic forces which result from the polarity of water and the 
subsequent affinity of the hydrophobic surfaces of the analyte to the hydrophobic 
stationary phase. There are a few primary factors driving the separation and affecting the 
analyte retention characteristics. The primary factors driving the separation and affect the 
analyte retention characteristics are: the structural properties of the analyte such as its 
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hydrophobic surface area and polar groups; longer hydrophobic chains in packings which 
are more retentive towards hydrophobic analytes; and, the addition of mobile phase 
modifiers, pH and manipulating the concentrations of water and organic solvent (gradient 
elution).  Buffers serve multiple purposes in the mobile phase by controlling pH, 
neutralizing any charges on exposed silica in the stationary phase and acting as ion 
pairing agents to neutralize charges on the analyte. The mobile phase (A) is generally 
prepared with strong acid. This low pH environment suppresses the ionization of the 
acidic groups in the analyte molecules and, therefore, changes their retention 
characteristics. Silanol groups on the surface of silica-based media, which will be 
discussed in the section on the columns, can arise from inadequate end-capping and 
column aging. This can cause a negative effect called mixed mode retention which can be 
eliminated by creating low pH environment causing suppression of the ionizable silanol 
groups. Acids such as acetic acid or formic acid are used to improve the chromatographic 
peak shape and to provide a source of protons, if mass spectrometry is used to analyze the 
column effluent. Ammonium formate can be used as a buffer and is commonly added in 
mass spectrometry to improve detection of certain analytes by the formation of 
ammonium adducts. Elution can be performed isocratic where the mobile phase 
composition remains constant throughout the separation process or by using a gradient, 
where the mobile phase composition is changed during the separation process. Gradient 
elution tends to be the method of choice because separation efficiency is greatly 
enhanced. Gradient elution proceeds from a condition of high polarity to low polarity so 
the concentration of organic solvent is lower in the initial mobile phase (A) than it is in 
the final mobile phase (B). Mobile phase (A) often water or an aqueous buffer and mobile 
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phase (B) an organic solvent, are varied continuously or in a series of steps to form the 
gradient slope which are combinations of a linear gradient and isocratic conditions. 
Gradient elution decreases the retention of the later-eluting components, improves tailing 
and produces narrower taller peaks for many analytes. In general, decreasing gradient 
slope increases resolution, however, peak volume and retention time increase with 
decreasing gradient slope so the gradient shape should be adjusted to optimize the 
separation of the desired components. 
 
 
 
 
Figure 3: HPLC Column showing solid phase and surface 
chemistry (Phenomenex) 
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When determining a column for reversed-phase chromatography the important 
characteristics to evaluate are chemical composition of the packing, pore and particle size 
of the beads, the type and density of ligand bond to the surface of the bead, and the 
capping chemistry. The base packing media used is normally silica produced as porous 
beads which are chemically stable at low pH (dissolve at high pH) and in the organic 
solvents. The chemistry of the silica gel allows simple derivatization with ligands of 
various carbon chain lengths and it is these alkyl groups that are predominantly 
responsible for its analyte retention properties (Figure 3). Many columns are composed of 
siloxanes bonded to an octadecyl carbon chain (C18) although there are others carbon 
chains such as C8 and phenyl bonded silica (Figure 4).  
 
 
 
(a)  
 
(b)  
 
Figure 4: Carbon chains that are bonded to the siloxanes of 
the solid phase, (a) octal carbon chain (C8) (b) octadecyl 
carbon chain (C18) 
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However, due to steric hindrance, not all silanol is treated and a secondary 
bonding step to cover unreacted silanols on the silica surface is needed.  These untreated 
or unreacted silanols cause undesirable polarity to the surface called mixed mode 
retention. Mixed-mode retention causes skewed and broader peaks, and retention times 
increase by ion exchange interaction. End-capping is a process which unreacted silanols 
are treated with short-chain organosilanes (Figure 5) (Figure 6).  
 
 
 
 
Figure 5: End-capping: The bonding process of the carbon 
chain to the unreacted silanols of the solid phase 
 
 
 
The choice of the alkylsilane reagent to treat these sites will change the selectivity 
of the column allowing for variation among packaging with the same alkyl groups. So 
although it is not possible to predict which ligand will be best for a particular application 
there are varying degrees of selectivity that can be achieved through different C18 
columns alone. When examining column size it can be said that for the same packing 
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material, shorter columns would provide faster run times, while longer columns provide 
better resolution.  
 
 
 
 
Figure 6: Solid phase with an unreacted silanol, C18, and 
C8 group attached 
 
 
 
There are many factors to consider such as the characteristics of the packing 
material, and the relationship between column length, diameter and volume. The 
resolution of high molecular weight biomolecules in reversed phase separations is less 
sensitive to column length than is the resolution of small organic molecules. However, 
the use of gradient elution reduces the significance of column length with regard to 
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resolution although longer columns with small diameters often provide increased 
resolution, they will have lower sample loading capacity and higher back-pressures 
requiring modifications of other HPLC parameters. HPLC prefilter cartridge systems can 
be employed to protect the HPLC columns from contaminants, and chemical damage 
without altering your chromatographic results (Figure 7).   
 
 
 
  
Figure 7: HPLC prefilter that is attached to the front end of 
the column (Phenomenex) 
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Other parameters to consider in reversed phase chromatography are flow rate, 
temperature, and mobile phase. Flow rate is not as critical during analytical experiments 
as large scale preparative reversed phase chromatography. However other factors such as 
column size, stationary phase particles size and temperature affect the flow rate. 
Increasing flow rate can impact analysis time, quality of the chromatography, and exceed 
pressure limitations of the system. The viscosity of the mobile phase decreases with 
increasing column temperature. Decreasing solvent viscosity has the effect of reducing 
pressure when high pressures become a concern. Further, mass transfer between the 
mobile and stationary phase becomes more efficient leading to higher resolution. 
 
HPLC is equipped with one or more glass or stainless steel reservoirs that hold the 
solvents. The reservoirs are equipped with degassers to remove dissolved gases that 
would form bubbles in the column and the detector systems and cause band spreading 
and interfere with the detector. Proportioning valves select solvents and change the 
amounts of the mobile phase over time in gradient elutions. The solvent delivery system 
is a high-pressure pump used to produce a specified flow rate of mobile phase and it is 
necessary to pump the eluent at a constant flow rate and pressure. An autosampler is 
equipped with six-port valves; so that a sample can be injected into the flowing mobile 
phase stream at continuous pressure into the HPLC column flowed by the detector 
(Figure 8).  
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Figure 8: HPLC block diagram 
 
 
 
1.4.2 Electrospray Ionization Tandem Mass Spectrometry 
 
Ionization is required in mass spectrometry because only ions can be accurately 
measured and electrospray ionization is useful because molecules being ionized are not 
broken apart, providing a known ion mass to use to determine the chemical composition 
(soft ionization). It forms ions of multiple charges making their mass-to-charge ratio 
small enough to be detectable, especially in the analysis of large molecules such as 
proteins. Atmospheric pressure ionization (API) or in particular electrospray ionization 
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(ESI) is a technique used in mass spectrometry to produce ions and is ideal for LCMS 
systems because analysis can be performed with direct sample introduction from the 
HPLC column directly to electrospray ionization source. A liquid containing the 
analyte(s) of interest is pumped through a stainless steel capillary needle and a very high 
voltage is applied to the sharply pointed tip. The needle electrically charges the liquid to a 
very high voltage creating highly charged molecules all with the same charge. This 
causes the liquid to blow apart into fine aerosol of tiny, highly charged droplets 
sometimes with additional nebulization by an inert gas such as nitrogen. Under a field 
and pressure gradient, the droplets move through the interface where it is heated and 
nitrogen gas pumped to aid further solvent evaporation. As the solvent evaporates from 
the charged droplets, they decreases in size, and become unstable. When the electrical 
charge reaches a critical state, its Rayleigh limit, the droplet violently blows apart 
(Coulomb force). This continues until the solvent is completely evaporated and the 
droplets have split up to the point that each is a single, charged molecule (Figure 9).  
 
Modifying the mobile phase can also help to change the types of ions produced. 
Both positive (addition of a proton [M + H] +) and negative-ion (removal of a proton, [M 
− H]-) spectra can be obtained by adding an acid or base to the mobile phase. Adding 
formic acid or acetic acid will promote protonation in the positive-ion mode and NH4OH 
for deprotonation in the negative-ion mode. Also adding compounds such as acetic acid 
have the benefit of increasing the conductivity and decreasing the initial droplet size.  
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To achieve optimum ion production the ion source parameters; ionspray voltage 
(IS), ion source gas 1 (GS1), ion source gas 2 (GS2), temperature (TEM), and curtain gas 
(CUR) should be optimized (Figure 9). IonSpray Voltage (IS) is the voltage applied 
between the needle and orifice plate that “ionizes” and nebulizes the liquid containing the 
analyte(s) of interest. The polarity of the applied voltage determines what type of ions 
will be produced (positive or negative ions). Ion Source Gas 1 (GS1) controls the flow of 
the nebulizer gas that facilitates droplet formation and is optimized based upon the flow 
rate of the liquid. Temperature (TEM) is the temperature of the heater that heats the gas 
(GS2) to promote desolvation of the liquid and is optimized based on flow rate and 
mobile phase composition.  Ion source gas 2 (GS2), increases ion efficiency with heated 
gas that intersects nebulized liquid stream at about 90° right in front of the curtain plate 
to aid in solvent evaporation. This parameter is also optimized based on flow rate. 
Curtain gas (CUR) is composed of high purity nitrogen that flows between the orifice and 
the curtain plate to prevent large droplets and neutral compounds from entering Q0. This 
is normally set to the highest setting before loss of the signal is seen (loss of analyte). 
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Figure 9: Electrospray Ionization (ESI) Process (AB 
Sciex) 
 
 
 
A Quadrupole is a mass analyzer that uses an electric field to separate ions. A 
quadrupole consists of four parallel cylindrical metal rods with adjacent rod pairs 
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connected together electrically with opposite voltage polarity.  One pair is attached to the 
positive side of a variable DC source and the other pair to the negative terminal both 
superimposed on a variable radio frequency (RF) voltage 180-deg out of phase between 
adjacent rod pairs (Figure 10).  
 
 
 
Figure 10: Quadrupoles with DC and RF voltages of the 
mass spectrometer (AB Sciex) 
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The voltage and radio frequency on the quadrupole, causes the ions to oscillate, 
orbit, and/or accelerated down the quadrupoles between the rods according to their mass-
to-charge ratio m/z. Ions not in the range of the selected mass-to-change ratio will strike 
the rods and are converted to neutral molecules, while ions with a particular mass-to-
charge ratio selected by the operator continue towards the detector. Quadrupole 
instruments can resolve ions that differ in mass by one unit and have greatly improved 
resolution and peak shape in recent decades. 
 
A linear series of three consecutive quadrupoles is known as a triple quadrupole 
mass spectrometer or tandem mass spectrometer. The first quadrupole (Q1) serves as 
mass filter which is set across a preset m/z range and select an ion of a known mass to 
send to the second quadrupole.  The second quadrupole (q2) is RF-only (non-mass 
filtering) and acts as a collision cell where the selected ions are broken into fragments 
introducing an inert collision gas into its flight path such as nitrogen. The fragments are 
then passed through the third quadrupoles (Q3) which like Q1 serves as mass filter, 
where they may be filtered or fully scanned for a tandem MS fragmentation pattern. 
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Figure 11: Full scan mode to determine precursor ions within a selected range 
 
 
 
In a triple quadrupole mass spectrometer, there are several types of scan modes 
that are possible. A single scan where ion sources can be passed through the quadrupoles 
without collision to the detector can yield molecular weight information (Figure 11). 
There are four main scan modes that can be performed. In a product ion scan, product 
ions are formed by collisions of the precursor ions and give qualitative structural 
information. In a product ion scan, the first quadrupole (Q1) selects an ion of a known 
m/z and it is passed into Q2 were fragments are formed by collisions. The third 
quadrupole (Q3) scans the entire m/z giving a MS/MS spectrum for information on the 
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sizes of the fragments. From this information, the structure of the original ion can be 
determined and it also can serve as a qualifier, therefore, so even if two precursor ions 
have the same m/z they can be differentiated by their product ions. 
 
 
 
 
 
Figure 12: Steps of the Product Ion Scan in the triple 
quadrupole mass spectrometer (AB Sciex) 
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A precursor ion scan provides structural information on the source of a specific 
product ion by choosing a product ion and determining the precursor ions. In this scan 
type, Q1 is scanned across an m/z range of precursor ions and the ions are fragmented in 
the Q2 to produce the product ions. Q3 is set to transmit only ions of a known m/z. 
Therefore, all precursor ions that are passed through Q1 and fragment to produce ions 
with the selected m/z are detected (Figure 13). 
 
 
 
 
Figure 13: Steps of the Precursor Ion Scan in the triple 
quadrupole mass spectrometer (AB Sciex) 
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Neutral loss scans provide compound class specificity by screening for ions that 
undergo a common loss. In a neutral loss scan Q1 is scanned across a mass range of 
precursor ions, and the ions are fragmented in Q2 to produce the product ions as with the 
precursor ion scan. However Q3 selects ions of a specific m/z off set by the loss of a 
selected neutral fragment mass, allowing selective identification in a class of closely 
related compounds (Figure 14).  
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Figure 14: Steps of the Neutral Loss Scan in the triple 
quadrupole mass spectrometer (AB Sciex) 
 
 
 
Multiple Reaction Monitoring (MRM) or Single Reaction Monitoring (SRM) is 
used for quantitation where only the ions of interest are monitored resulting in a very 
sensitive scan. . Both Q1 and Q3 are set to a selected m/z so the scans are focused on the 
precursor and product ions, increasing sensitivity. In this mode the Q1 selects an ion 
(SRM) or ions (MRM) of a known m/z and they are passed into Q2 where fragments are 
formed by collisions. Q3 is set to transmit only selected ions of a known m/z. Ions 
selected by the first mass analyzer are only detected if they produce the selected 
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fragments in Q3 (Figure 15).   
 
 
 
 
Figure 15: Steps of the Multiple Reaction Monitoring 
(MRM) Scan in the triple quadrupole mass spectrometer 
(AB Sciex) 
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Once the analytes are introduced in the mass analyzer, compound optimization 
parameters have to be adjusted to achieve the optimum selectivity and sensitivity. 
Declustering Potential [DP] is the potential applied to the orifice plate (OR) that breaks 
clusters such as [M+H3O] +, [M+Na] + in the orifice region of the interface. DP is 
typically set to a value between 0 to 100 V, however if it is set to high it can fragment the 
compound of interest. Entrance Potential [EP] guides and focuses the ions through the 
high-pressure Q0 region and is typically set at 10 V in positive ion mode. Collision Cell 
Entrance Potential [CEP] is generally the most mass dependent parameter and controls 
the potential difference between Q0 and IQ2 focusing ions into Q2 (collision cell). 
Collision Energy [CE] is a voltage difference between the Q0 and Q2 and controls the 
energy of the collision of precursor ion with low pressure N2 in the collision cell. The 
larger the energy, the greater the fragmentation, dictating the nature and abundance of the 
product ions produced. The Collision Energy can be optimized for each analyte and 
produce the maximum amount of the selected product ion. Collision Cell Exit Potential 
[CXP] is the potential difference between Q2 and IQ3 focusing ions into Q3 (Figure 16). 
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Figure 16: Zones of the triple quadrupole mass spectrometer 
showing the area the various energies and potentials are active 
(AB Sciex) 
 
 
 
 
1.5 Method Development and Validation 
 
Method Development and Method Validation in analytical toxicology are 
extremely important in forensic and clinical toxicology as well as quality assurance, 
accreditation, and publication. Well-characterized and fully validated analytical data are 
necessary for generating reproducible and reliable results that can be correctly interpreted 
and which objectively demonstrate their applicability for the intended use. Analytical 
data of toxicological findings in forensics must withstand the scrutiny of court to avoid 
being contested and could lead to unjustified legal consequences. Proper method 
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development and validation are imperative for an analytical method to be used in forensic 
or clinical toxicology. Method development is much more important to ensure the quality 
of an analytical method; however validation can objectively demonstrate this quality by 
fulfilling acceptance criteria. Method development is as the name implies the 
development of a method. Therefore, in chromatography it is the setting up of an 
analytical procedure appropriate for the analysis of a particular sample. This includes 
much of what is discussed in this study such as the choice of the purification and 
separation techniques, (i.e.; LLE or SPE and GC or LC), stationary/mobile phase, type of 
detector, internal standards, gradient elution, temperature programming, detector 
sensitivity etc... Some of these choices are determine based on current scientific analyses, 
what resources the lab already has and what can be obtained. 
 
Bioanalytical method validations demonstrate that, given a biological matrix such 
as blood, plasma, serum, or urine, a particular method for quantitation is reliable and 
reproducible for the intended analytical applications. Typical parameters for this type of 
validation include: accuracy, precision, selectivity, sensitivity, reproducibility, and 
stability which can be determined through different tests. 
 
Selectivity is the ability of a method to determine and/or quantitate target analytes 
in the presence of other compounds and components endogenous to the matrix without 
interference. Selectivity is usually concentration dependent and is determined by 
comparing blank samples without analytes or intended Internal Standard (IS)) of biologic 
matrices to determine if any potentially interfering substances are present. When 
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employing deuterated internal standards it is also necessary to compare samples of the 
biologic matrix with IS only, and with analytes only, to check for the absence of analyte 
fragmentation ions in the IS peak or vice versa. 
 
Linearity or calibration model is a measure of the ability of the method to provide 
data proportional to the concentration of analytes within samples within a given range. 
This is done by the analysis of multiple replicates at different levels to identify outliers or 
variations across the calibration range. Accuracy (bias) and precision analysis of the data 
is also examined among the replicates relative to calibration range and the data is 
evaluated to determine if it fits a linear or non-linear model. 
 
In this study the limit of detection (LOD), lower limit of quantitation (LLOQ) and 
the upper limit of linearity (ULOL) are defined as the lowest and highest calibrator used 
in the assay. The successful validation of these parameters is dependent on the success of 
the calibration model. 
 
Accuracy (bias) is how close the measured analyte concentration of an assay 
matches the "true" concentration present in the sample and precision is the variability of 
the measurement about a mean. Accuracy (bias) and precision of the method is 
determined by analysis of replicates of the calibration range within and between days. 
 
In recovery and matrix effect, analyte recovery is measured by comparing the data 
obtained from a known amount of analyte added to the matrix prior to extraction 
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compared with the data obtained from the same amount of analyte added to the matrix 
after the extraction. This technique attempts to produce the same matrix effects in both 
samples, eliminating it as a variable leaving only the change in recoveries. Matrix effect 
is measured by comparing the data obtained from a known amount of non-extracted 
analyte to the same amount of analyte added to the matrix after the extraction. This 
technique attempts to produce the same recovery in both samples, eliminating it as a 
variable leaving only the change caused by matrix effects.  
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CHAPTER TWO: Experimental Section 
2.1 Materials and Methods 
 
2.1.1 Chemicals and Reagents 
 
9-Hyroxyrisperidone, Aripiprazole, Aripiprazole-D8, Chlorpromazine, 
Chlorpromazine-D3, Clozapine, Clozapine-D4, Fluphenazine, Haloperidol, Haloperidol-
D4, Olanzapine, Promethazine, Quetiapine, Quetiapine-D8, Risperidone, Thioridazine, 
and Ziprasidone were purchased from Cerilliant (Round Rock, TX. USA) 9-
Hyroxyrisperidone-D4, Buspirone-D8, Fluphenazine-D8, Loxapine-D8, Olanzapine-D3, 
Pipamperone, Pipamperone-D10, Perphenazine-D8, Promethazine-D6, Risperidone-D4, 
Thioridazine-D3, Trifluoperazine-D3, and Ziprasidone-D8 were purchased from Toronto 
Research Chemicals Inc. (North York, ON. Canada). Buspirone and Mesoridazine were 
purchased from W. R. Grace and Company, formerly Alltech (Cambridge, MA. USA). 
Loxapine was purchased from Lederle Laboratories (Pearl River, NY. USA). 
Perphenazine was purchased from Merck & Co., formerly Schering-Plough Corporation 
(Whitehouse Station, NJ. USA). Thiothixene was purchased from Pfizer Inc. (New York, 
NY. USA). The trifluoperazine manufacturer was unknown. Compounds and internal 
standards were matched as shown in Table 4. Ethyl acetate, methanol, acetic acid, 
chloroform, acetone, ammonium hydroxide and acetonitrile were purchased from J.T. 
Baker (Phillipsburg, NJ. USA). Formic acid and ammonium formate were purchased 
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from Sigma-Aldrich (St. Louis, MO. USA). All chemicals were of HPLC-grade or better 
and water was purified using the Barnstead* EASYpure* RoDi Water System (Thermo 
Scientific, Rydalmere, Asheville, NC. USA). Phosphate buffer (pH 6) was prepared by 
dissolving 27.24 g KH2PO4 in 1.8 L DI water. The pH was adjusted to 6 with KOH and it 
was filled to 2 L with DI water.  
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Table 4: Analytes with corresponding internal standards 
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2.1.2 Specimens 
 
Plastic vials for storing 6 mL of whole blood were prepared with 50 mg NaF and 
10 mg K2C2O4 in 1 L of DI water and dried. Drug-free sheep blood (with Heparin) and 
serum samples were obtained from Hemostat (Dixon, CA. USA) transferred to prepared 
plastic vials (for blood), vortexed, and filtered. Post-mortem blood samples were also 
placed in prepared plastic vials given to the medical examiner to obtain post-mortem 
blood for routine toxicological analysis in the laboratory. The post-mortem blood samples 
were regarded as drug free if none of the existing tests showed the presence of the studied 
drugs in any specimen. Classification of the post-mortem blood samples as decomposed 
was based upon pathology description of the body from which the specimen was taken. 
All blood samples were stored at −10°C prior to analysis. 
 
2.1.3 Instrumentation 
 
The LC-MS/MS system consisted of an Applied Biosystems 3200 Q-TRAP® 
linear ion-trap quadrupole mass spectrometer (AB SCIEX, Framingham, MA. USA) 
equipped with a Turbo V ion source, operated in the electron spray ionization (ESI) 
mode, and a Prominence UFLC Shimadzu HPLC system (Shimadzu Marlborough, MA. 
USA) equipped with a Phenomenex Synergi Hydro-RP® Polar endcapped C18 column 
(4 µm, 150 × 4.6 mm) and SecurityGuard® prefilter (Phenomenex, Torrance, CA. USA). 
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2.2 MS Method Development (Compound Optimization) 
 
The goal of compound optimization is to determine the optimal parameters for 
detecting a specific compound.  Stock solutions of each compound were prepared based 
on the original concentration purchased and in the recommended solvent for that 
compound, resulting in stock solution concentrations of 1000, 100, 40, and 10 µg/mL. 
Compounds were mixed and diluted to a reasonable concentration in a 10 mL volumetric 
flask. 10 µL of 1000 µg/mL stocks, 100 µL of 100 µg/mL stocks, 250 µL of 40 µg/mL 
stocks, and 1 mL of 10 µg/mL stocks, were all mixed in a 10 mL volumetric flask and 
methanol was added to the 10mL mark of the volumetric flask to make a 1 µg/mL 
concentration of all the compounds. 5 µL of formic acid was added to the sample to 
promote ion production. Compound optimization was done using the syringe pump 
method to obtain compound optimization information for the specific compounds. The 
sample mixture was loaded in a syringe and air bubbles in the syringe were removed. It 
was placed in the Harvard pump system of the MS and tubing was attached between the 
syringe and the ion source of the MS. Analyst® Software was used to ensure the S. 
Diameter was 4.6 and the flow rate set to 90 µL/min for the first 30 seconds, then 
returned to 10 µL/min for the duration of the procedure. 
  
Analyst® software is then used to perform a Q1 MS (Q1) scan to obtain the m/z 
(Q1) value of the precursor ion of the analytes and/or internal standards in mixture. The 
scan was adjusted to start and stop 50 units above and below the molecular weight of the 
biggest and smallest compound. The scan time was set for 0.5 seconds each for 5 
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minutes. Declustering potential (DP) was set to 40 V and entrance potential (EP) to 10 V. 
In the spectra, the peaks represent ions with the taller peaks being the isotopic masses of 
the compounds. Figure 17 is a snap shot of the information that this type of scan displays. 
It is necessary to know the molecular weights of the compounds and then add one to this 
value, to account for the addition of a proton (positive ion mode) to identify the 
molecular ions (Figure 17). 
 
 Figure 17
chromatogram) 
compounds
m/z Da, Pro
here with m/z of 285.3 and 291.3 
: Snap shot of the Q1 MS scan (precursor ion 
identifying the molecular weight +1 of the 
 in the sample (a) 300-400 m/z Da, (b) 390-470 
methazine and Promethazine-D6 are not show
respectively 
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Once all analytes and internal standards have been identified, the m/z information 
can be recorded for the next step of the process. The Product Ion Scan (Q3 value) is used 
to determine ion products of analytes and internal standards in mixture after they are 
broken up with certain collision energies (CE). The m/z of one of the compounds was 
selected and in product ion mode, scans were done between 50 Da and slightly above the 
m/z of the compound. The time, duration, DP, and EP were the same as for the Q1 scan 
but CXP was set to 5 V and the CE was adjusted as needed, with an initial setting of 20 
V. As the CE is increased, the precursor ions (Q1) decrease and the product ions 
increased (Q3). The value of CE chosen is the one that provides the best spectra of 
product ions without breaking them down too much (a good spectrum has some of the 
precursor ion). Figure 18 are the product ion chromatograms of 9-hydroxyrisperadone 
and its deuterated internal standard. The precursor ion can still be observed with two 
large product ion peaks however choosing the product ions was not always simple. The 
primary purpose of the product ion is as a qualifier, to avoid improperly identifying ions 
with the same or similar mass charge ratios as well as cross talk between them. Some of 
the compounds of this study had the m/z that only differed by 1 Da and this coupled with 
a poor choice of product ion in deuterated internal standards could lead to a false 
interpretation of the data. Figure 19 (Pipamperone) is an example of many of the same 
product ions between the compound and its deuterated internal standard. Pipamperone 
also has the same m/z of Haloperidol (376.3 Da) making the choice of ions very 
important. 
 
 
 Figure 18: Product ion chromatogram of 9
(a) and 9-hydroxyrisperidone
 
-hydroxyrisperidone 
-D4 (b) with parent and product ions
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 Figure 19: Product ion chromatogram of Pipamperone (a) and 
Pipamperone
among the compound and its deuterated counterpart, adding to 
the difficulty of choosing product ions
-D10 (b) with colored circles showing common ions 
 for each compound 
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MRM method is done using the m/z of the mixture components and their chosen 
product ions to determine the optimum Collision Energy (CE), Declustering Potential 
(DP), Entrance Potential (EP), Collision Cell Entrance Potential (CEP), and Collision 
Cell Exit Potential (CXP) for each precursor/product ion pair. The values of precursor 
and product ion pairs were entered with a scan time of 150 msec and duration of 5 
minutes. Each parameter was ramped in "real time" between maximum and minimum 
values at selected increments to see the effect of increasing the voltage on the product ion 
pair production. The spectra were parabola-like shape (disregarding individual spikes) 
with the value at the climax indicating the optimal setting for that parameter. Table 5 
contains the setting of each parameter; entrance potential however was set at 10 based on 
the mass spectrometer manufacturer recommendations. 
 
 
 
Table 5: Parameters setting to determine optimum values 
 
 
 
 
Perameters Range Intervals
Collision Energy (CE) 5 − 150 1
Declustering Potential (DP) 5 − 80 0.2
Entrance Potential (EP)
Collision Cell Entrance Potential (CEP) 5-50 0.1
Collision Cell Exit Potential (CXP) 0-5 0.1
10
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The complete results of these three scans can be found in Table 6 and Table 7 however 
although these are the final values, the product ions (Q3) were changed in some cases. 
These changes were prompted by poor results in the later optimization steps causing the 
parameters to be revaluated to give the results provided in Table 6 and Table 7. 
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Table 6: Transitional pairs for each compound with 
optimized parameters 
 
 
Mass     
Q1
Q3 Name DP EP CEP CE CXP
427.3 207.3 9-hydroxyrisperidone 1 61 10 17 38 3
427.3 110.3 9-hydroxyrisperidone 2 61 10 22 58 3
431.3 211.3 9-hydroxyrisperidone-D4 1 61 10 19 38 3
431.3 114.3 9-hydroxyrisperidone-D4 2 61 10 20 58 2
448.3 176.3 Aripiprazole 1 64 10 20 41 3
448.3 98.3 Aripiprazole 2 64 10 20 52 3
456.3 293.3 Aripiprazole-D8 1 64 10 17 37 3
456.3 178.3 Aripiprazole-D8 2 64 10 17 45 3
386.3 122.3 Buspirone 1 68 10 16 42 3
386.3 95.3 Buspirone 2 68 10 22 75 3
394.3 122.3 Buspirone-D8 1 67 10 17 43 2
394.3 230 Buspirone-D8 2 63 10 40 38 3
319.3 58.3 Chlorpromazine 1 40 10 14 57 2
319.3 86.3 Chlorpromazine 2 40 10 13 29 3
322.3 61.3 Chlorpromazine-D3 1 41 10 14 60 3
322.3 89.3 Chlorpromazine-D3 2 41 10 13 29 3
327.3 270.3 Clozapine 1 51 10 32 30 3
327.3 192.3 Clozapine 2 51 10 18 58 3
331.3 272.3 Clozapine-D4 1 51 10 33 31 3
331.3 192.3 Clozapine-D4 2 51 10 20 59 3
438.3 171.3 Fluphenazine 1 60 10 16 35 3
438.3 143.3 Fluphenazine 2 60 10 23 39 3
446.3 151.3 Fluphenazine-D8 1 65 10 18 43 2
446.3 179.3 Fluphenazine-D8 2 62 10 40 34 2
376.3 123.3 Haloperidol 1 52 10 17 57 2
376.3 165.3 Haloperidol 2 52 10 15 32 3
380.3 169.3 Haloperidol-D4 1 53 10 14 33 2
380.3 127.3 Haloperidol-D4 2 53 10 19 55 2
328.3 271.3 Loxapine 1 50 10 34 29 3
328.3 193.3 Loxapine 2 50 10 20 59 3
336.3 276.3 Loxapine-D8 1 50 10 32 30 3
336.3 304.3 Loxapine-D8 2 50 10 39 32 3
387.3 98.3 Mesoridazine 1 55 10 17 56 2
387.3 126.3 Mesoridazine 2 55 10 15 34 2
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Table 7: Transitional pairs for each compound with 
optimized parameters 
 
Mass     
Q1
Q3 Name DP EP CEP CE CXP
313.3 256.3 Olanzapine 1 55 10 32 29 3
313.3 213.3 Olanzapine 2 55 10 30 39 3
316.3 256.3 Olanzapine-D3 1 55 10 34 29 3
316.3 87.3 Olanzapine-D3 2 50 10 13 32 3
404.3 143.3 Perphenzine 1 55 10 15 39 3
404.3 171.3 Perphenzine 2 55 10 39 31 3
412.3 151.3 Perphenzine-D8 1 59 10 14 40 2
412.3 179.3 Perphenzine-D8 2 59 10 14 39 2
376.3 331.3 Pipamperone 1 48 10 45 25 3
376.3 138.3 Pipamperone 2 48 10 15 37 2
386.3 165.3 Pipamperone-D10 1 47 10 15 40 3
386.3 341.3 Pipamperone-D10 2 48 10 45 25 3
285.3 86.3 Promethazine 1 30 10 12 27 3
285.3 198.3 Promethazine 2 30 10 12 30 3
291.3 92.3 Promethazine-D6 1 32 10 10 26 3
291.3 77.3 Promethazine-D6 2 30 10 14 62 3
384.3 253.3 Quetiapine 1 63 10 39 30 3
384.3 221.3 Quetiapine 2 63 10 18 50 3
392.3 258.3 Quetiapine-D8 1 67 10 38 32 3
392.3 226 Quetiapine-D8 2 67 10 19 50 3
411.3 191.3 Risperidone 1 56 10 17 39 3
411.3 110.3 Risperidone 2 56 10 30 69 3
415.3 195.3 Risperidone-D4 1 55 10 20 39 3
415.3 114.3 Risperidone-D4 2 58 10 45 69 2
371.3 126.3 Thioridazine 1 49 10 14 31 2
371.3 98.3 Thioridazine 2 49 10 17 52 2
374.3 129.3 Thioridazine-D3 1 50 10 15 31 2
374.3 101.3 Thioridazine-D3 2 48 10 16 50 3
444.3 221.3 Thiothixene 1 57 10 30 70 3
444.3 70.3 Thiothixene 2 57 10 19 70 3
408.3 141.3 Trifluoperazine 1 53 10 16 32 3
408.3 70.3 Trifluoperazine 2 53 10 20 68 3
411.3 144.3 Trifluoperazine-D3 1 53 10 16 33 2
411.3 73.3 Trifluoperazine-D3 2 53 10 20 69 2
413.3 194.3 Ziprasidone 1 72 10 30 39 3
413.3 166.3 Ziprasidone 2 65 10 30 60 3
421.3 194.3 Ziprasidone-D8 1 65 10 16 39 3
421.3 182.3 Ziprasidone-D8 2 60 10 17 39 3
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2.3 HPLC-MS Method Development 
 
The next step was to determine retention times, so scans could be focused on ions 
in specific time windows to improve sensitivity. The HPLC eluents were prepared 
according to lab procedure and current literature for HPLC modes with antipsychotics 
[66] [50]. Mobile phase (A) was composed of 50mmol/L ammonium formate in water at 
pH 3.5. 3.15g of ammonium formate was added to 1000 mL of distilled water and pH 
was adjusted to 3.5 with formic acid. Mobile phase (B) was composed of 0.1% formic 
acid in acetonitrile. 100µL of formic acid was added to a 1000mL beaker which was then 
filled to the 1000ml mark with acetonitrile. During use, the mobile phase was degassed 
by the UFLC Shimadzu DGU-20A3 degasser.  Stock solutions of the compounds were 
combined in methanol to make a concentration of 20µg/mL for each compound. 10µL of 
this compound mixture was completely dried down in the Zymark Turbovap LV (Caliper 
Life Sciences, Hopkinton, MA. USA) and reconstituted in 200µL of a mixture of mobile 
phase A and B (50:50) and transferred to an autosampler vial with an insert.  A blank 
solution of a mixture of mobile phase A and B (50:50) is also put in an autosampler vial. 
Two blanks were then run prior to the sample in an unscheduled run (Scanning for all 
ions throughout the entire run, no time window). During this phase, parameters were 
developed by trial and error for the type of column, mobile phase solvents, oven 
temperature, flow rate (Table 8), and type of gradient elution (Table 9) to insure good 
separation, selectivity, sensitivity, and speed. The mobile phase solvents and the column 
listed above are a result of this section of the study. 
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Table 8: Parameters and setting of the Shimadzu HPLC 
 
 
 
 
 
 
 
 
 
Equilibration time 5.00 min
Injection Volume 10.00 µL 
Run Time 14.50 min
Pumping Mode  Binary Flow
Total Flow Rate 1.5 mL/min.
Pump B Pct 10%
B Curve 0
Pressure Range (Pump A/B) 0 - 300 Bars
Rinsing Volume 200 uL
Needle Stroke 50 mm
Rinsing Speed 35 µL/sec.
Sampling Speed 15.0 µL/sec.
Purge Time 25.0 min.
Rinse Dip Time 10 sec.
Rinse Mode Before and after aspiration
Cooler Enabled Yes
Cooler Temperature 15 deg. C
Control Vial Needle Stroke 52 mm
Temperature 50 deg. C
Max.. Temperature 85 deg. C
Model: CTCH2CK
Shimadzu LC Method Parameters
Pumps
Pump A Motel: 1C-2QAD
Pump B Motel: IC-20AD
Autosampler
Model: SIL-2QSC
Oven
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Table 9: Gradient settings and ESI inlet parameters 
 
 
 
 
 
Once these HPLC settings were established, the Ion spray voltage (IS), curtain gas 
(CUR) gas1 (GS1), gas 2 (GS2), and temperature of gas 2 (TEM) adjustments of the 
mass spectrometer values were set based on common laboratory practices in the lab and 
literature [67] [55] with final adjustment made to maximizing signal intensities and 
performance (Table 9). Adjustments were then made to designate which of the product 
ions would be primary (Ion 1) and secondary (Ion 2) based on intensity with the primary 
ion assigned to the higher intensity ion (Figure 20). The retention times were determined 
for all the analytes and internal standards (Figure 20) to schedule scans for each 
compound at the appropriate time with a 60 second window (30 seconds on each side of 
the retention time) to increase sensitivity by reducing the amount of scans throughout the 
run. 
 
 
 
Time Module Events Parameter CUR 30 psi
1.00 Pumps Pump B Conc. 10 IS 5,500 V
12.00 Pumps Pump B Conc. 60 TEM 700°C
12.50 Pumps Pump B Conc. 10 GS1 65 psi
14.50 Systsn Controller GS2 65 psi
Shimadzu LC Method Parameters
 Time Program
Stop
AB Sceiex MS/MS
ESI-MS inlet parameters
 Figure 20: Determination of product ion position (intensity) and 
retention time
retention times in the figure are not accurate)
 
 
 
2.4 Method Validation 
 
In an effort to validate this analytical method
compounds, validation studies 
parameters that were evaluated for quantitative assays
were: Determination of Linearity, With
Carryover Evaluation, Matrix Effect and Recovery, and Peak Purity and Se
. (This scan was taken during optimization so 
 
 for analyzing the antipsychotic 
were performed to ensure reliability of 
 of the antipsychotic compounds 
in and Between Day Accuracy and Precision, 
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the results. The 
lectivity. Data 
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acquired from various sources (i.e. [17], Table 3) was used to compile information about 
therapeutic and lethal doses of all the 19 antipsychotic drugs. This information was used 
to generate a range in which to analyze these drugs. A stock solution of all of the analytes 
was prepared to a concentration of 5000 µg/L. Stock concentrations of the analytes were 
at concentrations of 1000 µg/mL, 100 µg/mL, and 40 µg/mL so 250 µL, 2.5 mL, and 6.25 
mL were taken from each respectively and added to a 50 mL volumetric flask. The flask 
was then filled to the 50 mL mark on the flask with acetonitrile. A further dilution to 
500µg/L was done by adding 2.5 mL of the first mixture to a 25 mL volumetric flask and 
filled to the 25 mL mark on the flask with acetonitrile. A stock solution of all of the 
internal standards were prepared to a concentration of 10 µg/L. Stock concentrations of 
the internal standards were at concentrations of 100 µg/mL and 10 µg/mL so 500 µL and 
50 µL were taken from each respectively and added to a 10 mL volumetric flask. The 
flask was then filled to the 10 mL mark on the flask with acetonitrile. All stock solutions 
were stored in dark brown reaction vials wrapped in aluminum foil and stored at -70°C. 
500 µL of blood, serum or urine is the amount always used that is spiked with the 
analytes and internal standard stocks. The blood concentration chosen were 10, 20, 50, 
100, 400, 800, and 1000 µg/L. Table 10 contains the calculated amounts of analytes and 
internal standard to add for a desired blood concentration and also shows how many nano 
grams (ng) will be on the LC column. 
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Table 10: Calculated values determine the amount of analyte and 
IS needed to achieve selected blood concentrations 
 
 
 
 
The calculated amount of analytes and internal standards were added to a test tube 
followed by 4mL of 0.1 mL phosphate buffer (pH 6.0) and vortexed briefly.  0.5mL of 
blood, serum, or urine was then added to the test tube vortex briefly, sonicated for 5 
minutes and centrifuged for 15 minutes at 3600 rpm.  
 
The samples were then loaded on to Clean Screen® 130mg 6 ml X-Cel 1 columns 
in the CEREX® System-48™ and eluted by gravity or at a rate of 1-2 mL/min (should be 
very slow rate). Columns were dried at max pressure for 5 minutes and rinsed with 2 mL 
of 0.1mL phosphate buffer (pH 6.0). All drying steps were performed with nitrogen. The 
columns were then washed with 1 mL of 2% acetic acid & 98% methanol and dried at 
maximum pressure for 15 minutes.  The acid/neutral wash was done with 1 mL of a 
50/50 mix of chloroform and acetone. Collection tubes were then placed under samples 
Analye IS
d(Blood) e(Stock Conc) X h j
µg/L µg/µL µL µg/µL µL ng ng
10 1.0E-05 5.0E-04 10 5.0 0.5
20 2.0E-05 5.0E-04 20 10.0 1
50 5.0E-05 5.0E-04 50 25.0 2.5
100 1.0E-04 5.0E-04 100 50.0 5
400 4.0E-04 5.0E-04 400 200.0 20
800 8.0E-04 5.0E-04 800 400.0 40
1000 1.0E-03 5.0E-04 1000 500.0 50
300 3.0E-04 5.00E-04 300 150.0 15
(c)*(d) = (e)*(X) (X)*(e)*(1000) = h Inject 10µL of c to get j on column
c(Blood Concentration)
Dry Down 
X and 
reconstitute 
with 100µL 
of Mobile 
phase 
(50:50) to 
get c
500.0
0.50mg/L = 0.5µg/mL = 0.5ng/µL = 500µg/L
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and the analytes and internal standards were eluted with 2 mL of 2% ammonium 
hydroxide and ethyl acetate by gravity or at a rate of 1-2 ml/min (should be very slow 
rate). The samples were then evaporated to dryness with the Zymark TurboVap LV 
Evaporator® using nitrogen, reconstituted with 100 µL of a 50/50 mix of mobile phases 
(A) and (B) and transferred to autosampler vials. The autosampler vials were centrifuged 
at 3600 rpm for 4 minutes and the sample was ready for analysis. 
 
2.4.1 Determination of Linearity 
 
Following the procedures above six replicate samples were prepared in negative 
sheep’s blood at concentrations of 10, 20, 50, 100, 400, 800, and 1000 µg/L (Table 10). 
Six replicates of the following samples (1-7) were prepared for a total of 48 extractions: 
Sample 1. Add 10 µL of analyte stock. (Blood conc. 20 µg/L) 
Sample 2. Add 20 µL of analyte stock. (Blood conc. 50 µg/L) 
Sample 3. Add 50 µL of analyte stock. (Blood conc. 100 µg/L) 
Sample 4. Add 100 µL of analyte stock. (Blood conc. 200 µg/L) 
Sample 5. Add 400 µL of analyte stock. (Blood conc. 500 µg/L) 
Sample 6. Add 800 µL of analyte stock. (Blood conc. 1000 µg/L) 
Sample 7. Add 1000 µL of analyte stock. (Blood conc. 2000 µg/L) 
Sample 8. No addition of analyte. (Blood conc. 0 µg/L) 
Then to each sample 300 µL of the internal standard stock was added (Blood conc. 300 
µg/L) followed by the addition of phosphate buffer and remaining steps above. 
78 
 
Using an Analyst® and Graph Pad® Prism software programs, calculations for 
precision and accuracy of the six replicates at each calibration point and the coefficient of 
determination (R2) were determined. 
 
2.4.2 Within and Between Day Accuracy and Precision 
 
Samples were prepared in negative sheep’s blood, serum and human urine at low, 
medium and high concentrations and analyzed in triplicate each day for a period of five 
days. The following samples were prepared for a total of 25 extractions per day: 
New calibration curves were established with each run (7 extractions) 
Sample 1. Add 10 µL of analyte stock. (Blood conc. 20 µg/L) 
Sample 2. Add 20 µL of analyte stock. (Blood conc. 50 µg/L) 
Sample 3. Add 50 µL of analyte stock. (Blood conc. 100 µg/L) 
Sample 4. Add 100 µL of analyte stock. (Blood conc. 200 µg/L) 
Sample 5. Add 400 µL of analyte stock. (Blood conc. 500 µg/L) 
Sample 6. Add 800 µL of analyte stock. (Blood conc. 1000 µg/L) 
Sample 7. Add 1000 µL of analyte stock. (Blood conc. 2000 µg/L) 
Three replicates in blood and one of serum and one of urine (15 extractions) 
Sample 8. Add 20 µL of analyte stock. (Blood conc. 50 µg/L) 
Sample 9. Add 100 µL of analyte stock. (Blood conc. 200 µg/L) 
Sample 10. Add 800 µL of analyte stock. (Blood conc. 1000 µg/L) 
Negative samples (3 extractions) 
Sample 11. Sheep Blood Negative (No IS) 
Sample 12. Sheep Plasma Negative (No IS)  
Sample 13. Human Urine Negative (No IS) 
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To each sample 300 µL of the internal standard stock was added (Blood conc. 300 µg/L) 
followed by the addition of phosphate buffer and remaining steps above. 
The within-day and between accuracy and precision was calculated with the 
following equations: 
 
 
% Accuracy = ((calculated conc. - target conc.) / target conc.)  X 100 (Equation 1) 
%. Precision = standard deviation / mean X 100 (Equation 2) 
 
 
The measured mean concentration at each level must be within ± 20 % of the 
target concentration and the precision of the assay cannot exceed ± 20 % at each 
concentration used in the validation study for acceptable performance. 
 
2.4.3 Carryover and Crosstalk Evaluation 
 
A sample of the highest calibrators was prepared in sheep blood and injected five 
times, each time followed by a negative sheep blood sample. The following samples 
would be prepared according to procedure and run in this order five times.  
Sample 1. Add 1000 µL of analyte stock. (Blood conc. 2000 µg/L) with IS (Blood conc. 
300 µg/L) 
Sample 2. 50/50 mix of mobile phases (Blank) 
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The analyte/IS abundance ratio should be 10% or less when compared to the 
highest calibrator. 
 
Crosstalk was evaluated to determine if analytes or internal standards were being 
interpreted as other compounds in the study. This was done by spiking negative sheep’s 
blood with each compound individually at a blood concentration of 2000 µg/L. 
 
2.4.4 Matrix Effect and Recovery 
 
A method considered useful in validation studies to determine the recovery and 
matrix effect is referred to as the Matuszewski approach [66] because it provides a 
quantitative estimation of matrix effects. This method was done with three different sets 
of six different blood samples (3*MEC, 2*MEC decomposed, 1*Pig/Sheep blood) for a 
total of 42 extractions.  
 
The first set consists of the (Nonextracted standards) (6 replicates). 
SET #1 NEAT (6 replicates) (No Extractions) 
200 µL of analyte stock was evaporated to dryness, reconstitute with 100 µL of a 50/50 
mobile phase (A) and (B) and transfer to autosampler vials. 
 
Set two (Recovery Post Extracted Standards) is composed of negative bloods that 
were extracted (SPE) and then fortified with the analytes. 
SET #2 RPES (3 replicates) (18 Extractions) 
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Procedure was followed except that after SPE was performed on the blood, the eluent 
was evaporated to dryness, reconstituted with 100 µL of a 50/50 mobile phase (A) and 
(B), 200 µL of analyte stock was added, and they were transferred to autosampler vials. 
 
Set three (Recovery Extracted Standards) is composed of negative bloods that 
were fortified with the analytes and then extracted (SPE). 
SET #3 RES (3 replicates) (18 Extractions) 
According to procedure 200 µL of analyte stock was added to blood and SPE was 
performed. They were evaporated to dryness, reconstituted with 100 µL of a 50/50 
mobile phase (A) and (B), and transferred to autosampler vials. 
 
All 42 samples were injected and the absolute abundance for each analyte used in the 
following equations to determine matrix effect and recovery. 
 
 
Matrix Effect (%) = (SET #2) / (SET #1) x 100 (Equation 3) 
Recovery (%) = (SET #3) / (SET #2) x 100 (Equation 4) 
 
 
 
2.4.5 Peak Purity and Selectivity 
 
Nine negative blood samples from different negative medical examiner case 
(MEC) bloods (Human) and one sheep blood without analyte(s) or intended Internal 
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Standard (IS) were analyzed according to procedure to check for endogenous peaks that 
might interfere with the analytes or the IS. Two of the MEC blood samples were from 
decomposed bodies however, all sample were processed and analyzed the same.  
 
Then according to procedure, one negative sheep blood plus IS only and one 
negative sheep blood containing the analytes and no IS was analyzed to check for the 
absence of analyte fragmentation ions in the IS peak or vice versa.  
Sample 1. Add 400 µL of analyte stock (Blood conc. 500 µg/L) to negative blood. 
Sample 2. Add 300 µL of the internal standard (Blood conc. 300 µg/L) to negative blood. 
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CHAPTER THREE: Results and Discussion 
3.1 Method Development (Compound Optimization) 
 
The individual acquisition parameters of the tandem mass spectrometer for the 
analytes as well as the internal standards are summarized in Table 11. The declustering 
potential (DP), entrance potential (EP), collision cell entrance potential (CEP), collision 
energy (CE) and collision cell exit potential (CXP) were optimized for each drug and can 
be found in Table 9. Also, retention times of each analyte and internal standard used for 
quantification are compiled in Table 11. Chromatographic separations for each 
compound to further distinguish compounds with identical or similar molecular and 
fragmental masses are shown in Figure 21. All of these parameters and settings were 
entered in a method file in the Analyst® software and the method was validated. 
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Table 11: Retention times for all Analytes and Internal 
standards 
 
 
Mass     
Q1
Q3
Time 
(min)
Name
Mass     
Q1
Q3
Time 
(min)
Name
427.3 207.3 6.6 9-hydroxyrisperidone 1 404.3 143.3 10.2 Perphenzine 1
427.3 110.3 6.6 9-hydroxyrisperidone 2 404.3 171.3 10.2 Perphenzine 2
431.3 211.3 6.6 9-hydroxyrisperidone-D4 1 412.3 151.3 10.2 Perphenzine-D8 1
431.3 114.3 6.6 9-hydroxyrisperidone-D4 2 412.3 179.3 10.2 Perphenzine-D8 2
448.3 176.3 9.6 Aripiprazole 1 376.3 331.3 6.2 Pipamperone 1
448.3 98.3 9.6 Aripiprazole 2 376.3 138.3 6.2 Pipamperone 2
456.3 293.3 9.5 Aripiprazole-D8 1 386.3 165.3 5.9 Pipamperone-D10 1
456.3 178.3 9.5 Aripiprazole-D8 2 386.3 341.3 5.9 Pipamperone-D10 2
386.3 122.3 7.4 Buspirone 1 285.3 86.3 8.9 Promethazine 1
386.3 95.3 7.4 Buspirone 2 285.3 198.3 8.9 Promethazine 2
394.3 122.3 7.4 Buspirone-D8 1 291.3 92.3 8.9 Promethazine-D6 1
394.3 230 7.4 Buspirone-D8 2 291.3 77.3 8.9 Promethazine-D6 2
319.3 58.3 10.2 Chlorpromazine 1 384.3 253.3 8.3 Quetiapine 1
319.3 86.3 10.2 Chlorpromazine 2 384.3 221.3 8.3 Quetiapine 2
322.3 61.3 10.2 Chlorpromazine-D3 1 392.3 258.3 8.3 Quetiapine-D8 1
322.3 89.3 10.2 Chlorpromazine-D3 2 392.3 226 8.3 Quetiapine-D8 2
327.3 270.3 8.2 Clozapine 1 411.3 191.3 7.2 Risperidone 1
327.3 192.3 8.2 Clozapine 2 411.3 110.3 7.2 Risperidone 2
331.3 272.3 8.1 Clozapine-D4 1 415.3 195.3 7.3 Risperidone-D4 1
331.3 192.3 8.1 Clozapine-D4 2 415.3 114.3 7.3 Risperidone-D4 2
438.3 171.3 11 Fluphenazine 1 371.3 126.3 11.2 Thioridazine 1
438.3 143.3 11 Fluphenazine 2 371.3 98.3 11.2 Thioridazine 2
446.3 151.3 10.9 Fluphenazine-D8 1 374.3 129.3 11.2 Thioridazine-D3 1
446.3 179.3 10.9 Fluphenazine-D8 2 374.3 101.3 11.2 Thioridazine-D3 2
376.3 123.3 8.9 Haloperidol 1 444.3 221.3 10 Thiothixene 1
376.3 165.3 8.9 Haloperidol 2 444.3 70.3 10 Thiothixene 2
380.3 169.3 8.8 Haloperidol-D4 1 408.3 141.3 11.7 Trifluoperazine 1
380.3 127.3 8.8 Haloperidol-D4 2 408.3 70.3 11.7 Trifluoperazine 2
328.3 271.3 9.1 Loxapine 1 411.3 144.3 11.7 Trifluoperazine-D3 1
328.3 193.3 9.1 Loxapine 2 411.3 73.3 11.7 Trifluoperazine-D3 2
336.3 276.3 9 Loxapine-D8 1 413.3 194.3 8 Ziprasidone 1
336.3 304.3 9 Loxapine-D8 2 413.3 166.3 8 Ziprasidone 2
313.3 256.3 4.5 Olanzapine 1 421.3 194.3 8 Ziprasidone-D8 1
313.3 213.3 4.5 Olanzapine 2 421.3 182.3 8 Ziprasidone-D8 2
316.3 256.3 4.5 Olanzapine-D3 1 387.3 98.3 8 Mesoridazine 1
316.3 87.3 4.5 Olanzapine-D3 2 387.3 126.3 8 Mesoridazine 2
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Figure 21: The extracted ion current chromatograms (XIC) of all 
analytes and internal standards (a) and labeled (b) 
Thioridazine,1
Thioridazine,2
Thioridazine-D3,1
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3.2 Method Validation 
 
3.2.1 Determination of Linearity 
 
Analyst® software performed the necessary calculations with the additional input 
of information such as peak integration, background range, curve smoothing, weighting 
factor (1/x for all compounds), and others to produce accurate data and curves. 
Transitioning between linear and quadratic fits produced an equation and a R2 value to 
assist with determining the best model. Below Figure 22 contains both models of 9-
hyroxyrisperidone and with a visual inspection and a R2 (liner = 0.9958 quadratic = 
0.9998) value it can be determined that this is second order (quadratic). 
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Figure 22: Liner (a) and quadratic (b) models for 9-
hydroxyrispiradone (six replicates for each of seven 
concentrations) 
9-hydroxyrisperidone (Linear)
9-hydroxyrisperidone (Quadratic)
(a) 
(b) 
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To further verify these findings, the x (Analyte conc. /IS conc.) and y (Analyte 
area/IS area) values were put in the Graph Pad® Prism software program and provided 
information for all the analytes like that of 9-hydroxyrisperidone in Table 12. This 
provided further evidence of the model along with other valuable statistical information 
that can be used in support of the quantitation results of unknown samples. Table 13 
contains a list of the antipsychotics and their predicted model. Analyst® charts and Prism 
data for each drug can be found in Appendix A. 
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Table 12: Graph Pad® Prism software out of quantitation 
data of 9-hydroxyrisperadone 
 
 
Null hypothesis First order polynomial (straight line)
Alternative hypothesis Second order polynomial (quadratic)
P value < 0.0001
Conclusion (alpha = 0.05) Reject null hypothesis
Preferred model Second order polynomial (quadratic)
F (DFn, DFd) 608.7 (1,38)
B0 0.006731
B1 0.3036
B0 0.001633
B1 0.004441
B0 0.003426 to 0.01003
B1 0.2946 to 0.3126
Degrees of Freedom 39
R square (weighted) 0.9917
Weighted Sum of Squares (1/X) 0.03067
Sy.x 0.02804
B0 0.000711
B1 0.3854
B2 -0.03014
B0 0.0004695
B1 0.003491
B2 0.001222
B0 -0.0002398 to 0.001662
B1 0.3783 to 0.3924
B2 -0.03262 to -0.02767
Degrees of Freedom 38
R square (weighted) 0.9995
Weighted Sum of Squares (1/X) 0.001802
Sy.x 0.006886
Analyzed 41
Goodness of Fit
Number of points
Comparison of Fits
First order polynomial (straight line)
Best-fit values
Std. Error
95% Confidence Intervals
Goodness of Fit
9-hydroxyrisperidone
Second order polynomial (quadratic)
Best-fit values
Std. Error
95% Confidence Intervals
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Table 13: List of drugs and their predicted quantification 
model 
 
 
Compound Preferred model
9-hydroxyrisperidone Second order polynomial (quadratic)
Aripiprazole First order polynomial (straight line)
Buspirone Second order polynomial (quadratic)
Chlorpromazine Second order polynomial (quadratic)
Clozapine Second order polynomial (quadratic)
Fluphenazine Second order polynomial (quadratic)
Haloperidol Second order polynomial (quadratic)
Loxapine Second order polynomial (quadratic)
Mesoridazine Additional testing needed (quadratic)
Olanzapine Second order polynomial (quadratic)
Perphenzine First order polynomial (straight line)
Pipamperone Second order polynomial (quadratic)
Promethazine Second order polynomial (quadratic)
Quetiapine First order polynomial (straight line)
Risperidone Second order polynomial (quadratic)
Thioridazine Second order polynomial (quadratic)
Thiothixene Inconclusive
Trifluoperazine Second order polynomial (quadratic)
Ziprasidone Second order polynomial (quadratic)
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In Table 13 mesoridazine is marked with “Additional testing need” because it was 
determined that thioridazine was being metabolized when mixed in blood. Figure 23 
displays the lack of accuracy and precision of the points on the mesoridazine curves. This 
was due to the peak splitting seen below the curves, which was reduced when the entire 
peak was integrated but still introduced error.  
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Figure 23: Mesoridazine curve with corresponding integrated 
peaks of a point showing spit peak behavior (a) and the effect of 
complete integration (b) 
 
 
Analyzing pure mesoridazine however, did not show this peak splitting but when pure 
thioridazine was analyzed it showed both mesoridazine and thioridazine peaks. 
Thioridazine was the only compound, when studying crosstalk that an additional analyte 
of interest was detected. With increasing amounts of time, thioridazine was spiked and 
left in negative blood the mesoridazine peak increased and the thioridazine peak 
decreased (Figure 24). This result was quantified and was able to be repeated. As a result, 
Antipsychotic mix 
Blood
Extracted
(b) (a) 
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mesoridazine could not be analyzed in a mixture with thioridazine or thioridazine-D3. 
Other internal standards for mesoridazine were tested but a suitable replacement, which 
will provide the quality of results needed has not yet been found. A more complete 
picture of these results can be found in Appendix B. 
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Figure 24: Pure mesoridazine (a) and pure thioridazine that 
has been in negative blood show a mesoridazine peak (b) 
Pure Thioridazine
Internal Standard
Blood 
2 Hour in Blood (matrix) 
before analyzed
Extracted
Pure Mesoridazine
Internal Standard
Blood
Extracted
Mesoridazine
Thioridazine
(a) 
(b) 
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Thiothixene was the other compound that did not have its own deuterated internal 
standard and also did not produce results suitable enough to meet the guide lines for 
validation. However the data obtained can be used with the knowledge of its short 
comings until a more suitable internal standard is found.  
 
3.2.2 Within and Between Day Accuracy and Precision 
 
Although only five days was required for this validation, a total of eight days was 
used. During this study the HPLC column had a significant reduction in performance and 
was changed. This change was acceptable as it added a normal variation but additional 
days were run to ensure the new column was properly equilibrated and would provide 
consistent separations. Table 14 contains within and between day accuracy and precision 
for 9-hydroxrisperidone. The first column next to the headings blood, serum, and urine 
are the target concentrations in (µL) with three replicates of each for blood. The next 
column for each day is the calculated concentration followed by the % Accuracy (In 
Bold). For blood, this column is followed by calculations of the mean, standard deviation 
and precision. This is the within day precision and accuracy for each of the days shown. 
The between day precision is located in the bottom right corner with calculations for the 
mean, standard deviation and precision. These calculations are taken from all eight days 
and include precision data for serum and urine. Data for all compounds can be found in 
APPENDIX C 
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Table 14: Within & between day study results for 9-hydroxyrisperidone 
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20 21.8 9.00% 21.2 6.00% 18.8 6.00%
20 21 5.00% 21.6 8.00% 19.5 2.50%
20 20.4 2.00% 20.8 4.00% 18.8 6.00%
100 101 1.00% 99.7 0.30% 103 3.00%
100 105 5.00% 105 5.00% 104 4.00%
100 107 7.00% 96.6 3.40% 97.3 2.70%
800 807 0.88% 782 2.25% 796 0.50%
800 824 3.00% 755 5.63% 801 0.13%
800 822 2.75% 768 4.00% 769 3.88%
20 21.1 5.50% 20.5 2.50% 19.5 2.50%
100 101 1.00% 105 5.00% 103 3.00%
800 818 2.25% 781 2.38% 763 4.63%
20 21.1 5.50% 22.1 10.50% 18.5 7.50%
100 101 1.00% 96.9 3.10% 105 5.00%
800 805 0.63% 771 3.63% 775 3.13%
9-hydroxyrisperidone
0.15 0.77% 20.03 0.90 4.47%19.00 1.10 5.79% 19.73
0.40
100.43 4.25
768.33 13.50
Urine
Day6 (09/22/11) Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
1.76% 788.67 17.21 2.18%
Serum
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
Quadratic
Blood
Blood
4.23% 101.43 3.61 3.56%
817.67 9.29 1.14%
1.89% 19.03 0.40 2.12%
104.33 3.06 2.93%
21.07 0.70 3.33% 21.20
20 20.1 0.50% 19.6 2.00% 20.5 2.50%
20 17.9 10.50% 19.7 1.50% 20.6 3.00%
20 19 5.00% 19.9 0.50% 19 5.00%
100 93.9 6.10% 104 4.00% 101 1.00%
100 95.4 4.60% 97.5 2.50% 95.2 4.80%
100 96.9 3.10% 99.5 0.50% 101 1.00%
800 781 2.38% 771 3.63% 798 0.25%
800 775 3.13% 751 6.13% 752 6.00%
800 750 6.25% 799 0.13% 776 3.00%
20 19 5.00% 21.5 7.50% 20.5 2.50%
100 98.5 1.50% 107 7.00% 99 1.00%
800 754 5.75% 765 4.38% 804 0.50%
20 19.2 4.00% 18.7 6.50% 18.5 7.50%
100 92.5 7.50% 111 11.00% 98.3 1.70%
800 740 7.50% 787 1.63% 765 4.38%
20 20.4 2.00% 21.1 5.50%
20 20.4 2.00%
20 20.3 1.50% 21.6 8.00%
100 102 2.00% 107 7.00%
100 108 8.00% 108 8.00%
100 109 9.00% 105 5.00%
800 800 0.00% 812 1.50%
800 819 2.38% 802 0.25%
800 785 1.88% 846 5.75%
20 19.9 0.50% 21.3 6.50% 20.41 0.89 4.36%
100 109 9.00% 112 12.00% 104.31 4.83 4.63%
800 809 1.13% 814 1.75% 788.50 25.72 3.26%
20 19.5 2.50% 19.8 1.00% 19.68 1.30 6.63%
100 116 16.00% 110 10.00% 103.84 8.05 7.76%
800 797 0.38% 804 0.50% 780.50 22.26 2.85%
789.21 25.65 3.25%
Serum
Urine
4.46%
801.33 17.04 2.13% 820.00 23.07 2.81%
3.56% 106.67 1.53 1.43% 101.75 4.53
0.35 1.66% 20.17 1.02 5.06%
106.33 3.79
Between Day
Blood
20.37 0.06 0.28% 21.35
Urine
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix
24.11 3.12% 775.33 23.01 2.97%
Serum
3.33 3.32% 99.07 3.35 3.38%
768.67 16.44
95.40 1.50 1.57% 100.33
2.14% 773.67
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3.2.3 Carryover Evaluation 
 
The carryover evaluation generated positive results. Analytes and IS showing 
peaks ranging between 1.0e5 to 6.0e6 cps and blank samples that followed each only 
showed maximums of up to 2186 cps or lower. This was significantly below the lower 
level of detection as previously defined meeting acceptable criteria for validation. Figure 
25 shows the ion chromatograms of the injected analytes and IS (a) followed by the blank 
(b), the other chromatograms of the blanks can be found in. APPENDIX D (Preceding 
analyte chromatograms not shown). 
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Figure 25: Carryover study, Sample 46 is the chromatogram of 
the analytes & IS injected (a) followed by a blank (b) 
 
Sample 46
Sample 47
5.5e6 cps
2186 cps
2.0e5 cps
(b) 
(a) 
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3.2.4 Matrix Effect and Recovery 
 
Table 15 contains the mean values and ranges of recoveries and matrix effects of 
each analyte. The matrix effects and recoveries of most of the analytes exceed 80% when 
examining the differences between the mean and the range. Only perphenazine had a 
range difference much greater than ±20% of the mean value (Table 15 in red), however, 
when employing deuterated internal standard, it is assumed that the deuterated compound 
will be affected the same as the compound itself. This, however, would have a very large 
impact on compounds not using a deuterated internal standard, nevertheless all other 
compounds produced acceptable results. Mesoridazine and promethazine had values that 
were slightly above ±20% (Table 15 in red), however there were other validation issues 
with mesoridazine and promethazine like perphenazine, also uses a deuterated internal 
standard. Therefore, a large variation in range should have very little impact on the 
quantification of perphenazine. Olanzapine is known to be an exceptionally unstable drug 
and these results where no exception [54]. Olanzapine had very poor recoveries and 
matrix effects but it also has its own deuterated internal standard. Detailed recoveries and 
matrix effects of each analyte with the different negative bloods can be found in 
APPENDIX E. 
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Table 15: Mean values and ranges of recoveries and matrix 
effects. Values in red were greater than ±20% of the mean 
value 
 
 
Compound Parameter Mean
Matrix Effect 105.17% 103.39% 106.22%
Recovery 71.09% 67.24% 75.51%
Matrix Effect 102.93% 101.27% 107.71%
Recovery 70.14% 61.90% 74.94%
Matrix Effect 107.35% 106.41% 108.06%
Recovery 77.72% 73.00% 80.93%
Matrix Effect 102.91% 98.84% 105.24%
Recovery 60.16% 54.04% 65.70%
Matrix Effect 103.99% 101.63% 107.44%
Recovery 76.27% 73.25% 79.78%
Matrix Effect 101.78% 98.65% 104.27%
Recovery 53.03% 45.54% 59.54%
Matrix Effect 104.86% 102.46% 107.40%
Recovery 73.39% 68.06% 78.07%
Matrix Effect 108.15% 105.84% 110.51%
Recovery 73.97% 67.46% 79.65%
Matrix Effect 103.92% 101.97% 107.02%
Recovery 54.72% 47.14% 66.02%
Matrix Effect 94.38% 89.82% 97.96%
Recovery 15.61% 13.12% 17.53%
Matrix Effect 49.15% 23.94% 101.62%
Recovery 71.58% 24.56% 177.36%
Matrix Effect 104.36% 97.54% 109.06%
Recovery 75.29% 72.70% 77.95%
Matrix Effect 105.74% 103.09% 107.88%
Recovery 69.93% 55.95% 87.25%
Matrix Effect 103.68% 100.47% 106.09%
Recovery 76.65% 69.31% 80.96%
Matrix Effect 106.86% 105.69% 107.97%
Recovery 71.89% 66.42% 79.85%
Matrix Effect 105.01% 102.21% 107.30%
Recovery 60.09% 52.67% 70.69%
Matrix Effect 101.19% 97.77% 104.59%
Recovery 57.27% 52.29% 61.71%
Matrix Effect 96.55% 87.50% 100.34%
Recovery 53.70% 47.17% 58.60%
Matrix Effect 109.89% 105.40% 111.70%
Recovery 67.16% 56.37% 74.09%
Clozapine
Range
9-hydroxyrisperidone
Aripiprazole
Buspirone
Chlorpromazine
Fluphenazine
Haloperidol
Loxapine
Mesoridazine
Olanzapine
Trifluoperazine
Ziprasidone
Pipamperone
Promethazine
Quetiapine
Risperidone
Thiotixene
Thioridazine
Perphenzine
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3.2.5 Peak Purity and Selectivity 
 
Ten negative specimens of the same matrix from different cases without 
analyte(s) or intended Internal Standard (IS) were analyzed to check for endogenous 
peaks that might interfere with the analyte or the IS. The analysis yielded no peaks above 
1700 cps which was significantly below the lower level of detection as previously 
defined. Figure 26 shows the ion chromatograms of an injected negative blood sample. 
Ion chromatograms of the other ten samples can be found in APPENDIX F. 
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Figure 26: Peak Purity and Selectivity: Chromatogram of 
one of the ten different samples of negative blood 
 
 
 
When analyzing negative specimens with IS or analytes, they showed no 
significant amounts of the other. So IS shows no analyte peaks and analytes show no IS 
peaks, therefore confirming the absence of analyte fragmentation ions in the IS peaks and 
vice versa. Figure 27 shows chromatograms for two samples with IS only (2A) and 
analytes only (1A), and that same chromatogram showing the amount of the opposing 
compound (i.e. IS or analytes (1&2B)).  
MEC Blood 1373-11  Decomp.
1197 cps
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Figure 27: Sample 1 & 2 show one chromatograms each just 
looking at the IS or analytes. Sample 2 is IS only and sample 1 is 
analytes only. 
 
 
 
Table 16 contains the analyte and IS peak area counts of the chromatogram (1) 
shown in Figure 27 for each sample showing the values of each of the peaks. 
 
 
1A (Analyte)
3.6e6 cps
1B (IS)
2269 cps
2B (Analyte)
4400 cps
2A (IS)
4.7e6 cps
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Table 16: Area counts of 1 A & B (Figure 27) showing the large 
range between IS & analytes within the same sample. 
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3.4 Nitrogen vs. Air 
 
 
Originally the SPE and all other drying processes were performed using air, 
however, poor results led to the possibility of chemical reactions such as sulfoxide 
formation, changing the compounds. Many of these compounds contained sulfur and the 
introduction of oxygen in the air and at many times with elevated temperatures, which 
could cause a reaction changing the structure and molecular weight to produce a new 
undetected compound. This was tested by using nitrogen instead of air and the effects 
were compared in the matrix study. The results can be viewed in Table 17 which shows 
improvements all analyte in terms of recovery and matrix effect in the column labeled % 
increase with nitrogen. Only two compounds appear to be partially improved with the use 
of air, but further examination will show this is because of the large range in the data 
reducing the accuracy and precision of these results. The range of the data about the mean 
with air was much greater then with nitrogen for all compounds, although only those 
exceeding ±20% are labeled in red. 
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Table 17: Matrix study comparison of air vs. nitrogen for each 
analyte. . Values in red were greater than ±20% of the mean 
value 
 
 
Mean Mean
Matrix Effect 105.17% 103.39% 106.22% 87.96% 81.55% 99.39% 16.36%
Recovery 71.09% 67.24% 75.51% 46.90% 42.39% 51.37% 34.03%
Matrix Effect 102.93% 101.27% 107.71% 89.50% 79.74% 102.56% 13.04%
Recovery 70.14% 61.90% 74.94% 44.36% 38.84% 49.95% 36.76%
Matrix Effect 107.35% 106.41% 108.06% 85.52% 75.73% 98.92% 20.33%
Recovery 77.72% 73.00% 80.93% 51.92% 46.04% 62.32% 33.19%
Matrix Effect 102.91% 98.84% 105.24% 73.79% 66.46% 84.72% 28.29%
Recovery 60.16% 54.04% 65.70% 29.37% 24.05% 33.06% 51.18%
Matrix Effect 103.99% 101.63% 107.44% 84.70% 78.17% 97.96% 18.55%
Recovery 76.27% 73.25% 79.78% 44.29% 38.01% 52.53% 41.93%
Matrix Effect 101.78% 98.65% 104.27% 71.88% 63.45% 80.72% 29.38%
Recovery 53.03% 45.54% 59.54% 27.09% 21.51% 38.14% 48.93%
Matrix Effect 104.86% 102.46% 107.40% 86.98% 76.26% 99.46% 17.05%
Recovery 73.39% 68.06% 78.07% 49.67% 45.01% 58.03% 32.32%
Matrix Effect 108.15% 105.84% 110.51% 87.53% 76.95% 101.00% 19.07%
Recovery 73.97% 67.46% 79.65% 48.37% 43.67% 57.16% 34.61%
Matrix Effect 103.92% 101.97% 107.02% 92.86% 77.65% 114.33% 10.64%
Recovery 54.72% 47.14% 66.02% 23.65% 17.41% 30.58% 56.78%
Matrix Effect 94.40% 89.82% 97.96% 3.65% 0.86% 6.55% 96.13%
Recovery 15.61% 13.12% 17.53% 17.44% 4.53% 33.43% -11.71%
Matrix Effect 49.15% 23.94% 101.62% 64.34% 57.38% 74.89% -30.91%
Recovery 71.58% 24.56% 177.36% 20.25% 15.68% 24.31% 71.71%
Matrix Effect 104.36% 97.54% 109.06%
Recovery 75.29% 72.70% 77.95%
Matrix Effect 105.74% 103.09% 107.88% 78.17% 70.03% 93.69% 26.08%
Recovery 69.93% 55.95% 87.25% 31.41% 24.42% 33.94% 55.08%
Matrix Effect 103.68% 100.47% 106.09% 89.00% 81.41% 101.44% 14.16%
Recovery 76.65% 69.31% 80.96% 52.05% 47.27% 59.51% 32.09%
Matrix Effect 106.86% 105.69% 107.97% 82.32% 72.91% 98.15% 22.96%
Recovery 71.89% 66.42% 79.85% 35.79% 29.65% 42.24% 50.21%
Matrix Effect 105.01% 102.21% 107.30% 84.60% 73.61% 96.59% 19.44%
Recovery 60.09% 52.67% 70.69% 29.91% 25.85% 34.23% 50.23%
Matrix Effect 101.19% 97.77% 104.59% 69.17% 62.93% 78.46% 31.64%
Recovery 57.27% 52.29% 61.71% 21.36% 16.36% 24.68% 62.71%
Matrix Effect 96.55% 87.50% 100.34% 65.95% 55.96% 79.84% 31.70%
Recovery 53.70% 47.17% 58.60% 24.69% 19.92% 29.91% 54.03%
Matrix Effect 109.89% 105.40% 111.70% 86.77% 78.09% 100.60% 21.04%
Recovery 67.16% 56.37% 74.09% 47.80% 43.00% 53.34% 28.83%
Ziprasidone
Range Range
Promethazine
Quetiapine
Risperidone
Thiothixene
Thioridazine
Trifluoperazine
Haloperidol
Loxapine
Mesoridazine
% Increase with 
Nitrogen
Olanzapine
Perphenzine
Pipamperone
9-hydroxyrisperidone
Aripiprazole
Buspirone
Chlorpromazine
Clozapine
Fluphenazine
Nitrogen Air
Compound Parameter
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CHAPTER FOUR: Summary and Conclusions 
The LC-MS/MS assay developed is a suitable analytical method for the 
simultaneous separation, detection and quantification of 18 antipsychotics in postmortem 
human blood. The selectivity, linearity, accuracy and precision of the method were found 
to be suitable for forensic toxicological analyses. Promethazine had two values that were 
slightly above ±20%. Perphenazine had a range difference much greater than ±20% of the 
mean value, which could be considered an unacceptable large variation within the matrix 
study. However, the use of deuterated perphenazine and promethazine as an internal 
standard would nullify this effect assuming that the deuterated compound is affected in 
the same way as the compound itself. Through each phase of the validation all but two 
antipsychotics met the acceptable criteria for full validation. Mesoridazine and 
thiothixene require further study to find a more suitable IS to improve their results in 
linearity, accuracy and precision; however, thiothixene can still be evaluated with the 
knowledge of its limitations in this method. Recent studies into the use of ascorbic acid as 
an antioxidant to improve stability may improve the detection of thiothixene as well as 
other compounds in this study [67]. Because thioridazine is metabolizing to mesoridazine 
in post-mortem blood very quickly, thioridazine and mesoridazine cannot be evaluated in 
the same assay. This also brings up the challenge of postmortem analysis because 
thioridazine represents one of possibly many of these drugs that is metabolizing in blood 
making the concentration of drug no longer what it was at the time of death. The use of 
nitrogen as opposed to air for sample drying and SPE resulted in very clean extracts with 
good recoveries which had an average increase in recoveries by more the 45% and an 
108 
 
increase in the value of matrix effect by more than 25%. The presented LC-MS/MS assay 
has been found to be a simple and sensitive procedure that is suitable for use in forensic 
toxicology investigations. 
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APPENDIX A 
Analyst® Software Calibration Model Data 
 
 
Buspirone (Linear)
Aripiprazole (Linear)
Buspirone (Quadratic)
9-hydroxyrisperidone (Quadratic)
Aripiprazole (Quadratic)
9-hydroxyrisperidone (Linear)
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Fluphenazine (Linear)
Clozapine (Linear) Clozapine (Quadratic)
Fluphenazine (Quadratic)
Chlorpromazine (Linear) Chlorpromazine (Quadratic)
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Loxapine (Quadratic)
Mesoridazine (Quadratic)Mesoridazine (Linear)
Haloperidol (Linear) Haloperidol (Quadratic)
Loxapine (Linear)
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Perphenazine (Quadratic)
Pipamperone (Linear) Pipamperone (Quadratic)
Perphenazine (Linear)
Olanzapine (Quadratic)Olanzapine (Linear)
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Quetiapine (Quadratic)Quetiapine (Linear)
Risperidone (Quadratic)Risperidone (Linear)
Promethazine (Linear) Promethazine (Quadratic)
121 
 
 
Thiotixene (Quadratic)Thiotixene (Linear)
Trifluoperazine (Linear) Trifluoperazine (Quadratic)
Thioridazine (Quadratic)Thioridazine (Linear)
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Ziprasidone (Linear) Ziprasidone (Quadratic)
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Graph Pad® Prism Software Calibration Model Data 
 
 
 
 9-hydroxyrisperidone Aripiprazole Buspirone Chlorpromazine
Null hypothesis First order polynomial (straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
Alternative 
hypothesis
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
P value < 0.0001 0.5759 < 0.0001 < 0.0001
Conclusion (alpha 
= 0.05) Reject null hypothesis
Do not reject null 
hypothesis Reject null hypothesis Reject null hypothesis
Preferred model
Second order 
polynomial (quadratic)
First order polynomial 
(straight line)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
F (DFn, DFd) 608.7 (1,38) 0.3183 (1,38) 233.9 (1,38) 20.26 (1,38)
B0 0.006731 0.0001091 0.0111 0.002083
B1 0.3036 0.0872 0.8175 1.007
B0 0.001633 0.0001307 0.002836 0.00113
B1 0.004441 0.0003554 0.007712 0.003072
B0 0.003426 to 0.01003 -0.0001553 to 0.0003735 0.005360 to 0.01684 -0.0002027 to 0.004369
B1 0.2946 to 0.3126 0.08648 to 0.08791 0.8019 to 0.8331 1.001 to 1.013
Degrees of Freedom 39 39 39 39
R square (weighted) 0.9917 0.9994 0.9965 0.9996
Weighted Sum of 
Squares (1/X) 0.03067 0.0001964 0.09249 0.01468
Sy.x 0.02804 0.002244 0.0487 0.0194
B0 0.000711 0.00006385 0.001104 -0.0004481
B1 0.3854 0.08781 0.9533 1.041
B2 -0.03014 -0.0002266 -0.05005 -0.01268
B0 0.0004695 0.0001543 0.001257 0.001082
B1 0.003491 0.001147 0.009348 0.008045
B2 0.001222 0.0004017 0.003272 0.002816
B0 -0.0002398 to 0.001662 -0.0002487 to 0.0003764 -0.001442 to 0.003650 -0.002640 to 0.001743
B1 0.3783 to 0.3924 0.08549 to 0.09013 0.9344 to 0.9723 1.025 to 1.058
B2 -0.03262 to -0.02767 -0.001040 to 0.0005868 -0.05667 to -0.04342 -0.01838 to -0.006973
Degrees of Freedom 38 38 38 38
R square (weighted) 0.9995 0.9994 0.9995 0.9998
Weighted Sum of 
Squares (1/X) 0.001802 0.0001947 0.01292 0.009573
Sy.x 0.006886 0.002264 0.01844 0.01587
Analyzed 41 41 41 41
Number of points
Goodness of Fit
Best-fit values
95% Confidence Intervals
Std. Error
Goodness of Fit
Comparison of Fits
First order polynomial (straight line)
Best-fit values
95% Confidence Intervals
Second order polynomial (quadratic)
Std. Error
124 
 
 
 Clozapine Fluphenazine Haloperidol Loxapine
Null hypothesis First order polynomial (straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
Alternative 
hypothesis
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
P value < 0.0001 < 0.0001 < 0.0001 < 0.0001
Conclusion (alpha 
= 0.05) Reject null hypothesis Reject null hypothesis Reject null hypothesis Reject null hypothesis
Preferred model Second order polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
F (DFn, DFd) 223.2 (1,38) 19.18 (1,38) 136.9 (1,38) 258.1 (1,38)
B0 0.01103 0.003397 0.01019 0.008873
B1 1.047 0.86 0.9534 0.9008
B0 0.003047 0.001063 0.002605 0.002392
B1 0.008284 0.002892 0.007084 0.006505
B0 0.004867 to 0.01719 0.001245 to 0.005548 0.004915 to 0.01546 0.004033 to 0.01371
B1 1.030 to 1.064 0.8542 to 0.8658 0.9391 to 0.9678 0.8876 to 0.9140
Degrees of Freedom 39 39 39 39
R square (weighted) 0.9976 0.9996 0.9979 0.998
Weighted Sum of 
Squares (1/X) 0.1067 0.013 0.07804 0.0658
Sy.x 0.05231 0.01826 0.04473 0.04108
B0 0.0003319 0.001057 0.00143 0.0003873
B1 1.192 0.8918 1.072 1.016
B2 -0.05357 -0.01172 -0.04385 -0.04249
B0 0.001378 0.001028 0.00144 0.001016
B1 0.01025 0.007643 0.01071 0.007556
B2 0.003586 0.002675 0.003748 0.002645
B0 -0.002459 to 0.003123 -0.001025 to 0.003139 -0.001487 to 0.004346 -0.001671 to 0.002446
B1 1.171 to 1.213 0.8763 to 0.9073 1.051 to 1.094 1.001 to 1.031
B2 -0.06084 to -0.04631 -0.01714 to -0.006300 -0.05144 to -0.03626 -0.04785 to -0.03714
Degrees of Freedom 38 38 38 38
R square (weighted) 0.9996 0.9997 0.9995 0.9997
Weighted Sum of 
Squares (1/X) 0.01553 0.00864 0.01696 0.008444
Sy.x 0.02021 0.01508 0.02113 0.01491
Analyzed 41 41 41 41
Number of points
Comparison of Fits
First order polynomial (straight line)
Best-fit values
Std. Error
Second order polynomial (quadratic)
Goodness of Fit
95% Confidence Intervals
Std. Error
Goodness of Fit
Best-fit values
95% Confidence Intervals
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 Mesoridazine Olanzapine Perphenzine Pipamperone
Null hypothesis First order polynomial (straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
Alternative 
hypothesis
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
P value 0.0072 < 0.0001 0.9713 < 0.0001
Conclusion (alpha 
= 0.05) Reject null hypothesis Reject null hypothesis
Do not reject null 
hypothesis Reject null hypothesis
Preferred model
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
First order polynomial 
(straight line)
Second order 
polynomial (quadratic)
F (DFn, DFd) 8.074 (1,38) 170.8 (1,38) 0.001313 (1,38) 139.7 (1,38)
B0 0.01759 0.007459 -0.0004807 0.001576
B1 1.244 0.9427 0.4698 0.08093
B0 0.007532 0.003002 0.0004042 0.0003056
B1 0.02048 0.008161 0.001099 0.000831
B0 0.002352 to 0.03283 0.001386 to 0.01353 -0.001298 to 0.0003370 0.0009579 to 0.002195
B1 1.202 to 1.285 0.9261 to 0.9592 0.4676 to 0.4720 0.07925 to 0.08261
Degrees of Freedom 39 39 39 39
R square (weighted) 0.9895 0.9971 0.9998 0.9959
Weighted Sum of 
Squares (1/X) 0.6521 0.1036 0.001878 0.001074
Sy.x 0.1293 0.05153 0.00694 0.005248
B0 0.02957 -0.002854 -0.0004717 0.0005467
B1 1.081 1.083 0.4697 0.09492
B2 0.05998 -0.05164 0.00004521 -0.005155
B0 0.008111 0.001518 0.0004793 0.0001676
B1 0.0603 0.01129 0.003564 0.001246
B2 0.02111 0.003951 0.001247 0.0004361
B0 0.01314 to 0.04599 -0.005929 to 0.0002205 -0.001442 to 0.0004990 0.0002073 to 0.0008861
B1 0.9588 to 1.203 1.060 to 1.106 0.4625 to 0.4769 0.09240 to 0.09744
B2 0.01723 to 0.1027 -0.05965 to -0.04364 -0.002481 to 0.002571 -0.006039 to -0.004272
Degrees of Freedom 38 38 38 38
R square (weighted) 0.9914 0.9995 0.9998 0.9991
Weighted Sum of 
Squares (1/X) 0.5378 0.01885 0.001878 0.0002296
Sy.x 0.119 0.02227 0.00703 0.002458
Analyzed 41 41 41 41
Number of points
Comparison of Fits
First order polynomial (straight line)
Best-fit values
Std. Error
Second order polynomial (quadratic)
Goodness of Fit
95% Confidence Intervals
Goodness of Fit
Best-fit values
95% Confidence Intervals
Std. Error
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 Promethazine Quetiapine Risperidone Thioridazine
Null hypothesis First order polynomial (straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
Alternative 
hypothesis
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
P value < 0.0001 0.3247 < 0.0001 < 0.0001
Conclusion (alpha 
= 0.05) Reject null hypothesis
Do not reject null 
hypothesis Reject null hypothesis Reject null hypothesis
Preferred model Second order polynomial (quadratic)
First order polynomial 
(straight line)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
F (DFn, DFd) 79.82 (1,38) 0.9956 (1,38) 599.9 (1,38) 79.62 (1,38)
B0 0.004382 0.001284 0.03164 0.01412
B1 0.7655 0.07504 0.8295 1.097
B0 0.001552 0.0001519 0.006624 0.002181
B1 0.00422 0.0004129 0.01801 0.005929
B0 0.001241 to 0.007522 0.0009773 to 0.001592 0.01824 to 0.04504 0.009710 to 0.01853
B1 0.7570 to 0.7740 0.07420 to 0.07587 0.7930 to 0.8659 1.085 to 1.109
Degrees of Freedom 39 39 39 39
R square (weighted) 0.9988 0.9988 0.9819 0.9989
Weighted Sum of 
Squares (1/X) 0.0277 0.0002651 0.5044 0.05466
Sy.x 0.02665 0.002607 0.1137 0.03744
B0 -0.0004717 0.001192 0.007239 0.007306
B1 0.8315 0.07629 1.161 1.19
B2 -0.0243 -0.0004616 -0.1222 -0.03413
B0 0.001045 0.0001778 0.001917 0.00147
B1 0.007772 0.001322 0.01425 0.01093
B2 0.00272 0.0004626 0.004989 0.003825
B0 -0.002589 to 0.001645 0.0008323 to 0.001552 0.003357 to 0.01112 0.004329 to 0.01028
B1 0.8157 to 0.8472 0.07361 to 0.07896 1.132 to 1.190 1.167 to 1.212
B2 -0.02981 to -0.01879 -0.001398 to 0.0004753 -0.1323 to -0.1121 -0.04187 to -0.02638
Degrees of Freedom 38 38 38 38
R square (weighted) 0.9996 0.9989 0.9989 0.9996
Weighted Sum of 
Squares (1/X) 0.008933 0.0002583 0.03004 0.01766
Sy.x 0.01533 0.002607 0.02812 0.02156
Analyzed 41 41 41 41
Number of points
Comparison of Fits
Best-fit values
Std. Error
Second order polynomial (quadratic)
Goodness of Fit
95% Confidence Intervals
First order polynomial (straight line)
Goodness of Fit
Best-fit values
95% Confidence Intervals
Std. Error
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 Thiotixene Trifluoperazine Ziprasidone
Null hypothesis First order polynomial (straight line)
First order polynomial 
(straight line)
First order polynomial 
(straight line)
Alternative 
hypothesis
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
P value 0.2992 0.0003 < 0.0001
Conclusion (alpha 
= 0.05)
Do not reject null 
hypothesis Reject null hypothesis Reject null hypothesis
Preferred model First order polynomial (straight line)
Second order 
polynomial (quadratic)
Second order 
polynomial (quadratic)
F (DFn, DFd) 1.108 (1,38) 15.54 (1,38) 67.64 (1,38)
B0 0.00318 0.001747 0.002881
B1 0.4881 0.8387 0.6418
B0 0.001416 0.001124 0.00143
B1 0.003851 0.003055 0.003887
B0 0.0003150 to 0.006045 -0.0005263 to 0.004020 -1.147e-005 to 0.005773
B1 0.4803 to 0.4959 0.8325 to 0.8449 0.6339 to 0.6496
Degrees of Freedom 39 39 39
R square (weighted) 0.9976 0.9995 0.9986
Weighted Sum of 
Squares (1/X) 0.02306 0.01451 0.02349
Sy.x 0.02431 0.01929 0.02454
B0 0.004086 -0.0005529 -0.001465
B1 0.4758 0.87 0.7008
B2 0.004534 -0.01152 -0.02176
B0 0.001655 0.001122 0.001017
B1 0.01231 0.008346 0.007559
B2 0.004308 0.002921 0.002646
B0 0.0007331 to 0.007438 -0.002826 to 0.001720 -0.003524 to 0.0005941
B1 0.4508 to 0.5007 0.8531 to 0.8869 0.6855 to 0.7161
B2 -0.004191 to 0.01326 -0.01743 to -0.005600 -0.02712 to -0.01640
Degrees of Freedom 38 38 38
R square (weighted) 0.9976 0.9996 0.9995
Weighted Sum of 
Squares (1/X) 0.0224 0.0103 0.008451
Sy.x 0.02428 0.01646 0.01491
Analyzed 41 41 41
Number of points
95% Confidence Intervals
Goodness of Fit
Std. Error
Std. Error
First order polynomial (straight line)
Comparison of Fits
Best-fit values
Best-fit values
95% Confidence Intervals
Goodness of Fit
Second order polynomial (quadratic)
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APPENDIX B 
Mesoridazine Peak-Spitting study 
 
 
 
 
 
 
 
5 Day Study 08/28/11 
Antipsychotic mix  
Blood 
Extracted 
Antipsychotic mix  
Blood 
Extracted 
5 Day Study 08/08/11 
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From Matrix Study 08/28/11 C2 
Blood 
Antipsychotic mix 
Added after extraction 
Extracted 
From Matrix Study 08/28/11 C3 
Antipsychotic mix  
Blood 
Extracted 
Nonextracted 
Antipsychotic mix  
 08/14/11 
Air drying 
Nonextracted 
Air drying 
Pure Mesoridazine 
 08/14/11 
Nonextracted 
Antipsychotic mix  
 08/14/11 
Nitrogen Drying 
Nonextracted 
Nitrogen drying 
Pure Mesoridazine 
 08/14/11 
3
21
65
4
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5 day Study 
08/24/11 
Extracted 
Serum 
Antipsychotic mix  
Internal Standard 
08/24/11  
Pure Mesoridazine 
Internal Standard 
Serum 
Extracted 
Matrix Study 088/28/11 E3 
Antipsychotic mix  
Blood 
Extracted 
Antipsychotic mix 
Added after extraction 
Blood 
Extracted 
Matrix Study 08/28/11 E2 
08/24/11 
Pure Mesoridazine 
Internal Standard 
Blood 
Extracted 
5 Day Study 
08/24/11 
Antipsychotic mix  
Extracted 
Blood 
Internal Standard 
7 8 
9 10 
11 12 
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08/24/11  
Pure Mesoridazine 
Extracted 
08/24/11 
Pure Mesoridazine 
Extracted 
Internal Standard 
5 Day Study 
08/24/11  
Antipsychotic mix  
Extracted 
Urine 
Internal Standard 
08/24/11  
Pure Mesoridazine 
Extracted 
Urine 
Internal Standard 
14 13 
16 15 
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09/03/11 
Pure Thioridazine 
Internal Standard 
Blood 
Extracted 
09/03/11 
Pure Thioridazine 
Internal Standard 
Blood  
Hours in Blood (matrix) 
before analyzed 
Extracted 
08/31/11 
Pure Mesoridazine 
Internal Standard 
Blood 
Extracted 
09/03/11 
Pure Mesoridazine 
Internal Standard 
Blood 
Extracted 
Mesoridazine 
Mesoridazine 
Thioridazine 
Thioridazine 
Mesoridazine 
Thioridazine 
17 
20 
19 
18 
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Quantified pure Thioridizine at different consentrations contained ~1% percent Mesoridizine. 
Mesoridazine peaks of Pure nonextracted Thioridizine at concentrations of: 
 
20 µg/mL 50 µg/mL 
100 µg/mL 400 µg/mL 
800 µg/mL 1000 µg/mL 
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APPENDIX C 
Within and Between Day Accuracy and Precision Data 
 
 
20 21.8 9.00% 21.2 6.00% 18.8 6.00%
20 21 5.00% 21.6 8.00% 19.5 2.50%
20 20.4 2.00% 20.8 4.00% 18.8 6.00%
100 101 1.00% 99.7 0.30% 103 3.00%
100 105 5.00% 105 5.00% 104 4.00%
100 107 7.00% 96.6 3.40% 97.3 2.70%
800 807 0.88% 782 2.25% 796 0.50%
800 824 3.00% 755 5.63% 801 0.13%
800 822 2.75% 768 4.00% 769 3.88%
20 21.1 5.50% 20.5 2.50% 19.5 2.50%
100 101 1.00% 105 5.00% 103 3.00%
800 818 2.25% 781 2.38% 763 4.63%
20 21.1 5.50% 22.1 10.50% 18.5 7.50%
100 101 1.00% 96.9 3.10% 105 5.00%
800 805 0.63% 771 3.63% 775 3.13%
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
Day6 (09/22/11) Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
3.56%
19.03 0.40 2.12%21.07 0.70 3.33% 21.20 0.40 1.89%
3.614.25 4.23% 101.43104.33 3.06 2.93% 100.43
2.18%1.14% 768.33 13.50 1.76% 788.67 17.21817.67 9.29
Blood
Serum
Urine
Quadratic
9-hydroxyrisperidone
20 20.1 0.50% 19.6 2.00% 20.5 2.50%
20 17.9 10.50% 19.7 1.50% 20.6 3.00%
20 19 5.00% 19.9 0.50% 19 5.00%
100 93.9 6.10% 104 4.00% 101 1.00%
100 95.4 4.60% 97.5 2.50% 95.2 4.80%
100 96.9 3.10% 99.5 0.50% 101 1.00%
800 781 2.38% 771 3.63% 798 0.25%
800 775 3.13% 751 6.13% 752 6.00%
800 750 6.25% 799 0.13% 776 3.00%
20 19 5.00% 21.5 7.50% 20.5 2.50%
100 98.5 1.50% 107 7.00% 99 1.00%
800 754 5.75% 765 4.38% 804 0.50%
20 19.2 4.00% 18.7 6.50% 18.5 7.50%
100 92.5 7.50% 111 11.00% 98.3 1.70%
800 740 7.50% 787 1.63% 765 4.38%
20 20.4 2.00% 21.1 5.50%
20 20.4 2.00%
20 20.3 1.50% 21.6 8.00%
100 102 2.00% 107 7.00%
100 108 8.00% 108 8.00%
100 109 9.00% 105 5.00%
800 800 0.00% 812 1.50%
800 819 2.38% 802 0.25%
800 785 1.88% 846 5.75%
20 19.9 0.50% 21.3 6.50% 20.41 0.89 4.36%
100 109 9.00% 112 12.00% 104.31 4.83 4.63%
800 809 1.13% 814 1.75% 788.50 25.72 3.26%
20 19.5 2.50% 19.8 1.00% 19.68 1.30 6.63%
100 116 16.00% 110 10.00% 103.84 8.05 7.76%
800 797 0.38% 804 0.50% 780.50 22.26 2.85%
19.00 1.10 5.79%
95.40
20.17 1.0220.37 0.06 5.06%0.28% 21.35 0.35 1.66%
4.46%
3.35
19.73 0.15 0.77% 20.03
99.07
1.53 1.43% 101.75 4.53
23.01 2.97%768.67 16.44 2.14% 773.67 24.11
0.90 4.47%
3.38%1.50 1.57% 100.33 3.33 3.32%Blood
Serum
Urine
Blood
801.33
Urine
2.13%17.04
Serum
Between DayDay6 (09/30/11) 19 mixDay6 (09/30/11) 18 mix
106.673.56%3.79106.33
3.25%820.00 23.07 2.81% 789.21 25.65
3.12% 775.33
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20 22.4 12.00% 22.4 12.00% 18.8 6.00%
20 21.4 7.00% 21.1 5.50% 18.5 7.50%
20 20.2 1.00% 20 0.00% 16.6 17.00%
100 98.5 1.50% 104 4.00% 100 0.00%
100 104 4.00% 106 6.00% 99.6 0.40%
100 103 3.00% 100 0.00% 96.1 3.90%
800 820 2.50% 827 3.38% 801 0.13%
800 850 6.25% 818 2.25% 815 1.88%
800 836 4.50% 819 2.38% 820 2.50%
20 20.1 0.50% 21.1 5.50% 19.4 3.00%
100 101 1.00% 103 3.00% 100 0.00%
800 840 5.00% 806 0.75% 807 0.88%
20 21 5.00% 22.1 10.50% 18.7 6.50%
100 103 3.00% 104 4.00% 102 2.00%
800 784 2.00% 814 1.75% 813 1.63%
20 23.3 16.50% 18.4 8.00% 21.3 6.50%
20 23.6 18.00% 19.4 3.00% 20.8 4.00%
20 21 5.00% 17.5 12.50% 21.9 9.50%
100 96.2 3.80% 94.8 5.20% 106 6.00%
100 95 5.00% 103 3.00% 104 4.00%
100 95.5 4.50% 102 2.00% 106 6.00%
800 799 0.13% 807 0.88% 861 7.63%
800 782 2.25% 786 1.75% 846 5.75%
800 803 0.38% 842 5.25% 858 7.25%
20 21.5 7.50% 18.1 9.50% 20.2 1.00%
100 101 1.00% 100 0.00% 110 10.00%
800 786 1.75% 785 1.88% 854 6.75%
20 25.4 27.00% 18 10.00% 20.9 4.50%
100 105 5.00% 101 1.00% 106 6.00%
800 833 4.13% 810 1.25% 865 8.13%
20 20.9 4.50% 20.5 2.50%
20
20 18.7 6.50% 20.9 4.50%
100 104 4.00% 106 6.00%
100 99.4 0.60% 99 1.00%
100 104 4.00% 102 2.00%
800 788 1.50% 861 7.63%
800 791 1.13% 842 5.25%
800 791 1.13% 855 6.88%
20 19.2 4.00% 20 0.00% 19.95 1.08 5.39%
100 103 3.00% 105 5.00% 102.88 3.36 3.26%
800 790 1.25% 832 4.00% 812.50 26.45 3.25%
20 20.4 2.00% 19 5.00% 20.69 2.34 11.33%
100 106 6.00% 102 2.00% 103.63 1.92 1.86%
800 783 2.13% 796 0.50% 812.25 27.10 3.34%
Day 1 (08/24/11) 19 mix Day2 (08/28/11) 19 mix Day3 (08/29/11) 19 mix
Day6 (09/22/11) 18 mix Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
Day6 (09/30/11) 18 mix
22.63 1.42
Blood
21.33 1.10 5.16%
6.28%
101.83 2.93 2.88% 103.33 3.06 2.96% 98.57 2.15
6.64%21.17 1.20
18.43 0.95 5.16% 21.33 0.55
5.68% 17.97 1.19
2.18%
102.33 3.51 3.43% 101.17 3.75 3.70%
105.33 1.15 1.10%99.93 4.47 4.48%
835.33 15.01 1.80% 821.33 4.93 0.60% 812.00
102.47 2.66 2.59%
95.57 0.60 0.63%
1.37% 20.44 1.82 8.89%
2.58%
25.89 3.15%
855.00 7.94 0.93%
9.85 1.21%
Between Day
1.73 0.22% 852.67 9.71
Day6 (09/30/11) 19 mix
Blood
Serum
Urine
Blood
Serum
Urine
1.14% 821.58
28.29 3.49%
790.00
794.67 11.15 1.40% 811.67
19.80 1.56 7.86% 20.70 0.28
Aripiprazole
Linear
Urine
Serum
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Quadratic
Buspirone
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.1 5.50% 20.7 3.50% 19.1 4.50%
20 20 0.00% 20.4 2.00% 18.5 7.50%
20 20.5 2.50% 20.7 3.50% 18.1 9.50%
100 102 2.00% 104 4.00% 100 0.00%
100 101 1.00% 103 3.00% 103 3.00%
100 106 6.00% 102 2.00% 101 1.00%
800 779 2.63% 789 1.38% 810 1.25%
800 812 1.50% 789 1.38% 819 2.38%
800 815 1.88% 787 1.63% 780 2.50%
20 20.8 4.00% 20.4 2.00% 18.5 7.50%
100 97.4 2.60% 106 6.00% 102 2.00%
800 752 6.00% 774 3.25% 765 4.38%
20 20.5 2.50% 21.4 7.00% 17.4 13.00%
100 103 3.00% 102 2.00% 103 3.00%
800 758 5.25% 812 1.50% 791 1.13%
20 20.5 2.50% 20.3 1.50% 20 0.00%
20 19.7 1.50% 20.8 4.00% 20.6 3.00%
20 18.7 6.50% 20.4 2.00% 20.1 0.50%
100 97.8 2.20% 104 4.00% 98.3 1.70%
100 102 2.00% 109 9.00% 100 0.00%
100 97.2 2.80% 107 7.00% 103 3.00%
800 788 1.50% 755 5.63% 840 5.00%
800 787 1.63% 768 4.00% 807 0.88%
800 790 1.25% 818 2.25% 847 5.88%
20 19.4 3.00% 21.2 6.00% 21.3 6.50%
100 98.2 1.80% 108 8.00% 101 1.00%
800 778 2.75% 815 1.88% 800 0.00%
20 19 5.00% 19.6 2.00% 19.6 2.00%
100 97.5 2.50% 106 6.00% 105 5.00%
800 832 4.00% 764 4.50% 781 2.38%
20 19.7 1.50% 20.4 2.00%
20
20 17.6 12.00% 20.4 2.00%
100 100 0.00% 109 9.00%
100 100 0.00% 106 6.00%
100 103 3.00% 106 6.00%
800 777 2.88% 835 4.38%
800 809 1.13% 815 1.88%
800 800 0.00% 815 1.88%
20 19.7 1.50% 20.5 2.50% 20.23 0.96 4.76%
100 102 2.00% 105 5.00% 102.45 3.70 3.61%
800 821 2.63% 793 0.88% 787.25 24.21 3.08%
20 18.5 7.50% 20.4 2.00% 19.55 1.26 6.44%
100 104 4.00% 106 6.00% 103.31 2.76 2.68%
800 776 3.00% 809 1.13% 790.38 25.60 3.24%
Day6 (09/30/11) 19 mix Between Day
Day6 (09/22/11)
20.60 0.17 0.84%
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
18.57 0.50 2.71%
19.63 0.90 4.59%
20.53 0.55 2.68%
1.00 0.97% 101.33 1.53 1.51%
99.00
103.00 2.65 2.57% 103.00
19.92 0.94 4.72%18.65 1.48 7.96% 20.40 0.00 0.00%
20.50 0.26 1.29%
1.73 1.62% 102.68 3.26 3.17%
2.38
101.00 1.73 1.71% 107.00
2.62 2.64% 106.67 2.52 2.36% 100.43
802.00 19.97
Serum
Serum
Day6 (09/30/11) 18 mix
2.54%
788.33 1.53 0.19% 780.33 33.26
2.49% 788.33 1.15 0.15% 803.00 20.42
2.37%
20.23 0.32 1.59%
Blood
Urine
Blood
Urine
Blood
Urine
2.07%
Serum
2.85%821.67 11.55 1.41% 801.29 22.81
4.26% 831.33 21.36 2.57%
795.33 16.50
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Quadratic
Chlorpromazine
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.5 7.50% 20.3 1.50% 19.1 4.50%
20 20.8 4.00% 20.5 2.50% 19 5.00%
20 19.9 0.50% 20 0.00% 17.9 10.50%
100 103 3.00% 101 1.00% 100 0.00%
100 108 8.00% 102 2.00% 101 1.00%
100 105 5.00% 100 0.00% 100 0.00%
800 822 2.75% 799 0.13% 813 1.63%
800 799 0.13% 827 3.38% 818 2.25%
800 780 2.50% 800 0.00% 798 0.25%
20 20.7 3.50% 19.1 4.50% 19 5.00%
100 102 2.00% 99.9 0.10% 98.6 1.40%
800 779 2.63% 790 1.25% 775 3.13%
20 21 5.00% 19.9 0.50% 17.5 12.50%
100 106 6.00% 103 3.00% 99.4 0.60%
800 766 4.25% 804 0.50% 803 0.38%
20 20.6 3.00% 20.4 2.00% 20.3 1.50%
20 20.1 0.50% 20.5 2.50% 20.3 1.50%
20 19.4 3.00% 19.7 1.50% 19.9 0.50%
100 98.3 1.70% 102 2.00% 101 1.00%
100 99.2 0.80% 103 3.00% 102 2.00%
100 98.7 1.30% 102 2.00% 104 4.00%
800 788 1.50% 766 4.25% 848 6.00%
800 793 0.88% 790 1.25% 855 6.88%
800 798 0.25% 806 0.75% 870 8.75%
20 20 0.00% 20.6 3.00% 21 5.00%
100 98.9 1.10% 101 1.00% 103 3.00%
800 777 2.88% 785 1.88% 815 1.88%
20 20.5 2.50% 20.5 2.50% 19.7 1.50%
100 103 3.00% 104 4.00% 104 4.00%
800 803 0.38% 773 3.38% 831 3.88%
20 20 0.00% 20.9 4.50%
20
20 18.2 9.00% 20.6 3.00%
100 97.5 2.50% 98.2 1.80%
100 96.7 3.30% 99.1 0.90%
100 96.2 3.80% 99.4 0.60%
800 793 0.88% 845 5.63%
800 797 0.38% 796 0.50%
800 821 2.63% 830 3.75%
20 19 5.00% 20.3 1.50% 19.96 0.82 4.12%
100 99.5 0.50% 103 3.00% 100.74 1.78 1.76%
800 789 1.38% 804 0.50% 789.25 13.93 1.76%
20 19.3 3.50% 20.9 4.50% 19.91 1.14 5.72%
100 103 3.00% 101 1.00% 102.93 2.00 1.94%
800 763 4.63% 786 1.75% 791.13 23.34 2.95%
Day6 (09/22/11)
3.57%
20.03 0.60 3.01% 20.20 0.44
3.87% 20.27 0.25 1.24% 18.67 0.6720.73 0.80
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
102.33 1.53 1.49%
100.33 0.58 0.58%
98.73 0.45 0.46%
105.33 2.52 2.39% 101.00 1.00 0.99%
2.16% 20.17 0.23 1.15%
10.41 1.29%15.89 1.96% 809.67
793.00
100.72 2.72
Between Day
96.80 0.66
800.33 21.03 2.63% 808.67
Blood
1.27
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix
0.62
1.31%
803.67 15.14 1.88% 823.67
5.00 0.63% 787.33 20.13 2.56% 857.67
0.63%
4.27%6.66% 20.75 0.21 1.02% 20.00 0.8519.10
11.24
102.33 0.58
2.71%0.68% 98.90
Serum
Urine
Serum
Serum
25.11 3.05%
0.56%
Blood
Urine
Blood
Urine
810.50 25.22 3.11%
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 Clozapine
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.9 9.50% 20.3 1.50% 18.8 6.00%
20 20.2 1.00% 20.6 3.00% 18.1 9.50%
20 20.4 2.00% 19.5 2.50% 17.9 10.50%
100 106 6.00% 102 2.00% 97.9 2.10%
100 102 2.00% 104 4.00% 98.8 1.20%
100 106 6.00% 101 1.00% 95.8 4.20%
800 802 0.25% 789 1.38% 830 3.75%
800 819 2.38% 815 1.88% 805 0.63%
800 762 4.75% 786 1.75% 785 1.88%
20 20.5 2.50% 19.9 0.50% 18.8 6.00%
100 98.5 1.50% 107 7.00% 96.7 3.30%
800 772 3.50% 808 1.00% 778 2.75%
20 20.4 2.00% 20.1 0.50% 16.8 16.00%
100 94 6.00% 101 1.00% 96.8 3.20%
800 756 5.50% 785 1.88% 816 2.00%
20 20.1 0.50% 19.5 2.50% 20 0.00%
20 19.3 3.50% 19.6 2.00% 20.6 3.00%
20 19.5 2.50% 19.5 2.50% 19.9 0.50%
100 99.3 0.70% 101 1.00% 105 5.00%
100 102 2.00% 101 1.00% 105 5.00%
100 97.9 2.10% 106 6.00% 107 7.00%
800 788 1.50% 767 4.13% 850 6.25%
800 778 2.75% 777 2.88% 814 1.75%
800 819 2.38% 813 1.63% 852 6.50%
20 19.4 3.00% 20.4 2.00% 21.2 6.00%
100 100 0.00% 105 5.00% 104 4.00%
800 784 2.00% 812 1.50% 814 1.75%
20 17.9 10.50% 18.4 8.00% 19.3 3.50%
100 96.5 3.50% 99 1.00% 108 8.00%
800 797 0.38% 769 3.88% 805 0.63%
20 19.4 3.00% 20.7 3.50%
20 19.7 1.50%
20 18.5 7.50% 20.6 3.00%
100 99.5 0.50% 102 2.00%
100 95.1 4.90% 101 1.00%
100 98 2.00% 103 3.00%
800 793 0.88% 862 7.75%
800 809 1.13% 796 0.50%
800 780 2.50% 851 6.38%
20 19.9 0.50% 20.3 1.50% 20.05 0.73 3.65%
100 97.7 2.30% 103 3.00% 101.49 3.77 3.72%
800 782 2.25% 811 1.38% 795.13 17.66 2.22%
20 19.6 2.00% 19.5 2.50% 19.00 1.21 6.38%
100 98.9 1.10% 98 2.00% 99.03 4.18 4.22%
800 719 10.13% 766 4.25% 776.63 31.07 4.00%
Day6 (09/30/11) 19 mix Between Day
Day6 (09/22/11)
20.13 0.57 2.82%
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
18.27 0.47 2.59%
19.63 0.42 2.12%
20.83 0.93 4.46%
1.53 1.49% 97.50 1.54 1.58%
99.73
104.67 2.31 2.21% 102.33
19.77 0.91 4.58%19.20 0.62 3.25% 20.65 0.07 0.34%
19.53 0.06 0.30%
1.00 0.98% 101.51 3.32 3.27%
1.15
97.53 2.24 2.29% 102.00
2.08 2.09% 102.67 2.89 2.81% 105.67
794.33 29.26
Serum
Serum
Day6 (09/30/11) 18 mix
2.79%
795.00 21.38 2.69% 785.67 24.19
3.68% 796.67 15.95 2.00% 806.67 22.55
1.09%
20.17 0.38 1.88%
Blood
Urine
Blood
Urine
Blood
Urine
1.83%
Serum
3.45%836.33 35.36 4.23% 805.92 27.84
3.08% 838.67 21.39 2.55%
794.00 14.53
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 Fluphenazine
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.9 9.50% 21.7 8.50% 19.2 4.00%
20 22 10.00% 20.4 2.00% 18.6 7.00%
20 21.5 7.50% 20.6 3.00% 17.6 12.00%
100 100 0.00% 106 6.00% 98.9 1.10%
100 102 2.00% 103 3.00% 97.4 2.60%
100 101 1.00% 101 1.00% 99.2 0.80%
800 799 0.13% 787 1.63% 797 0.38%
800 854 6.75% 821 2.63% 797 0.38%
800 808 1.00% 784 2.00% 824 3.00%
20 21.3 6.50% 20.1 0.50% 19.2 4.00%
100 102 2.00% 102 2.00% 99.6 0.40%
800 774 3.25% 783 2.13% 779 2.63%
20 21.9 9.50% 21.7 8.50% 17.4 13.00%
100 104 4.00% 99 1.00% 98.8 1.20%
800 763 4.63% 788 1.50% 817 2.13%
20 20.8 4.00% 21.2 6.00% 20.4 2.00%
20 19.2 4.00% 20.4 2.00% 20.4 2.00%
20 20.7 3.50% 21.6 8.00% 20 0.00%
100 98.7 1.30% 104 4.00% 97 3.00%
100 102 2.00% 109 9.00% 102 2.00%
100 99.7 0.30% 106 6.00% 103 3.00%
800 801 0.13% 756 5.50% 810 1.25%
800 790 1.25% 773 3.38% 838 4.75%
800 785 1.88% 788 1.50% 875 9.38%
20 20.9 4.50% 21.6 8.00% 21.3 6.50%
100 101 1.00% 110 10.00% 105 5.00%
800 773 3.38% 772 3.50% 779 2.63%
20 20.8 4.00% 21.4 7.00% 20.7 3.50%
100 102 2.00% 104 4.00% 109 9.00%
800 804 0.50% 785 1.88% 780 2.50%
20 20.4 2.00% 20.9 4.50%
20 19.2 4.00%
20 18.5 7.50% 21 5.00%
100 98.4 1.60% 102 2.00%
100 93.3 6.70% 101 1.00%
100 99.1 0.90% 98.9 1.10%
800 776 3.00% 851 6.38%
800 806 0.75% 806 0.75%
800 779 2.63% 842 5.25%
20 19.6 2.00% 20.5 2.50% 20.56 0.87 4.22%
100 99.4 0.60% 104 4.00% 102.88 3.47 3.38%
800 771 3.63% 794 0.75% 778.13 7.64 0.98%
20 20 0.00% 20.9 4.50% 20.60 1.43 6.93%
100 98.3 1.70% 104 4.00% 102.39 3.64 3.55%
800 744 7.00% 772 3.50% 781.63 22.87 2.93%
Day6 (09/22/11)
101.00 1.00 0.99% 103.33 2.52
Urine
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
28.97 3.59%
3.88%
4.38%
20.23 0.90 4.43% 21.07 0.61
1.21% 20.90 0.70 3.35% 18.47 0.8121.80 0.26
2.44%
4.96% 0.34%
2.90%
Serum
Serum
3.27% 1.57%
106.33 2.52 2.37%100.13 1.69 1.69%
20.55 2.58% 806.00 15.59 1.93%
792.00
820.33 29.50 3.60% 797.33
Blood
100.67 3.21 3.19%
98.50 0.96 0.98%
2.86% 806.13
32.608.19 1.03% 772.33 16.01 2.07% 841.00
Urine
Blood
Urine
20.27 0.23 1.14%
Blood
23.81
20.36 1.16 5.72%19.37 0.96 20.95 0.07
100.94 3.32 3.29%96.93 3.17
833.002.10%16.52787.00
Serum
100.63 1.58
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Quadratic
Haloperidol
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 20.6 3.00% 20.3 1.50% 18.6 7.00%
20 20.2 1.00% 20.2 1.00% 18.6 7.00%
20 21.6 8.00% 19.5 2.50% 17.1 14.50%
100 96.5 3.50% 105 5.00% 103 3.00%
100 103 3.00% 106 6.00% 101 1.00%
100 97.1 2.90% 102 2.00% 102 2.00%
800 828 3.50% 797 0.38% 773 3.38%
800 813 1.63% 791 1.13% 777 2.88%
800 836 4.50% 773 3.38% 774 3.25%
20 20.5 2.50% 20.9 4.50% 18.4 8.00%
100 95.1 4.90% 102 2.00% 100 0.00%
800 737 7.88% 800 0.00% 757 5.38%
20 21 5.00% 21.5 7.50% 17.3 13.50%
100 97.9 2.10% 105 5.00% 103 3.00%
800 766 4.25% 807 0.88% 822 2.75%
20 19.3 3.50% 19.5 2.50% 20.8 4.00%
20 19.3 3.50% 19.8 1.00% 21 5.00%
20 18.6 7.00% 20.3 1.50% 20.6 3.00%
100 100 0.00% 104 4.00% 110 10.00%
100 98.2 1.80% 108 8.00% 106 6.00%
100 94.4 5.60% 103 3.00% 113 13.00%
800 772 3.50% 798 0.25% 805 0.63%
800 777 2.88% 791 1.13% 821 2.63%
800 781 2.38% 814 1.75% 836 4.50%
20 18.9 5.50% 20.2 1.00% 20.7 3.50%
100 95.2 4.80% 111 11.00% 107 7.00%
800 774 3.25% 794 0.75% 781 2.38%
20 17.5 12.50% 19.5 2.50% 19.8 1.00%
100 96.1 3.90% 112 12.00% 112 12.00%
800 848 6.00% 808 1.00% 791 1.13%
20 20.3 1.50% 20.3 1.50%
20
20 19.4 3.00% 19.6 2.00%
100 102 2.00% 105 5.00%
100 103 3.00% 102 2.00%
100 106 6.00% 103 3.00%
800 822 2.75% 837 4.63%
800 818 2.25% 787 1.63%
800 816 2.00% 863 7.88%
20 19.9 0.50% 19.7 1.50% 19.90 0.88 4.41%
100 103 3.00% 108 8.00% 102.66 5.82 5.67%
800 820 2.50% 838 4.75% 787.63 32.75 4.16%
20 20.1 0.50% 20.4 2.00% 19.64 1.52 7.75%
100 112 12.00% 106 6.00% 105.50 6.32 5.99%
800 797 0.38% 855 6.88% 811.75 29.44 3.63%
Day6 (09/22/11)
18.10 0.87 4.78%
Day6 (09/24/11) 18 mix
102.00 1.00 0.98%
2.18%
Day6 (09/24/11) 19mix Rerun 27th
2.08 2.00%
19.87 0.4019.07 0.40 2.12%
20.80 0.72 3.47% 20.00 0.44
3.51 3.20%2.86 2.93% 105.00 2.65 2.52% 109.67
Blood
Serum
97.53
98.87 3.59 3.63% 104.33
5.02%
2.03% 20.80 0.20 0.96%
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
Urine
Blood 103.67 2.08 2.01% 103.33
19.80
3.16%
15.50
0.9919.85 0.64 3.21%
Serum
1.89%
818.67 3.06
0.27%
776.67 4.51 0.58% 801.00 11.79
1.41% 787.00 12.49 1.59% 774.67 2.08825.67 11.68
1.53 1.48% 103.05 4.18 4.05%
0.37% 829.00 38.63 4.66% 804.17 25.43
1.47% 820.67
19.95 0.49 2.48%
Urine
Serum
Blood
Urine
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 Loxapine
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21 5.00% 19.5 2.50% 19.1 4.50%
20 20.5 2.50% 19.7 1.50% 18.3 8.50%
20 20.1 0.50% 19.4 3.00% 17.2 14.00%
100 97.5 2.50% 104 4.00% 103 3.00%
100 101 1.00% 101 1.00% 103 3.00%
100 101 1.00% 98.3 1.70% 101 1.00%
800 837 4.63% 784 2.00% 796 0.50%
800 859 7.38% 806 0.75% 807 0.88%
800 814 1.75% 802 0.25% 790 1.25%
20 20.4 2.00% 19.2 4.00% 19.1 4.50%
100 95.4 4.60% 102 2.00% 101 1.00%
800 774 3.25% 808 1.00% 767 4.13%
20 21.6 8.00% 20.1 0.50% 17.4 13.00%
100 98.3 1.70% 100 0.00% 100 0.00%
800 747 6.63% 802 0.25% 817 2.13%
20 20.6 3.00% 19.5 2.50% 19.6 2.00%
20 19.6 2.00% 20 0.00% 19.8 1.00%
20 18.8 6.00% 20.8 4.00% 20.2 1.00%
100 98.8 1.20% 103 3.00% 104 4.00%
100 100 0.00% 106 6.00% 99.5 0.50%
100 97.3 2.70% 103 3.00% 104 4.00%
800 783 2.13% 784 2.00% 824 3.00%
800 797 0.38% 819 2.38% 810 1.25%
800 807 0.88% 827 3.38% 863 7.88%
20 19.8 1.00% 20.5 2.50% 20.7 3.50%
100 100 0.00% 108 8.00% 103 3.00%
800 774 3.25% 745 6.88% 803 0.38%
20 19.1 4.50% 19.8 1.00% 19.1 4.50%
100 101 1.00% 103 3.00% 102 2.00%
800 817 2.13% 816 2.00% 807 0.88%
20 19.5 2.50% 21.4 7.00%
20
20 19.1 4.50% 20.6 3.00%
100 101 1.00% 102 2.00%
100 104 4.00% 99.8 0.20%
100 101 1.00% 101 1.00%
800 799 0.13% 871 8.88%
800 804 0.50% 811 1.38%
800 781 2.38% 844 5.50%
20 19.1 4.50% 19.9 0.50% 19.84 0.65 3.30%
100 102 2.00% 105 5.00% 102.05 3.68 3.60%
800 777 2.88% 811 1.38% 782.38 23.00 2.94%
20 19.4 3.00% 20.3 1.50% 19.60 1.20 6.15%
100 105 5.00% 102 2.00% 101.41 2.07 2.04%
800 767 4.13% 833 4.13% 800.75 28.96 3.62%
Day6 (09/22/11) Day6 (09/24/11) 18 mix
2.02% 101.10 2.85 2.82%
1.08%797.33
Blood
1.54%
19.30 0.28
5.24%
19.67 0.90 4.59% 20.10 0.66
2.20% 19.53 0.15 0.78% 18.20 0.9520.53 0.45
Day6 (09/24/11) 19mix Rerun 27th
Between Day
4.75%1.47% 21.00 0.57 2.69% 19.74 0.94
3.26% 19.87 0.31
2.69%
1.70% 100.93 1.10 1.09%
104.00 1.73
795.67
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix
102.00 1.73
836.67 22.50
2.22%
1.67% 102.50 2.60 2.53%
102.33 1.15 1.13%
98.70 1.35 1.37%
99.83 2.02
1.52% 810.00 22.87 2.82% 832.33
11.72 1.47% 797.67 8.62
101.43 2.25
Urine
Blood
Serum
Urine
Serum
Serum
Urine
Blood
30.05 3.57% 813.29 25.61 3.15%
27.47 3.30%
794.67 12.10 1.52% 842.00
12.06
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 Olanzapine
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.4 7.00% 20.4 2.00% 18.4 8.00%
20 20.5 2.50% 20.6 3.00% 18.1 9.50%
20 19.7 1.50% 19.6 2.00% 17.6 12.00%
100 104 4.00% 100 0.00% 100 0.00%
100 104 4.00% 101 1.00% 104 4.00%
100 104 4.00% 97 3.00% 102 2.00%
800 785 1.88% 808 1.00% 818 2.25%
800 791 1.13% 820 2.50% 809 1.13%
800 779 2.63% 798 0.25% 780 2.50%
20 21.6 8.00% 20.3 1.50% 18.1 9.50%
100 106 6.00% 103 3.00% 101 1.00%
800 718 10.25% 787 1.63% 761 4.88%
20 20.8 4.00% 20.4 2.00% 18.1 9.50%
100 107 7.00% 99.7 0.30% 103 3.00%
800 721 9.88% 786 1.75% 794 0.75%
20 17.3 13.50% 20.1 0.50% 19.8 1.00%
20 17.5 12.50% 19.7 1.50% 20.4 2.00%
20 16.1 19.50% 19.4 3.00% 18.9 5.50%
100 96.6 3.40% 103 3.00% 99.5 0.50%
100 94.5 5.50% 106 6.00% 101 1.00%
100 94 6.00% 104 4.00% 102 2.00%
800 790 1.25% 772 3.50% 804 0.50%
800 784 2.00% 776 3.00% 832 4.00%
800 813 1.63% 813 1.63% 838 4.75%
20 16.4 18.00% 21 5.00% 21.3 6.50%
100 102 2.00% 103 3.00% 103 3.00%
800 775 3.13% 746 6.75% 786 1.75%
20 18.3 8.50% 19.9 0.50% 20.3 1.50%
100 109 9.00% 106 6.00% 106 6.00%
800 829 3.63% 761 4.88% 780 2.50%
20 18.6 7.00% 21 5.00%
20 19 5.00%
20 18 10.00% 21 5.00%
100 92.4 7.60% 98.5 1.50%
100 90.8 9.20% 102 2.00%
100 95.6 4.40% 101 1.00%
800 779 2.63% 836 4.50%
800 802 0.25% 786 1.75%
800 814 1.75% 820 2.50%
20 18.8 6.00% 20.6 3.00% 19.76 1.82 9.22%
100 96.7 3.30% 107 7.00% 102.71 3.14 3.06%
800 773 3.38% 781 2.38% 765.88 23.68 3.09%
20 19.4 3.00% 22.3 11.50% 19.94 1.36 6.84%
100 103 3.00% 106 6.00% 104.96 2.91 2.77%
800 736 8.00% 774 3.25% 772.63 33.83 4.38%
Day6 (09/22/11)
0.40 2.24%
16.97 0.76 4.46% 19.73
0.85 4.14% 20.20 0.53 2.62% 18.0320.53
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
1.380.50 2.72% 21.00 0.00 0.00% 19.27
0.35
104.00 0.00 0.00% 99.33 2.08
18.53
2.10% 102.00 2.00 1.96%
95.03 1.38
1.78% 19.70 0.75 3.83%
808.67 11.02 1.36% 802.33 19.86 2.48%
7.18%
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
785.00 6.00 0.76%
1.79% 99.87 4.12
798.33 17.79 2.23%
Serum
Urine
Blood
Serum
104.33
18.15 2.20%795.67 15.31 1.92% 787.00 22.61 2.87%
1.53 1.46% 100.83 1.26
Urine
Blood
Urine
Serum
Blood
814.00 25.53 3.14% 801.96 19.78 2.47%
824.67
4.13%
1.25%
92.93 2.44 2.63% 100.50 1.80
1.45%
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 Perphenzine
Linear
Day 1 (08/24/11) 19 mix Day2 (08/28/11) 19 mix Day3 (08/29/11) 19 mix
20 21.3 6.50% 22 10.00% 18.6 7.00%
20 20.7 3.50% 20.5 2.50% 18.4 8.00%
20 20.6 3.00% 19.7 1.50% 17.4 13.00%
100 95.9 4.10% 107 7.00% 99.1 0.90%
100 97.9 2.10% 102 2.00% 99.1 0.90%
100 96 4.00% 105 5.00% 100 0.00%
800 827 3.38% 823 2.88% 800 0.00%
800 847 5.88% 836 4.50% 802 0.25%
800 815 1.88% 799 0.13% 780 2.50%
20 21.3 6.50% 20 0.00% 19.2 4.00%
100 95.1 4.90% 102 2.00% 97.8 2.20%
800 813 1.63% 798 0.25% 804 0.50%
20 22.8 14.00% 21.5 7.50% 17.6 12.00%
100 102 2.00% 99.1 0.90% 102 2.00%
800 825 3.13% 821 2.63% 790 1.25%
20 20.8 4.00% 20 0.00% 20.7 3.50%
20 19.7 1.50% 19.6 2.00% 20.2 1.00%
20 19.6 2.00% 20.1 0.50% 20 0.00%
100 98.2 1.80% 101 1.00% 98 2.00%
100 99.7 0.30% 105 5.00% 95.2 4.80%
100 96.7 3.30% 110 10.00% 101 1.00%
800 794 0.75% 755 5.63% 816 2.00%
800 803 0.38% 790 1.25% 852 6.50%
800 782 2.25% 823 2.88% 864 8.00%
20 21.1 5.50% 19.9 0.50% 21.4 7.00%
100 104 4.00% 109 9.00% 107 7.00%
800 819 2.38% 789 1.38% 842 5.25%
20 20.2 1.00% 21.1 5.50% 20.9 4.50%
100 99.8 0.20% 105 5.00% 108 8.00%
800 828 3.50% 821 2.63% 847 5.88%
20 19.2 4.00% 20.2 1.00%
20
20 17.8 11.00% 20.3 1.50%
100 104 4.00% 103 3.00%
100 100 0.00% 98.1 1.90%
100 109 9.00% 99.6 0.40%
800 798 0.25% 845 5.63%
800 813 1.63% 805 0.63%
800 788 1.50% 840 5.00%
20 19.7 1.50% 20.3 1.50% 20.36 0.81 4.00%
100 106 6.00% 107 7.00% 103.49 4.88 4.71%
800 803 0.38% 817 2.13% 810.63 16.17 1.99%
20 18.5 7.50% 20.7 3.50% 20.41 1.66 8.13%
100 112 12.00% 105 5.00% 104.11 4.34 4.16%
800 777 2.88% 809 1.13% 814.75 22.26 2.73%
Day6 (09/22/11) 18 mix Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
3.55%
20.03 0.67
Blood
20.87 0.38 1.81% 20.73 1.17
3.32% 19.90 0.26 0.36
5.63% 18.13 0.64
96.60 1.13 1.17% 104.67 2.52 2.40% 99.40 0.52 0.52%
0.35% 19.88
1.33% 20.30
4.02%
98.07 2.90 2.96%
Between Day
799.67
12.17 1.53%
793.00 10.54 1.33% 789.33
12.58 1.57% 830.00 21.79 2.63% 812.38 26.18 3.22%
24.98 2.96%
1.09
34.00 4.31% 844.00
5.49%
4.51 4.28%
0.07
Day6 (09/30/11) 19 mix
100.23 2.51 2.50% 100.85 4.05
829.67 16.17 1.95% 819.33 18.77 2.29% 794.00
1.78%
104.33 4.51 4.32%
98.20 1.50 1.53% 105.33
18.50 0.99 5.35% 20.25
Day6 (09/30/11) 18 mix
Urine
Urine
Blood
Serum
Urine
Blood
Serum
Serum
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 Pipamperone
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 20.6 3.00% 22.4 12.00% 18.4 8.00%
20 21.3 6.50% 20.6 3.00% 21.1 5.50%
20 22.4 12.00% 20.4 2.00% 18.4 8.00%
100 105 5.00% 103 3.00% 98 2.00%
100 105 5.00% 105 5.00% 99.4 0.60%
100 103 3.00% 103 3.00% 103 3.00%
800 824 3.00% 802 0.25% 797 0.38%
800 849 6.13% 795 0.63% 791 1.13%
800 781 2.38% 771 3.63% 761 4.88%
20 20.9 4.50% 19.9 0.50% 19 5.00%
100 103 3.00% 98.9 1.10% 98.7 1.30%
800 732 8.50% 737 7.88% 742 7.25%
20 21.1 5.50% 22.5 12.50% 17.5 12.50%
100 107 7.00% 104 4.00% 109 9.00%
800 741 7.38% 763 4.63% 795 0.63%
20 19 5.00% 20.4 2.00% 19.1 4.50%
20 19.7 1.50% 20.3 1.50% 18.4 8.00%
20 18.9 5.50% 21 5.00% 21.5 7.50%
100 94 6.00% 98.1 1.90% 98.5 1.50%
100 94.7 5.30% 102 2.00% 97.5 2.50%
100 96.2 3.80% 95 5.00% 101 1.00%
800 788 1.50% 759 5.13% 795 0.63%
800 787 1.63% 715 10.63% 794 0.75%
800 783 2.13% 758 5.25% 869 8.63%
20 20.7 3.50% 21.4 7.00% 20.6 3.00%
100 97.6 2.40% 101 1.00% 98.7 1.30%
800 755 5.63% 770 3.75% 761 4.88%
20 20 0.00% 19.7 1.50% 19.5 2.50%
100 98.6 1.40% 100 0.00% 104 4.00%
800 833 4.13% 760 5.00% 740 7.50%
20 20.6 3.00% 21.3 6.50%
20 20.1 0.50%
20 18.2 9.00% 20.9 4.50%
100 106 6.00% 102 2.00%
100 95.6 4.40% 99 1.00%
100 103 3.00% 103 3.00%
800 784 2.00% 846 5.75%
800 841 5.13% 768 4.00%
800 741 7.38% 855 6.88%
20 18.1 9.50% 20.6 3.00% 20.15 1.10 5.44%
100 98.5 1.50% 102 2.00% 99.80 1.94 1.94%
800 792 1.00% 788 1.50% 759.63 22.58 2.97%
20 19.7 1.50% 19.8 1.00% 19.98 1.42 7.12%
100 101 1.00% 105 5.00% 103.58 3.54 3.42%
800 772 3.50% 752 6.00% 769.50 31.19 4.05%
Day6 (09/30/11) 19 mix Between Day
Day6 (09/22/11)
21.13 1.10 5.21%
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
19.30 1.56 8.08%
19.20 0.44 2.27%
21.43 0.91 4.23%
1.15 1.11% 100.13 2.58 2.58%
94.97
104.33 1.15 1.11% 103.67
20.22 1.25 6.20%19.63 1.27 6.45% 21.10 0.28 1.34%
20.57 0.38 1.84%
2.08 2.05% 100.42 3.67 3.66%
1.80
101.53 5.35 5.27% 101.33
1.12 1.18% 98.37 3.51 3.57% 99.00
818.00 34.39
Serum
Serum
Day6 (09/30/11) 18 mix
2.46%
786.00 2.65 0.34% 744.00 25.12
4.20% 789.33 16.26 2.06% 783.00 19.29
1.82%
19.67 1.63 8.27%
Blood
Urine
Blood
Urine
Blood
Urine
6.36%
Serum
4.74%823.00 47.84 5.81% 793.92 37.65
3.38% 819.33 43.02 5.25%
788.67 50.16
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Quadratic
Promethazine
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.4 7.00% 20.6 3.00% 18.5 7.50%
20 21.2 6.00% 20 0.00% 18.6 7.00%
20 20.6 3.00% 20 0.00% 17 15.00%
100 102 2.00% 101 1.00% 103 3.00%
100 102 2.00% 101 1.00% 103 3.00%
100 104 4.00% 99.5 0.50% 98.9 1.10%
800 807 0.88% 784 2.00% 805 0.63%
800 833 4.13% 815 1.88% 814 1.75%
800 796 0.50% 792 1.00% 789 1.38%
20 21.3 6.50% 19.5 2.50% 19 5.00%
100 104 4.00% 99.4 0.60% 98 2.00%
800 768 4.00% 782 2.25% 767 4.13%
20 21.8 9.00% 21.1 5.50% 17.6 12.00%
100 105 5.00% 101 1.00% 102 2.00%
800 771 3.63% 790 1.25% 797 0.38%
20 20.3 1.50% 20.4 2.00% 20 0.00%
20 19.2 4.00% 19.8 1.00% 21.2 6.00%
20 19.7 1.50% 20.4 2.00% 19.8 1.00%
100 94.9 5.10% 101 1.00% 99.9 0.10%
100 100 0.00% 103 3.00% 98.1 1.90%
100 97.8 2.20% 102 2.00% 103 3.00%
800 791 1.13% 740 7.50% 834 4.25%
800 784 2.00% 756 5.50% 851 6.38%
800 789 1.38% 795 0.63% 885 10.63%
20 19.6 2.00% 20.7 3.50% 20.4 2.00%
100 103 3.00% 105 5.00% 102 2.00%
800 780 2.50% 760 5.00% 843 5.38%
20 20 0.00% 20.3 1.50% 19 5.00%
100 101 1.00% 104 4.00% 106 6.00%
800 793 0.88% 786 1.75% 815 1.88%
20 19.6 2.00% 20.6 3.00%
20
20 18.8 6.00% 20 0.00%
100 99.7 0.30% 106 6.00%
100 99.8 0.20% 103 3.00%
100 101 1.00% 103 3.00%
800 791 1.13% 849 6.13%
800 805 0.63% 804 0.50%
800 820 2.50% 836 4.50%
20 19.7 1.50% 20.8 4.00% 20.13 0.79 3.92%
100 101 1.00% 108 8.00% 102.55 3.19 3.11%
800 801 0.13% 820 2.50% 790.13 29.05 3.68%
20 20 0.00% 21.3 6.50% 20.14 1.35 6.73%
100 106 6.00% 106 6.00% 103.88 2.23 2.15%
800 777 2.88% 798 0.25% 790.88 13.56 1.71%
Day6 (09/22/11) Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
4.97%
2.79% 20.20 0.35
1.98% 20.20 0.35 1.71% 18.03 0.9021.07 0.42
19.73 0.55
5.11%2.95% 20.30 0.42 2.09% 19.90 1.02
1.71% 20.33 0.76
19.20 0.57
2.48 2.47%
101.63 2.37 2.33%
97.57 2.56 2.62%
102.67 1.15 1.12% 100.50 0.87 0.86%
3.72%
101.11 2.36 2.34%100.17 0.72 0.72% 104.00 1.73 1.67%
102.00 1.00 0.98% 100.33
806.88 31.02 3.84%
25.97
805.33 14.50 1.80% 829.67
3.61 0.46% 763.67 28.29 3.70% 856.67788.00
Serum
Serum
23.16 2.79%
Urine
Blood
Urine
Blood
Blood
Serum
Urine
3.03%
16.09 2.02% 802.67 12.66 1.58%812.00 19.00 2.34% 797.00
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Quadratic
Quetiapine
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 20.4 2.00% 18.9 5.50% 19.3 3.50%
20 21.1 5.50% 20.6 3.00% 21.2 6.00%
20 21.1 5.50% 19.6 2.00% 17.1 14.50%
100 101 1.00% 97.8 2.20% 97.9 2.10%
100 102 2.00% 101 1.00% 104 4.00%
100 101 1.00% 95 5.00% 103 3.00%
800 843 5.38% 817 2.13% 775 3.13%
800 853 6.63% 814 1.75% 794 0.75%
800 846 5.75% 800 0.00% 795 0.63%
20 20.3 1.50% 19.3 3.50% 20.1 0.50%
100 97.1 2.90% 98.1 1.90% 93.9 6.10%
800 812 1.50% 753 5.88% 788 1.50%
20 21.6 8.00% 20.2 1.00% 15.1 24.50%
100 99.3 0.70% 92.8 7.20% 99.8 0.20%
800 805 0.63% 779 2.63% 783 2.13%
20 20.8 4.00% 19.2 4.00% 20.2 1.00%
20 19.5 2.50% 18.9 5.50% 20.8 4.00%
20 19.3 3.50% 21.3 6.50% 20.5 2.50%
100 96 4.00% 96.7 3.30% 105 5.00%
100 100 0.00% 101 1.00% 102 2.00%
100 100 0.00% 103 3.00% 111 11.00%
800 797 0.38% 805 0.63% 799 0.13%
800 777 2.88% 851 6.38% 835 4.38%
800 797 0.38% 836 4.50% 892 11.50%
20 19.5 2.50% 18.8 6.00% 21.3 6.50%
100 101 1.00% 101 1.00% 105 5.00%
800 803 0.38% 813 1.63% 774 3.25%
20 19.6 2.00% 16.1 19.50% 17.5 12.50%
100 99.4 0.60% 80.3 19.70% 93.3 6.70%
800 805 0.63% 664 17.00% 687 14.13%
20 19.3 3.50% 23.4 17.00%
20
20 17.4 13.00% 21.3 6.50%
100 104 4.00% 106 6.00%
100 103 3.00% 114 14.00%
100 104 4.00% 121 21.00%
800 758 5.25% 826 3.25%
800 772 3.50% 882 10.25%
800 764 4.50% 908 13.50%
20 19.7 1.50% 20.3 1.50% 19.91 0.76 3.84%
100 101 1.00% 97.4 2.60% 99.31 3.39 3.41%
800 764 4.50% 827 3.38% 791.75 26.27 3.32%
20 14.6 27.00% 15.3 23.50% 17.50 2.66 15.19%
100 78.6 21.40% 73.8 26.20% 89.66 10.52 11.74%
800 577 27.88% 613 23.38% 714.13 90.83 12.72%
Day6 (09/30/11) 19 mix Between Day
Day6 (09/22/11)
19.70 0.85 4.34%
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
19.20 2.05 10.69%
19.87 0.81 4.10%
20.87 0.40 1.94%
3.00 3.07% 101.63 3.27 3.22%
98.67
101.33 0.58 0.57% 97.93
20.05 1.40 6.96%18.35 1.34 7.32% 22.35 1.48 6.64%
19.80 1.31 6.60%
7.51 6.60% 102.89 5.77 5.61%
4.58
103.67 0.58 0.56% 113.67
2.31 2.34% 100.23 3.22 3.21% 106.00
847.33 5.13
Serum
Serum
Day6 (09/30/11) 18 mix
1.43%
790.33 11.55 1.46% 830.67 23.46
0.61% 810.33 9.07 1.12% 788.00 11.27
4.32%
20.50 0.30 1.46%
Blood
Urine
Blood
Urine
Blood
Urine
0.92%
Serum
4.91%872.00 41.90 4.81% 818.17 40.16
2.82% 842.00 46.89 5.57%
764.67 7.02
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 Risperidone
Quadratic
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 20.8 4.00% 20.5 2.50% 18.8 6.00%
20 21.4 7.00% 20.7 3.50% 18.6 7.00%
20 21.2 6.00% 20.2 1.00% 17.6 12.00%
100 104 4.00% 105 5.00% 105 5.00%
100 105 5.00% 107 7.00% 107 7.00%
100 105 5.00% 103 3.00% 104 4.00%
800 788 1.50% 773 3.38% 790 1.25%
800 851 6.38% 794 0.75% 763 4.63%
800 767 4.13% 764 4.50% 782 2.25%
20 21 5.00% 20.7 3.50% 18.3 8.50%
100 105 5.00% 105 5.00% 105 5.00%
800 715 10.63% 804 0.50% 744 7.00%
20 21.1 5.50% 21.5 7.50% 17.4 13.00%
100 102 2.00% 103 3.00% 105 5.00%
800 711 11.13% 761 4.88% 813 1.63%
20 20 0.00% 19.6 2.00% 21.1 5.50%
20 18.9 5.50% 19.8 1.00% 21.2 6.00%
20 18.5 7.50% 20.1 0.50% 19.4 3.00%
100 98.6 1.40% 105 5.00% 105 5.00%
100 101 1.00% 107 7.00% 103 3.00%
100 99.8 0.20% 110 10.00% 108 8.00%
800 752 6.00% 699 12.63% 731 8.63%
800 751 6.13% 677 15.38% 791 1.13%
800 774 3.25% 733 8.38% 890 11.25%
20 18.8 6.00% 20.2 1.00% 21.7 8.50%
100 99 1.00% 108 8.00% 104 4.00%
800 734 8.25% 711 11.13% 730 8.75%
20 17.9 10.50% 19.3 3.50% 18.9 5.50%
100 98.4 1.60% 110 10.00% 105 5.00%
800 782 2.25% 709 11.38% 706 11.75%
20 20 0.00% 20.9 4.50%
20
20 18.5 7.50% 20.7 3.50%
100 102 2.00% 106 6.00%
100 104 4.00% 111 11.00%
100 106 6.00% 107 7.00%
800 727 9.13% 876 9.50%
800 787 1.63% 757 5.38%
800 745 6.88% 819 2.38%
20 19.4 3.00% 20.2 1.00% 20.04 1.14 5.70%
100 104 4.00% 109 9.00% 104.88 3.00 2.86%
800 762 4.75% 742 7.25% 742.75 29.62 3.99%
20 19.1 4.50% 20.3 1.50% 19.44 1.45 7.46%
100 110 10.00% 107 7.00% 105.05 3.97 3.78%
800 681 14.88% 755 5.63% 739.75 45.04 6.09%
Day6 (09/22/11)
105.33 1.53 1.45%104.67 0.58 0.55%
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
3.51%
4.06% 19.83 0.25
1.45% 20.47 0.25 1.23% 18.33 0.6421.13 0.31
19.13 0.78
19.93 1.07
1.27% 20.57 1.01 4.92%
19.25 1.06
99.80 1.20 1.20%
804.00703.00 28.21 4.01%
0.68%
105.00 2.00 1.90%
13.00 1.71%
5.51% 20.80 0.14
104.93 2.89104.00 2.00 1.92% 108.00 2.65 2.45%
107.33 2.52
774.21 49.51 6.39%
13.87 1.78%
759.00
802.00 43.71 5.45% 777.00
2.75%
2.34% 105.33 2.52 2.39%
5.38%
80.29 9.99%
753.00
15.39 1.98% 778.33
Blood
Urine
59.52 7.28%30.79 4.09% 817.33
Serum
Serum
Urine
Blood
Serum
Urine
Blood
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Quadratic
Thioridazine
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.5 7.50% 20.2 1.00% 18.6 7.00%
20 21.3 6.50% 20.3 1.50% 18.3 8.50%
20 20.7 3.50% 20.9 4.50% 16.7 16.50%
100 104 4.00% 103 3.00% 99.9 0.10%
100 105 5.00% 101 1.00% 103 3.00%
100 107 7.00% 104 4.00% 105 5.00%
800 777 2.88% 811 1.38% 810 1.25%
800 822 2.75% 821 2.63% 803 0.38%
800 784 2.00% 806 0.75% 799 0.13%
20 21.1 5.50% 20.2 1.00% 18.7 6.50%
100 104 4.00% 102 2.00% 101 1.00%
800 710 11.25% 790 1.25% 747 6.63%
20 21.3 6.50% 21.1 5.50% 17.7 11.50%
100 104 4.00% 103 3.00% 101 1.00%
800 735 8.13% 776 3.00% 802 0.25%
20 21.9 9.50% 20.6 3.00%
20 21.4 7.00%
20 20.6 3.00% 20.2 1.00%
100 104 4.00% 104 4.00%
100 105 5.00% 107 7.00%
100 106 6.00% 103 3.00%
800 744 7.00% 855 6.88%
800 778 2.75% 788 1.50%
800 810 1.25% 838 4.75%
20 21.5 7.50% 20.3 1.50% 20.36 1.08 5.29%
100 107 7.00% 111 11.00% 105.00 4.06 3.87%
800 768 4.00% 767 4.13% 756.40 30.07 3.98%
20 20.7 3.50% 20.7 3.50% 20.30 1.48 7.27%
100 107 7.00% 107 7.00% 104.40 2.61 2.50%
800 744 7.00% 773 3.38% 766.00 26.88 3.51%
0.42
102.63 2.57
804.00
5.72%1.97% 20.47 0.38
3.08% 20.40 0.28 1.39% 20.23 1.43
1.85% 17.87 1.02
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/30/11) 19 mix Between Day
7.09%21.30 0.66
21.17
102.67 1.53
5.57 0.69%
2.50%105.33 1.53 1.45% 1.49%
104.06 1.96 1.88%105.00 1.00 0.95% 104.67 2.08 1.99%
777.33 33.01 4.25% 827.00
24.21 3.05% 812.67 7.64 0.94%794.33
Blood
Serum
Urine
Blood
Serum
Urine
34.83 4.21% 803.07 26.95 3.36%
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Quadratic
Trifluoperazine
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 21.7 8.50% 21.1 5.50% 18.8 6.00%
20 20.9 4.50% 20 0.00% 18.2 9.00%
20 21.7 8.50% 19.6 2.00% 17.2 14.00%
100 98 2.00% 99.4 0.60% 97.8 2.20%
100 101 1.00% 101 1.00% 98.9 1.10%
100 103 3.00% 101 1.00% 97.6 2.40%
800 811 1.38% 799 0.13% 790 1.25%
800 825 3.13% 811 1.38% 808 1.00%
800 801 0.13% 797 0.38% 787 1.63%
20 21 5.00% 19.9 0.50% 18.9 5.50%
100 98.9 1.10% 102 2.00% 95.4 4.60%
800 760 5.00% 795 0.63% 765 4.38%
20 21 5.00% 20.6 3.00% 17.4 13.00%
100 101 1.00% 100 0.00% 98.3 1.70%
800 766 4.25% 807 0.88% 788 1.50%
20 20.4 2.00% 19.8 1.00% 20 0.00%
20 19.1 4.50% 19.7 1.50% 19.9 0.50%
20 19.4 3.00% 20 0.00% 19.6 2.00%
100 98.6 1.40% 99.2 0.80% 101 1.00%
100 98.2 1.80% 101 1.00% 101 1.00%
100 100 0.00% 101 1.00% 103 3.00%
800 793 0.88% 787 1.63% 822 2.75%
800 798 0.25% 776 3.00% 833 4.13%
800 812 1.50% 806 0.75% 867 8.38%
20 20.4 2.00% 20 0.00% 20.7 3.50%
100 101 1.00% 104 4.00% 104 4.00%
800 786 1.75% 794 0.75% 822 2.75%
20 20.1 0.50% 20.1 0.50% 19.5 2.50%
100 103 3.00% 102 2.00% 103 3.00%
800 801 0.13% 792 1.00% 811 1.38%
20 19.7 1.50% 20.8 4.00%
20 19.6 2.00%
20 18.8 6.00% 20.2 1.00%
100 98.6 1.40% 101 1.00%
100 96.1 3.90% 100 0.00%
100 101 1.00% 100 0.00%
800 784 2.00% 839 4.88%
800 814 1.75% 787 1.63%
800 801 0.13% 845 5.63%
20 19.1 4.50% 19.9 0.50% 19.99 0.73 3.63%
100 100 0.00% 102 2.00% 100.91 2.85 2.82%
800 779 2.63% 810 1.25% 788.88 21.10 2.67%
20 19.1 4.50% 20.5 2.50% 19.79 1.14 5.76%
100 103 3.00% 102 2.00% 101.54 1.69 1.66%
800 767 4.13% 791 1.13% 790.38 16.75 2.12%
Urine
Day6 (09/24/11) 19mix Rerun 27th
3.84%
0.49
Blood
Day6 (09/22/11)
4.47%
19.63 0.68 3.47% 19.83 0.15
2.15% 20.23 0.78 18.07 0.8121.43 0.46
5.25%2.55% 20.50 0.42 2.07% 19.83 1.04
0.77% 19.83 0.21
19.37
98.10 0.70 0.71%
98.93 0.95 0.96%
100.67 2.52 2.50% 100.47 0.92 0.92%
1.05%
812.33 12.06 1.48% 802.33 11.36 1.43%
1.14%
Day6 (09/24/11) 18 mix
1.69 1.69%98.57 2.45 2.49% 100.33 0.58 0.58%
100.40 1.04 1.04% 101.67 1.15
99.89
801.00
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
789.67 15.18 1.92% 840.67
7.57 0.94% 795.00
31.90 3.87% 808.04 21.74 2.69%
Serum
Serum
Urine
Blood
Serum
Urine
Blood
23.46 2.79%
799.67 15.04 1.88% 823.67
9.85 1.23%
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Quadratic
Ziprasidone
Day 1 (08/24/11) Day2 (08/28/11) Day3 (08/29/11)
20 22.2 11.00% 21.2 6.00% 18.4 8.00%
20 20.7 3.50% 21.6 8.00% 18 10.00%
20 21.8 9.00% 21.2 6.00% 18 10.00%
100 99.9 0.10% 104 4.00% 96.7 3.30%
100 105 5.00% 108 8.00% 98.4 1.60%
100 100 0.00% 107 7.00% 97.4 2.60%
800 813 1.63% 805 0.63% 772 3.50%
800 843 5.38% 810 1.25% 765 4.38%
800 786 1.75% 783 2.13% 762 4.75%
20 21.8 9.00% 20.9 4.50% 19 5.00%
100 101 1.00% 110 10.00% 99.7 0.30%
800 771 3.63% 821 2.63% 764 4.50%
20 22 10.00% 20.5 2.50% 17.6 12.00%
100 103 3.00% 109 9.00% 97.6 2.40%
800 744 7.00% 790 1.25% 773 3.38%
20 21.1 5.50% 19.8 1.00% 20.8 4.00%
20 18.9 5.50% 20.1 0.50% 20 0.00%
20 20.4 2.00% 20.3 1.50% 19.4 3.00%
100 99.4 0.60% 95.6 4.40% 94.1 5.90%
100 102 2.00% 104 4.00% 102 2.00%
100 96.7 3.30% 101 1.00% 102 2.00%
800 785 1.88% 825 3.13% 790 1.25%
800 790 1.25% 860 7.50% 872 9.00%
800 804 0.50% 867 8.38% 921 15.13%
20 19.7 1.50% 20.3 1.50% 20.3 1.50%
100 97.2 2.80% 107 7.00% 107 7.00%
800 811 1.38% 819 2.38% 855 6.88%
20 23.2 16.00% 23.1 15.50% 17.3 13.50%
100 114 14.00% 127 27.00% 84.8 15.20%
800 940 17.50% 890 11.25% 662 17.25%
20 20.5 2.50% 20.8 4.00%
20 19.6 2.00%
20 20.1 0.50% 19.9 0.50%
100 103 3.00% 107 7.00%
100 99.6 0.40% 103 3.00%
100 102 2.00% 105 5.00%
800 844 5.50% 925 15.63%
800 846 5.75% 834 4.25%
800 812 1.50% 853 6.63%
20 18.5 7.50% 18.7 6.50% 19.90 1.15 5.75%
100 100 0.00% 104 4.00% 103.24 4.46 4.32%
800 810 1.25% 818 2.25% 808.63 29.07 3.59%
20 24.7 23.50% 24.3 21.50% 21.59 2.87 13.28%
100 125 25.00% 123 23.00% 110.43 14.81 13.42%
800 947 18.38% 968 21.00% 839.25 112.26 13.38%
Day6 (09/22/11)
18.13 0.23 1.27%21.57 0.78 3.60% 21.33 0.23
Urine
Day6 (09/24/11) 19mix Rerun 27th Day6 (09/24/11) 18 mix
Day6 (09/30/11) 18 mix Day6 (09/30/11) 19 mix Between Day
20.13 1.12 5.58%
2.29% 870.67 48.00 5.51% 823.63 44.45834.00 19.08
97.50 0.85 0.88%
99.37
101.63 2.92 2.87% 106.33
20.21 1.14 5.62%20.07 0.45 2.25% 20.35 0.64 3.13%
20.07 0.25 1.25% 20.07
Blood
2.00 1.90%101.53 1.75 1.72% 105.00
2.65 2.67% 100.20 4.26 4.25%
2.08 1.96%
1.08%
0.67%
793.00 9.85 1.24% 850.67 22.50
3.50% 799.33 14.36 1.80% 766.33 5.13814.00 28.51
4.56 4.59%99.37
0.70 3.50%
2.65% 861.00
5.40%
66.19 7.69%
101.37 3.73 3.68%
Serum
Serum
Urine
Blood
Serum
Urine
Blood
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APPENDIX D 
Carryover Evaluation Data 
 
 
Sample 47 
Sample 49 
Sample 55 Sample 53 
Sample 51 
Sample 46 
152 
 
APPENDIX E 
Matrix Effect and Recovery Data 
 
Matrix Effect 107.45% 103.09% 103.11% 106.09%
Recovery 62.52% 69.08% 79.16% 78.61%
Matrix Effect 107.88% 105.20% 104.93% 105.46%
Recovery 62.06% 82.70% 69.31% 75.22%
Matrix Effect 106.84% 103.98% 100.47% 102.02%
Recovery 55.95% 87.25% 76.67% 80.96%
Matrix Effect 96.86% 89.82% 98.76% 102.20%
Recovery 14.50% 17.53% 56.68% 59.54%
Matrix Effect 97.96% 95.26% 103.41% 103.41%
Recovery 17.26% 16.08% 54.24% 45.54%
Matrix Effect 94.39% 91.98% 104.27% 98.65%
Recovery 13.12% 15.19% 51.10% 51.10%
Matrix Effect 107.48% 105.69% 105.40% 111.45%
Recovery 69.89% 79.85% 74.09% 70.36%
Matrix Effect 106.34% 106.18% 108.17% 111.70%
Recovery 67.43% 72.13% 71.33% 56.37%
Matrix Effect 107.97% 107.48% 111.70% 110.94%
Recovery 66.42% 75.64% 63.84% 66.98%
Matrix Effect 97.54% 109.06% 101.62% 23.94%
Recovery 77.95% 77.93% 49.33% 177.36%
Matrix Effect 103.64% 107.65% 29.43% 60.44%
Recovery 72.83% 73.13% 57.40% 54.36%
Matrix Effect 103.17% 105.09% 34.35% 45.09%
Recovery 72.70% 77.22% 24.56% 66.45%
Matrix Effect 106.09% 106.09% 102.46% 105.81%
Recovery 70.30% 75.51% 78.07% 75.88%
Matrix Effect 106.22% 103.66% 107.40% 104.97%
Recovery 67.83% 72.26% 72.72% 68.06%
Matrix Effect 105.55% 103.39% 106.09% 102.46%
Recovery 67.24% 73.39% 68.97% 76.65%
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
9-hydroxyrisperidone Haloperidol
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
Pipamperone Perphenzine
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
Risperidone Ziprasidone
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
Olanzapine Fluphenazine
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
Promethazine Quetiapine
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
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Matrix Effect 106.90% 108.03% 104.20% 107.02%
Recovery 80.93% 78.56% 48.83% 66.02%
Matrix Effect 107.13% 106.41% 103.19% 104.73%
Recovery 78.96% 77.43% 47.14% 52.74%
Matrix Effect 107.54% 108.06% 101.97% 102.39%
Recovery 73.00% 77.43% 54.90% 58.67%
Matrix Effect 103.40% 106.56% 101.68% 107.71%
Recovery 60.59% 70.69% 73.17% 74.94%
Matrix Effect 107.30% 105.77% 101.27% 103.26%
Recovery 56.67% 52.67% 72.27% 61.90%
Matrix Effect 104.78% 102.21% 102.15% 101.52%
Recovery 60.23% 59.67% 68.17% 70.39%
Matrix Effect 108.35% 107.59% 104.59% 101.29%
Recovery 73.98% 79.65% 55.01% 61.71%
Matrix Effect 110.42% 106.19% 100.90% 102.96%
Recovery 72.09% 72.95% 61.38% 52.29%
Matrix Effect 110.51% 105.84% 97.77% 99.62%
Recovery 67.46% 77.72% 54.66% 58.56%
Matrix Effect 87.50% 99.46% 104.33% 107.44%
Recovery 58.42% 58.60% 76.13% 78.43%
Matrix Effect 97.22% 99.06% 104.30% 104.33%
Recovery 51.34% 47.17% 76.22% 73.81%
Matrix Effect 100.34% 95.74% 101.91% 101.63%
Recovery 55.39% 51.29% 73.25% 79.78%
Matrix Effect 104.22% 103.74%
Recovery 62.73% 65.70%
Matrix Effect 103.27% 105.24%
Recovery 62.25% 54.04%
Matrix Effect 98.84% 102.18%
Recovery 58.64% 57.59%
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
Chlorpromazine
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
Trifluoperazine Clozapine
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
Loxapine Thioridazine
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
Thiotixene Aripiprazole
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2727-10 0256 
Fresh
MEC Blood 
0215-11 3951 
Decomp
MEC Blood 
2648-10 0256 
Fresh
Sheep Blood
Buspirone Mesoridazine
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
MEC Blood 
1364-11 0256 
Fresh
MEC Blood 
1373-11  
Decomp
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APPENDIX F 
 
Peak Purity and Selectivity 
  
 
Sample 59 (Analyte) 
Sample 60 (IS) 
Sample 59 (IS) 
Sample 60 (Analyte) 
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Analyze one zero sample (negative specimen plus I.S.) and one sample containing the analyte(s) but no I.S. to check for the 
absence of analyte fragmentation ions in the I.S. peak or vice versa.  
 
Add 400 µL of Stock 2. (For 20 ng, on column) to negative specimen (Sheep Blood). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 59 (Analyte) 
Sample 60 (IS) 
Sample 59 (IS) 
Sample 60 (Analyte) 
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Add 300 µL of the Standard Solution (15 ng of standard on column) to negative specimen (Sheep Blood). 
 
 
Analyte Peak Name
Analyte Peak 
Area (counts)
IS Peak Area 
(counts)
Calculated 
Concentration 
(ng/mL)
Analyte Peak Name
Analyte Peak 
Area (counts)
IS Peak Area 
(counts)
Calculated 
Concentration 
(ng/mL)
9-hydroxyrisperidone 1 3.60E+03 1.76E+07 < 0 9-hydroxyrisperidone 1 4.21E+03 1.78E+07 < 0
Aripiprazole 1 1.73E+02 9.36E+05 0.192 Aripiprazole 1 1.66E+02 9.34E+05 0.17
Buspirone 1 1.53E+03 5.22E+06 < 0 Buspirone 1 1.30E+03 5.19E+06 < 0
Chlorpromazine 1 7.37E+02 1.26E+06 0.0722 Chlorpromazine 1 9.50E+02 1.24E+06 0.124
Clozapine 1 1.24E+03 2.14E+06 < 0 Clozapine 1 1.18E+03 2.17E+06 < 0
Fluphenazine 1 8.91E+02 1.03E+06 < 0 Fluphenazine 1 9.27E+02 1.02E+06 < 0
Haloperidol 1 1.81E+03 3.00E+06 < 0 Haloperidol 1 1.85E+03 2.99E+06 < 0
Loxapine 1 8.02E+02 2.16E+06 < 0 Loxapine 1 1.24E+03 2.17E+06 < 0
Mesoridazine 1 9.68E+03 2.45E+06 < 0 Mesoridazine 1 9.69E+03 2.46E+06 < 0
Olanzapine 1 1.52E+03 8.94E+05 1.1 Olanzapine 1 1.39E+03 8.70E+05 1.08
Perphenzine 1 3.01E+02 1.10E+06 0.261 Perphenzine 1 1.71E+02 1.09E+06 0.186
Pipamperone 1 1.03E+03 2.67E+06 < 0 Pipamperone 1 1.07E+03 2.62E+06 < 0
Promethazine 1 7.71E+02 3.23E+06 0.0321 Promethazine 1 7.22E+02 3.25E+06 0.0259
Quetiapine 1 2.56E+03 1.73E+06 0.86 Quetiapine 1 2.11E+03 1.72E+06 < 0
Risperidone 1 1.14E+04 1.18E+07 < 0 Risperidone 1 1.11E+04 1.17E+07 < 0
Thioridazine 1 1.73E+04 2.45E+06 < 0 Thioridazine 1 1.79E+04 2.46E+06 < 0
Thiotixene 1 1.55E+02 1.03E+06 < 0 Thiotixene 1 5.88E+01 1.02E+06 < 0
Trifluoperazine 1 2.38E+02 1.56E+06 0.00549 Trifluoperazine 1 7.80E+01 1.56E+06 < 0
Ziprasidone 1 4.00E+02 1.09E+06 0.595 Ziprasidone 1 1.50E+02 1.09E+06 0.496
Sample 62 Sample 63
Sample 62 (Analyte) 
Sample 63 (Analyte) Sample 63 (IS) 
Sample 62 (IS) 
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Analyze ten negative specimens of the same matrix from different cases without analyte(s) or intended Internal 
Standard (I.S.) to check for endogenous peaks that might interfere with the analyte or the I.S. 
 
MEC Blood 1364-11 0256 Fresh                        MEC Blood 2648-10 0256 Fresh 
 
MEC Blood 2727-10 0256 Fresh 
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MEC Blood 1373-11  Decomp 
 
MEC Blood 0215-11 3951 Decomp 
 
MEC Blood 1602-11 3875 Fresh    MEC Blood 1532-11 4371 Fresh 
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MEC Blood 1363-11  Fresh               MEC Blood 1473-11  Fresh 
 
 
Sheep Blood 
 
